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SUMMARY
STRUCTURE OF THE THESIS
In Chapter 1 I have discussed the assessment of control of 
carbohydrate, lipid and protein metabolism in insulin treated 
diabetes mellitus, those factors which can affect metabolic 
control, and epidemiological and pathophysiological aspects of 
diabetic complications. In Chapter 2 the design of the Salford 
Heme Blood Glucose Monitoring Study is reported and the subjects, 
materials and methods described along with results from the 
initial laboratory evaluations of the assays for glycosylated 
serum albumin, urinary albumin and filter paper blood glucose 
measurement. The effects of continued blood glucose monitoring 
in the heme blood glucose monitoring study when compared to urine 
glucose monitoring are discussed in Chapter 3. In Chapter 4 I 
have reported the results of the various analyses on aspects of 
lipid metabolism that were carried out and in Chapter 5 on the 
clinical utility of the various measures of glycaemic control 
used in the heme blood glucose monitoring study. The effects of 
residual C-peptide secretion on metabolic control and 
complications during the blood glucose monitoring study are 
presented in Chapter 6 along with an assessment of the 
association between autonomic neuropathy and renal function in 
insulin-dependent diabetes mellitus. In Chapter 7 I have 
presented the results of the psychological evaluations that were 
carried out at inception to the blood glucose monitoring study 
and after 1 year. Finally in Chapter 8 I have discussed the 
results in relation to previously published work and the 
implications for future research into metabolic control and
7
complications in insulin-treated diabetes mellitus.
RESULTS
A filter card blood glucose assay was modified for large- 
scale use and blood glucose levels were found to be stable 
without the need for preservatives if filter cards were 
refrigerated. A commercial kit for measurement of glycosylated 
albumin was evaluated and found to be insensitive at low levels 
necessitating establishment of a two stage affinity 
chromatography and immunoturbidimetric method for accurate 
retrieval and measurement of glycosylated and non-glycosylated 
serum albumin. The Friedewald formula for the measurement of 
LDL cholesterol in insulin dependent diabetes mellitus (IDEM) was 
compared with LDL cholesterol measured by preparative 
ultracentrifugation and found to correlate closely in subjects 
without advanced nephropathy.
The Salford Home blood glucose monitoring study initially 
involved 153 diabetic patients and showed that continued access 
to a blood glucose meter following an intensified period of 
management and education was associated with marginal 
improvements in various measures of glycaemic control over 1 
year, and somewhat better retention of diabetic self-care skills. 
Regardless of the means of glucose monitoring, stable glycaemic 
control and improved educational skills were maintained for a 
period of 1 year following the intensive management period. The 
Reflolux blood glucose meter was found consistently to 
overestimate low normal and hypoglycaemic blood glucose values.
Conformational changes in low density lipoprotein (LDL) and 
high density lipoprotein (HDL) are described in stable IDEM in the
8
absence of nephropathy which were modified by genetically 
determined structural changes in apolipoprotein E, early diabetic 
nephropathy, and inadequate diabetic care. 40% of 205 patients 
with IDDM were found to have hypercholesterolaemia and/or 
hypertriglyceridaemia at the initial assessment.
The use of several glycosylated blood protein measures 
provided conplimentary information about glycaemic instability in 
IDDM in addition to direct measures of glycaemia. Glycosylated 
albumin (GSA) was found to be a more sensitive indicator of short 
term improvements or fluctuations in glycaemia than HbAx or 
fructosamine. GSA and fructosamine measurements in IDDM provided 
discrepant information on occasions and fructosamine levels were 
apparently lowered in hypertriglyceridaemic sera.
Residual C-peptide secretion was associated with minor 
improvements in glycaemic control and lower insulin requirements, 
although it was not associated with any differences in measures 
of lipid metabolism. Subjects with long standing IDDM and 
residual C-peptide secretion had more peripheral vascular disease 
but less proliferative retinopathy at entry to the Salford Hicme 
Blood Glucose Monitoring Study but after 1 year significant 
differences were no longer apparent. Autonomic neuropathy was 
associated with enhanced natriuresis and albumin excretion, 
particularly in overnight urine collections.
Higher anxiety and depression ratings were reported more 
frequently in patients with neuropathy, impotence, coronary and 
peripheral vascular disease and proliferative retinopathy, but 
bore no relation to glycaemic control apart frcm a higher anxiety 
score in patients who allegedly experienced daily hypoglycaemic
9
episodes.
The importance of these findings to patient management, the 
natural history of diabetic complications, and the link between 
metabolic control and complications are discussed.
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CHAPTER 1
IKERODUCrrCN
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INTRODOCEICN
The introduction of insulin into clinical use in 1922 for 
the management of insulin-dependent diabetes mellitus (IDEM) 
transformed the prognosis from one of inevitable early death to a 
situation where symptoms could be relieved and life prolonged. 
At that time controversy existed over the degree of metabolic 
control that should be achieved owing to the development of 
hypoglycaemic reactions which were sometimes severe or even, on 
occasions, fatal (1). This controversy still exists not only 
because of the acute consequences and possible sequelae of 
hypoglycaemia (2-5), but with the realisation that the long term 
vascular complications of diabetes might be the result of 
inadequate metabolic control (6). Diabetic microangiopathy and 
the aggressive atherosclerotic phenomena that accompany IDEM have 
been found primarily to be associated with the duration of the 
diabetes and the age of the individual (7, 8, 9). Glycaemic 
control has been suggested from both prospective and 
retrospective epidemiological studies to be a major determinant 
of microangiopathic complications (10-15), although the evidence 
for atheromatous cardiovascular disease is less compelling; here 
additional environmental, clinical (14-18) and genetic (19) 
components are likely to be more important.
At present the question of whether effective metabolic 
control prevents or leads to regression of established vascular 
disease is unresolved for several reasons:
(i) the means by which effective metabolic control could be 
achieved has only recently become available.
(ii) objective assessment of long term glycaemic control
25
has only beccme possible with the introduction of the 
measurement of glycosylated (glycated) proteins into 
clinical practice.
(iii) the intimate association between the development of 
complications and the duration of diabetes means that the 
question of prevention of vascular complications will not 
be answered until prospective studies have run for perhaps 
ten years or more.
Over the last 5 years several small prospective clinical 
trials have evaluated the effects of improved glycaemic control 
on established diabetic microvascular carplications. No 
prospective studies as yet have attempted to investigate the role 
of glycaemic control in the development or progression of 
atheromatous (macrovascular) disease in IDDM.
Critical scrutiny of studies of the effects of near-normo- 
glycaemia on established microvascular complications reveals 
conflicting results (20), due to the paucity of randomised trials 
with well characterised insulin-dependent diabetics and adequate 
quantification of end points. Diabetic retinopathy probably 
iirproves or its progression is arrested after two years of 
improved glycaemic control (21, 22), assuming that normoglycaemic 
re-entry is gradually achieved because of the frequently noted 
transient deterioration after 1 year (23-25), due possibly to the 
effects of relative hypoglycaemia on the impaired autoregulation 
of retinal blood flow. Other studies (26, 27) conducted over 1-2 
years, however, did not support such reports. Although 
established diabetic nephropathy (persistent proteinuria) is 
unlikely to resolve with improved glycaemic control (26, 28, 29),
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the situation for incipient nephropathy (albuminuria excretion 
rates > 15pg/minute without overt proteinuria) remains 
inconclusive, and the progression of overt nephropathy may be 
delayed (20, 24, 30-35). Peripheral neuropathy, likewise, may 
improve with near normoglycaemia when assessed by 
neurophysiological measures (21, 36-40), but autonomic
dysfunction is probably not amenable to correction (22, 40). 
Most of these prospective studies (21-35, 37, 39) instituted 
effective glycaemic control by continuous subcutaneous insulin 
infusion (CSII) pumps, which however are applicable and effective 
only in selected highly-motivated patients (41, 42).
In practical terms, there is probably enough evidence for the 
modem diabetic clinic to employ the general principle that, the 
better glycaemic control, the better the long term outlook for 
patients with IDEM. However, despite these recent studies, major 
questions remain unresolved. Perhaps most important, are how 
best to manage all individuals with IDEM in the outpatient clinic 
setting, how to evaluate and improve their metabolic control, and 
whether effective metabolic control can prevent macrovascular as 
well as microvascular disease.
Although IDEM is clearly a disorder of lipid and protein as 
well as carbohydrate metabolism, the assumption has been that 
control of the latter will normalise protein and lipoprotein 
metabolism. This is supported by findings in several short-term 
studies (43-49), but only a few long term studies of small 
numbers have reported the effects of intensified insulin therapy 
either by CSII or multiple insulin injections on protein (50) or 
lipid (50-54) metabolism, where qualitative as well as
27
quantitative disturbances m y  be present (54-56). Furthermore, 
abnormal postprandial patterns of intermediary metabolites of 
lipid and protein metabolism persist with all modes of 
subcutaneous insulin delivery (42,43). Macrovascular disease is 
the major cause of premature death in IDEM, and epidemiological 
studies have suggested that hypertension and disturbed lipid 
metabolism are more important than glycaemic control in 
determining the risk of cardiovascular death and morbidity (17,
18, 57, 58).
The work reported in this thesis extends back to 1983 when 
over 150 insulin-dependent diabetics were consecutively recruited
to a large prospective study to try to answer the following broad 
questions:-
1. Do different measures of carbohydrate, lipid and protein 
metabolism give comparable or complementary information in 
assessing metabolic control in IDDM?
2. What factors determine metabolic control in IDEM, and does home 
blood glucose monitoring help, independently of other factors?
3. What is the effect of improved metabolic control on the 
health of patients with IDDM?
1. METABOLIC CONTROL
The concept of 1 control1 of diabetes relates to 
pharmacological and dietary efforts to regulate those metabolic 
disturbances in diabetics which have immediate or long term 
adverse consequences. The relationship between metabolic control 
and the development and progression of complications has still to
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be fully resolved, perhaps because most studies have relied 
solely on assessment of glycaemic control to investigate the 
issue.
If one does take into account other aspects of metabolism it 
has been questioned whether conventional insulin therapy could 
ever fully normalize all the biochemical disturbances of IDEM 
(59).
Within the limitations of measures of glycaemia that are 
generally used to reflect metabolic control, there are still no 
accepted criteria as to what constitutes perfect, adequate or 
poor control. The suggestion that poor metabolic control is 
reflected by a fasting blood glucose of greater than 8.2mmol/l or 
a post prandial value greater than 11.2mmol/l (60, 61), would 
condemn the vast majority of people with IDEM to this category. 
If one accepts a variation from normal mean blood glucose as 
assessed by an M value (an index of glycaemic fluctuation) of 
less than 10 (62) as perfect metabolic control, then even CSII 
does not normalize such fluctuations (63). Data suggesting that 
'inpaired glucose tolerance1 is a risk factor for vascular 
disease (18) suggests that even near normoglycaemia may not 
reduce the risk of angiopathy to that of the general population. 
The assessment of diabetic control is further complicated by the 
inherent variability of results on retesting under identical 
conditions, in individuals who are said to have 'labile' diabetes 
(64).
The other purpose of the assessment of diabetic control, in 
addition to investigation of a pathogenetic role, is to allow 
optimization of therapy which has to take into account all
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factors which may determine metabolic control (vide infra). At 
present, clinical evaluation and quantitative measures of 
carbohydrate metabolism remain the standards whereby the 
metabolic status of diabetic patients is judged.
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1:1 CARBOHYDRATE METABOLISM
URINARY GLUCOSE MEASUREMENT
Perhaps the first 'qualitative' assessment of glycosuria was 
made by the Hindu physician Sushrutu 2000 years ago when he 
described the sweet flavour of the urine of individuals afflicted 
with diabetes (65). After the introduction of insulin, 
qualitative assessments of glycosuria by the Clinitabs methods 
was superceded by semiquantitative and quantitative methods which 
remain in clinical practice. Most semi-quantitative methods 
employ glucose as a reducing agent, for example in the glucose 
oxidase/peroxidase reaction when glucose is oxidised to S-(D)~ 
gluconolactone, with the production of hydrogen peroxide which 
oxidises the colour sensitive indicator. In the absence of large 
quantities of ascorbic and salicylic acid, the test is 
reproducible and accurate (66). Currently Clinistix, Diastix, 
Clinitest and Diabur-test 5000 are ccmmonly used in clinical 
practice with reasonable accuracy (67, 68). The use of well 
timed urine collections has been reported to provide a reasonable 
indicator of simultaneously recorded continuously analysed blood 
glucose (69) in insulin-dependent diabetics without advanced 
nephropathy. Timing of urine analysis is important and post­
prandial measurements may reflect more closely the tendency for 
hyperglycaemia (70), although double voiding of urine does not 
necessarily improve the precision (71). The question of altered 
renal threshold and collection problems has focussed disfavour on 
urinary glucose measurement as an assessment of carbohydrate 
metabolism particularly in patients with high renal thresholds 
(70). A diurnal variation of the renal threshold for glucose may
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further confound matters (69-70). The less direct information 
may prejudice against the patient with IDEM achieving better 
glycaemic control than with blood glucose testing, although this 
question remains unresolved. A poor quantitative correlation 
between semi-quantitative measures of urine glucose concentration 
and simultaneous blood glucose values has been noted (72), 
although fractional quantitative glucose analysis (gm/hour) is 
more reproducable (69) but impractical for routine use. Even 
fractional quantitative urine collection may be inadequate as a 
basis for therapeutic decision making (73). In the volatile 
state of childhood IDEM, studies comparing urine and blood 
glucose testing as a means of assessing glycaemic control have 
produced conflicting conclusions (74, 75). In careful studies of 
adult IDEM the degree of glycosuria was found to be of value as a 
index of glycaemia when the blood/urine glucose relationship was 
known for each individual, in the absence of established diabetic 
nephropathy (76). The most recent study to try to isolate the 
effects of blood versus urine glucose monitoring failed to 
demonstrate any advantage of the fomer {11).
The premature suggestion that urine glucose testing is 
obsolete in any case neglects the fact that many patients with 
IDEM are reluctant to carry out blood testing and with 
appropriate advice might use urine analysis to achieve reasonable 
glycaemic control without hypoglycaemia.
Perhaps more important is the potential role of 24 hour 
urinary glucose excretion not only as a marker of carbohydrate 
metabolism but as a possible direct independent mediator of renal 
damage. Excessive glycosuria for example has direct effects on
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renal tubular handling of cations which may explain the disturbed 
glcmerulo-proximal tubular balance in diabetes (78). This may be 
of relevance to the pathogenesis of diabetic hypertension, in 
that sodium reabsorption may be altered leading to the phenomenon 
of increased total exchangeable sodium seen in diabetes (79). 
Furthermore, glycosuria may be relevant to the development of 
early changes in the glomeruli such as basement membrane 
thickening which may result from glycosylation secondary to the 
free filtration of excess amounts of glucose (80).
GLYCAEMIA
The measurement of glycaemic control as an aid to management 
of IDEM is less straightforward than is at first apparent. First, 
there are methodological differences in the measurement of blood 
glucose. The capillary tends to be higher than the venous blood 
glucose value, and whole blood glucose values tend to be lower 
than those in plasma or serum (81). In addition enzymatic 
measurements of glucose by glucose dehydrogenase and hexokinase 
may give different degrees of precision, with the hexokinase 
method more accurate in the measurement of borderline 
hypoglycaemic levels (81, 82).
The inherent variation in blood glucose in IDEM makes a 
random measurement of little use in assessing glycaemia, and 
fasting blood glucose levels, whilst important in reflecting the 
efficacy of nocturnal insulin delivery and the frequency of the 
'dawn phenomenon' in IDEM (83, 84), have been found to correlate 
poorly with integrated measures of glycaemia such as glycosylated 
(glycated) haemoglobin (HbAx) in IDEM (85-88). Mean blood glucose
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determination, based on a series of blood glucose measurements, 
is more closely related to Hh^ (83, 85, 87, 89-92). However for 
obvious reasons this often does not include a measure of 
nocturnal blood glucose levels. Since intermediate acting 
insulin is frequently administered in the evening in IDEM, and a 
high fasting blood glucose raises the question of either relative 
insulin deficiency or an excessive counter-regulatory response as 
part of the Sanogyi effect in hypoglycaemia (83), the failure to 
use nocturnal glucose measures in mean blood glucose 
determination may give incomplete information.
In addition mean blood glucose values do not reflect the 
variability of glycaemia. The mean amplitude of glucose 
excursions (MAGE) or the mean of daily difference (MDDD) reflect 
the within day or day to day glycaemic variability frcm the mean 
value (83, 93-96). This approach may be more fruitful in 
assessing the potential for changes in transmembrane glucose flux 
to initiate or aggravate cellular damage in diabetes. The 'Mf 
value of Schlichtkrull is a quantitative index of the deviations 
of several blood, glucose determinations frcm the mean over a 24 
hour period (97), and has been modified to measure glycaemic 
variability in SI units. It gives as a single figure an 
expression of mean glycaemia and the effect of glucose swings and 
may be the most relevant measure of glycaemic stability in that 
it gives a weighted average of glucose values with hypoglycaemic 
fluctuations having relatively more bearing on the derived M 
value (83). Hypoglycaemia per se or normoglycaemiac 're-entry1, 
as stated previously, has clearly been demonstrated to be 
relevant to exacerbation of retinopathy (3, 5), and potentially
34
to other microvascular complications.
Therefore the measurement of glycaemia to assess metabolic 
control effectively should utilise a robust method, stating what 
the source of blood was, and should provide an estimate of fasting 
and mean blood glucose levels as well as sane estimation of the 
diurnal instability.
NCN-ENZYMMTC OXGOSYLKCECN OF BLOOD PROTEINS AS AN INDICATOR OF 
SHORT AND LONG-TERM INTEGRATED GLXCAEMIA
1. Glycosylated (Glycated) Haemoglobin
Glycosylated haemoglobin was first isolated by starch gel 
electrophoresis in 1955 (98), and it was identified as a
heterogeneous fast fraction in 1958 (HhAla, HbAlb and HhAlc) (99). 
However it was only in 1962 that Huisman and Dozy (100) correlated 
this haemoglobin variant with diabetes mellitus, and in 1969 
Rahbar et al (101) confirmed that it was the HhAlc fraction that 
was specifically elevated. Improvements in elution conditions 
revealed that glycosylated haemoglobin (HhAx c) was formed as a 
consequence of non-enzymatic post-translational modifications of 
haemoglobin (HhAo). The prime site for glycosylation is the 
terminal amino group of the p-chain of HhAo, but glycosylation 
also takes place at the alpha chain amino termini and at the d -  
amino groups of lysyl residues. In health roughly 5-8% of HhAo 
has detectable glycosylation (102).
The chemical process involved is common to all blood 
proteins. First, glucose forms an aldimine adduct with the amino 
group. This rapidly formed 'Schiff base1 is labile and reflects 
ambient glycaemia in addition to 'prevailing' glycaemic control.
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Thereafter 'Amadori' rearrangement, which is a slower process, 
takes place, to produce a stable ketoamine. Both the labile and 
ketoamine bonded fractions of HhAlc may be clinically relevant in 
the assessment of glycaemic control (102-106). A longer term 
rearrangement after stable glycosylation to the state of protein 
'browning' in tissue glycosylated proteins by the 'Maillard' 
reaction may be relevant to the pathogenesis of diabetic 
angiopathy.
Assuming a steady state of synthesis of red blood cells, 'a 
slightly reversible' equation for the determination of the rate 
of synthesis and net accumulation of HbAx was developed. Based 
on an assumption of red cell life span of 120 days a computer 
simulated model (107) reached the following conclusions:-
1. The maximal half time for approach to a new equilibrium if a 
patient with persistent hyperglycaemia was abruptly returned 
to normoglycaemia would be eight and a half weeks. 
Decreased red cell survival would clearly shorten the time.
2. A short term loss of glucose control (2-4 fold increase in 
mean blood glucose) will cause a more rapid rise in HhAlc 
than the fall which occurs following improved glycaemic 
control of an equivalent degree.
This model does not necessarily operate precisely the same in 
different individuals. For example, the rate of glycosylation of 
HhAx has also been found to be dependent on red cell glucose 
permeability (108), red cell oxygenation and pH, and erythrocyte 
concentration of 2, 3 diphosphoglycerate (2, 3 DPG) (109).
However the extent of these alterations in vivo is unlikely to 
have a major bearing on HbAx levels in clinical practice (110).
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The system is likely to be saturable however, and post 
translational modification of HB^ c may be influenced by the 
duration of diabetes (92).
METHODS FOR DETERMINING GLYCOSYLATED HAEMOGLOBIN
For clinical use the ideal method should be quick, 
economical, sensitive and reproducible. The most widely used 
methods involve spectrophotcmetric estimation following isolation 
by chromatographic or electrophoretic procedures.
1. Ion Exchange Chromatography
Cation exchange chromatography utilises the difference in 
molecular charge arising frcm glycosylation of the N-terminus of 
the p chain, and was the method used initially in the assessment 
of Hh&lc in diabetes. When macrocolumns or HPLC (high performance 
liquid chromatography) are used, HfcAlc can be differentiated frcm 
HfcAx and the other minor fast haemoglobin components (HfcAla and 
HfcAlb), although in practice this is unnecessary and measurement 
of the total fast fraction (Hh^) has been found to be more 
easily measured and as precise for clinical use (92,102). The 
mini column method reliably isolates the total Hh^ fraction, 
assuming there is rigid temperature control and due attention to 
buffer composition and a relatively consistent sanple load (92, 
102). The labile aldimine fraction will be incorporated into the 
measurement so preparatory elimination by dialysis, saline 
incubation or chemical treatment (e.g. cell lysis with saponic 
reagent at pH 5.0) is required (111). Other factors which may 
affect values are the presence of haemoglobin variants such as 
HbF, HbG and HbH, which by virtue of their negative charge lead
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to an artefactual increase in ’Hh^ 1 measurement, or positively 
charged HbS and HbC where false decreases result (102).
Mditional sources of artefactual elevations are marked 
jaundice, severe lactescence, heparin monoidoacetate in the 
collection vial, sample ageing and high dose aspirin therapy 
leading to acetylation of haemoglobin (102, 112, 113). A more 
clinically relevant limitation is the measurement of carbamylated 
haemoglobin in uraemic diabetics which would lead to an apparent 
increase in glycosylated haemoglobin (102, 114, 115).
2. Boronic Acid Affinity Chromatography
Cross-linked agarose activated with carbonyl dimidazole and
subsequently coupled to M-aminophenyl boronic acid provides a
highly efficient matrix for separation of all sugar cis-glycols
(102). This method has the capacity to detect haemoglobin
glycosylated at sites in addition to the N-terminus of the p chain
(115). Modification of the ligand by addition of sepharose
particles allows separation of proteins containing sugar. After
application of haemolysate, only glycosylated haemoglobin
therefore remains adherent to the gel until it is eluted with
sorbitol or acetic acid (116). The percentage of glycosylated
haemoglobin is thereafter determined by measuring
spectrophotcmetric absorbance at 414nm by the formula:-
%HhA.1 = Bound A414 xlOO
Bound A414 + Non Bound A414
Unlike ion exchange chromatography, the affinity method is
relatively insensitive to changes in pH and temperature (116-
118). The labile aldimine fraction has been suggested to account
for up to 6% of the total HhAx measured in one study where its
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removal was recommended (119), although this was not confirmed in 
a later report (120).
The presence of haemoglobin variants do not affect 
measurement of Hh^ by this method (115, 119) and likewise
carbamylated and acetylated Hb probably do not affect the assay 
(115). Further potential benefits are the lack of effect of 
anticoagulant, hyperlipidaemia or hyperbilirubinaemia on sample 
analysis, and the capacity for the commercial gel filled columns 
to be re-used (119) up to 12 times assuming the gel is stored at 
4°C in the dark. Overloading the columns with more than 4mg of 
haemoglobin does however reduce the yield of Hh^ (119) and 
recent reports have suggested difficulties in standardisation 
between different batches of gel (121-124), although individual 
laboratory modifications of the amounts of equilibration wash and 
elution buffers may account for these discrepancies.
3. Agar Gel Electrophoresis
This uses electrochrcmatographic separation, and is 
insensitive to changes in buffer pH over the range 5-6.5, as well 
as being temperature independent (102). In addition, positively 
charged haemoglobin variants (HbS and HbC) can be detected and 
excluded frcm measurement although the same does not hold for HbF 
and HbG (102, 115). Labile aldimine is measured by the assay so 
pre-incubation with saline or preliminary dialysis or chemical 
lysis are required (102, 115). Furthermore carbamylated and 
acetylated haemoglobin can produce artefactual increases in the 
!H h V  detected (115).
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4. Polyacrylamide Gel Isoelectric Focussing
This method is similar to simple agar gel electrophoresis, 
but is more reliable in separating HhAlc frcm HbF, unless 30% or 
more of the HbF is acetylated (102). Likewise high dose aspirin 
treatment and renal failure may lead to falsely elevated levels of 
'Hh&i! (112, 115), although aspirin ordinarily does not interfere 
with the method (113). Whilst closely correlating with
chromatographic methods, the specialised equipment required make 
this method unsuitable for clinical practice (102).
5. Colorimetric methods
This approach directly estimates the extent of all ketoamine 
linked glucose by measuring the conversion to 
hydroxymethylfurfural (HMF) following limited hydrolysis with a 
weak acid (oxalic) (102, 125). HMF is then converted to a 
coloured complex by reacting with thiobarbituric acid (TEA). The 
method theoretically has the advantage of only measuring the 
stable glycosylated protein fraction, and does not detect either 
haemoglobin variants or carbamylated or acetylated proteins (102, 
105, 113, 115). However despite the excellent specificity and a 
potential advantage over column methods with regard to 
reproducability after long term storage of samples (102), the 
method is lengthy and difficult to standardise due to varying or 
poor yields of HMF, (92, 102, 105, 122) or de novo formation of 
HMF frcm hydrolysis of glucose at high concentrations (92, 102, 
105, 126), and poor precision has been reported (102, 126). In 
addition the colour development involved in the assay varies with 
the site of the ketoamine bond and is eight times the amount
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derived frcm alpha linked valine compared to lysine residues 
(105, 127).
Other chemical methods have measured the glycosylated 
protein bonds indirectly by formaldehyde generation after 
periodate oxidation (128). Phenol and sulphuric acid hydroxolysis 
and hydrolysis may also be reliable (129). Most recently phytic 
acid was employed to saturate 2, 3 DPG binding sites in
haemoglobin (130). As HbAx cannot bind phytic acid, the change 
in spectral absorption after phytic acid binding is thus 
inversely proportional to the percentage of glycosylated 
haemoglobin, although HbF will also be estimated by the same 
principle. None of these latter methods, despite their 
ingenuity, are sufficiently economical in time and cost to be of 
clinical relevance.
6. Immunoassays
Sheep immunised with HbAlc purified by large column 
chromatography can produce antibodies which are extensively 
absorbed (90%) with HhAo linked to agarose, although the remaining 
10% of the titre is highly specific for HhAlc by radioimmunoassay 
(131). Apart frcm the potential ease of application, this method 
allows precise measurement of HbAlc in the presence of fetal 
haemoglobin, but has yet to be developed commercially. 
Nephelometric quantitation of immune precipitants of HhAi and 
antibody may also be advantageous in its potential for automation 
and in its sensitivity (132), although preliminary separation of 
HhAo and HbAx by column chromatography would be required, and the 
procedure has not been validated in clinical practice.
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Glycosylated haemoglobin methods: Conclusions
At present a choice lies between minicolumn and affinity
chromatography, agar gel electrophoresis or colorimetry using the
TBA reaction. The clinical workload, ethnic population and
existing laboratory facilities of the area providing diabetic
services should dictate which method is employed.
In the data to be presented in my thesis, HbAx (HbAla +
HhAlb + HtAlc) has been measured by cation exchange
chromatographic method. The method has operated since 1982, and
is precise and reproducible. The Department of Chemical Pathology
at Hope Hospital participated in the external quality control
scheme for glycosylated haemoglobin determination which would
appear to be essential for validation of results, particularly
whilst several methods are operated nationally.
A glycosylation index (____  observed HbAj______ )
mean laboratory normal range Hh^
has been suggested as a means to allow comparison of HbAx data
from different centres, but has not as yet been put into practice.
CLINICAL UTILITY OF GLYCOSYLATED HAEMOGLOBIN
The elevation of HhAlc in diabetes first prompted suggestions 
that its presence might act as a genetic marker for insulin- 
dependent diabetes mellitus, although this was not borne out by 
twin studies (133). The recognition that HhAlc levels were 
elevated in secondary diabetes (e.g. due to Cushing's syndrome) 
(134) led to the concept of glycosylated haemoglobin as a monitor 
of metabolic control. This was borne out by Trivelli et al (135)
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in one of the first clinical studies of Hh^ when highest levels 
were found in diabetics with ketoacidosis or infection. The 
interesting observation of a lack of association between Hh^ 
concentrations and duration of diabetes or the extent of 
angiopathy in this study has subsequently been reinforced (105).
HbA-i or HhA.! c concentrations correlate with various 
parameters of glycaemic control to a greater or lesser degree in 
studies that combined patients with insulin-dependent and non­
insulin-dependent diabetes mellitus (NIDDM). These have included 
fasting blood glucose, random blood glucose, mean daily blood 
glucose during the previous 3 months, the sum of bracketed blood 
glucose values around meals, maximum glucose concentration in the 
area under an oral glucose tolerance curve, the highest mean 
blood glucose occurring during the 12 hours of continuous 
monitoring, and 24 hour urinary glucose excretion obtained 4-12 
weeks previously (85-92, 102, 136). Seme studies have also 
revealed a correlation between Hh^ and triglycerides and 
cholesterol (137-139).
Unfortunately very few studies have looked solely at IDEM 
following removal of the labile fraction of Hh^. The 24 hour 
glycaemic variability of NIDEM is much less than IDEM and may be 
predicted frcm the fasting blood glucose making serial blood 
glucose sampling of little use and close correlations with Hh^ 
unsurprising. When studied, HbAx correlated poorly (r = 0.38) 
with fasting blood glucose in IDEM (85-88). The relationship 
between Hh^ and the amplitude of glycaemic excursions assessed 
by MAGE or M values in IDDM has to my knowledge not been examined 
in detail. HbAi has been reported to bear little relation to the
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standard deviation frcm the mean blood glucose of IDEM (85) 
although in one report on 9 subjects, the standard deviation (SD) 
of glucose recorded continuously for 12 hours did correlate with 
Hh^ presumably due to stable glycaemia (SD l-3mmol/L) (89). 
Bearing in mind the observation that whilst a significant 
increase in stable Hh^ follows 1 week after induction of poor 
glycaemic control in IDEM (104), but a similar fall in Hh^ lags 
3-10 weeks behind achievement of improved glycaemic control (102, 
137), the HfcAi assay seems to reflect disproportionately 
hyperglycaemic rather than hypoglycaemic fluctuations, although 
the latter may also have a role in the initiation or aggravation 
of diabetic microangiopathy. Indeed, it has been suggested that 
since a particular Hh^ level can result frcm varying degrees of 
glucose control between individuals, and mean blood glucose 
demonstrates a curvilinear relationship with Hh^ suggesting a 
saturable system (maximum Hh^ 23%), stable HhA-i is an 
insensitive index of fluctuating glycaemic control for a 
particular individual with a higher range of mean blood glucose 
levels (140).
Many earlier studies in IDEM failed to remove the labile 
Schiff base limiting interpretation of the relationships between 
different measures of glycaemic control and Hh^. However 
longitudinal studies have since demonstrated the capacity of 
serial Hh^ measurements to parallel improved glycaemic control 
assessed by mean blood glucose and M value determination (44). 
The labile fraction of Hh^ should now be routinely removed prior 
to Hh^ measurement, although it has been suggested that in 
addition to the stable ketoamine ccmponent, the labile fraction
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may be of particular value in assessing the relationship between 
short and longer tem integrated measures of glycaemia (106).
The introduction of Hh^ has had a major impact on clinical 
practice by offering the potential to modify treatment regimes 
more effectively and allowing reliable prospective examination of 
the role of glycaemic control in the development of vascular 
complications. Acceptable levels of Hh^ for individual IDEM 
subjects need further clarification. The suggestion of 3% above 
the mean normal HhAi (141) (i.e. 10% in our laboratory) as an 
acceptable upper limit for insulin-dependent diabetic subjects is 
I feel far too liberal.
Measurement of stable Hh^ though now routine, should not be 
taken out of clinical context and in isolation. Relevant 
glycaemic data whether self generated by the patient or produced 
by a technique that allows quality control of the patient's heme 
blood glucose monitoring result (v.i) should also be analysed in 
a complementary fashion to confirm the reliability for that 
individual patient and to assess what degree of glycaemic control 
(near-normoglycaemia, normal Hh^, minimal hypoglycaemia) is 
justifiable for the individual patient.
The previously mentioned clinical limitations of certain of 
the methods for measurement of HhAi must also be borne in mind:-
(i) Haematological Disturbances
Unless colorimetric methods or perhaps affinity 
chromatography is employed, haemoglobinopathies such as sickle 
cell disease or thalassaemia may lead to falsely low or high 
values of HhAi (102, 115).
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Any condition leading to shortened red cell survival 
secondary to haemolysis may lead to artificially lav values of 
HhA-L (102). Likewise conditions of accelerated erythropoesis 
such as pregnancy (102, 142) or treatment of iron deficiency 
anaemia lead to lower values of Hh^ (143). By contrast 
increased Hh^ levels accompany increased erythrocyte survival 
following splenectany (144).
(ii) Aspirin
High dose aspirin therapy can produce elevations of fast 
haemoglobin due to acetylation which could be detected by 
electrophoretic methods for measuring HbAi (112, 113).
(iii) Uraemia
Diabetic nephropathy affects 45% of IDEM. Most studies 
reporting high Hh^ levels have used electrophoretic methods 
where carbamylated haemoglobin may be falsely detected in such 
patients (102, 114, 145-148). In addition depressed
erythropoesis resulting in secondary anaemia and the possible use 
of frequent blood transfusions particularly in haemodialysed 
patients further complicates interpretation of HbAx (102, 114).
(iv) Sex and Racial Differences
The effects of gender on Hh^ are controversial. Studies 
have suggested that HhA! levels are either higher in non-diabetic 
men (149) or alternatively lower in diabetic men than women 
(141, 150). Menstruation and psychosocial factors have been
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postulated to account for these differences, but most 
laboratories do not take gender into account when reporting 
levels, or quote sex dependent normal ranges. A further important 
factor is ethnically determined differences in Hh^ levels in 
normal populations with identical fasting blood glucose levels. 
Thus a statistically significant graded increase in levels of 
HtAx was noted by Gctno between Caucasian, Negroid and Arab 
populations (149). This needs confirmation particularly if 
similar differences can be demonstrated in the respective 
diabetic populations for given levels of glycaemia, and if this 
can be shown to have a bearing on the prevalence of vascular 
complications between different racial groups. For example, 
Asian diabetics in Natal have been shown to have a higher 
retinopathy rate than black Africans (151): is this reflected by 
a higher HbAx range in non-diabetic Asians?
Finally, HfcA-L itself may have a pathogenetic role. A higher 
oxygen affinity of HhAi compared to HhAo has been reported in 
vitro (110), and it has been hypothesised that the consequent 
tissue hypoxia leads to diabetic vascular complications (152). 
However in vivo studies have shown that at mean HhAi levels 
(labile and stable combined) of 11.6-12.2%, the higher oxygen 
affinity patterns for diabetics do not affect oxygen dissociation 
once values are normalised with respect to levels of 2,3, DPG and 
pH (110). A lack of correlation between HbAx and vascular 
complications in IDEM has been reported (7, 105, 135), which 
further reduces the likelihood that HhAi itself contributes to 
diabetic angiopathy. Nevertheless, non-enzymatic glycosylation 
of intra-erythrocytic proteins involved in nucleoside and
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nucleotide metabolism has been reported (153) and may be relevant 
to the role of disturbed red cell function (154) in microvascular 
disease.
h. GbyCOSYIATED SERUM PROTEINS
(a) Glycosylated (Glycated) Albumin (GSA)
Albumin is the predominant serum protein, circulating in a 
concentration of 35-50g/L and accounting for roughly 55-70% of 
the measured total serum protein.
Glycosylated serum albumin was first isolated from human 
serum in 1979 (155), and elevated levels were subsequently
demonstrated in diabetic serum (156, 157) although its existence 
in horse serum had previously been identified in 1956 (158). 
Human glycosylated albumin has been found to fom in vivo by the 
same chemical reaction as glycosylated haemoglobin with an 
initial non-enzymatic reaction to form a labile Schiff base, 
which thereafter undergoes Amadori rearrangement (155). 
Consequently other non-enzymatic glycosylated proteins have been 
confirmed to undergo the same process (159).
Unlike haemoglobin, the site of in vivo glycosylation of 
albumin has been demonstrated to be predominantly at the 525- 
lysine residue (160). Using 500mg of albumin applied to a large 
(2.5x18cm) affinity chromatographic column with a slow flow rate 
(6Qml/hour), 10-12% of freshly prepared radioactive human serum 
albumin was found to be glycosylated, of which 48% was found by 
cation exchange chromatography to take place at this site (160). 
Previous work suggested that like acetylation, seme glycosylation 
of albumin also takes at the 189-lysine and 199-lysine residues
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(155, 160). Bearing in mind that the half life of albumin is 19 
days, the rate of non enzymatic glycosylation of albumin has 
been estimated to be approximately 9 times greater than that of 
haemoglobin (160), whose half life is 120 days, and where 5-8% is 
normally glycosylated. This suggests that direct measurement of 
glycosylated albumin, in addition to reflecting shorter term 
improvements in glycaemia than glycosylated haemoglobin, may also 
be a more sensitive indicator of acute hyperglycaemic 
fluctuations than Hh^ (156, 161). As yet, there have been very 
few studies on the kinetics of human glycosylated albumin, 
although glycosylated total plasma protein levels were found to 
increase by 29% frcm basal levels after 48 hours of maintained 
hyperglycaemia (22mmol/L), using the Biostator in well 
controlled IDDM, in whan a maximum rise was noted by 12 hours, 
which thereafter plateaued (161). Animal work has also suggested 
that glycosylated serum albumin is formed more quickly than HbAx 
in response to hyperglycaemia, although the half life of GSA was 
not affected (162).
Early studies suggested that 6-15% of total serum albumin 
was glycosylated in normal human serum (155), but levels may be 
higher with different methods, and reference ranges of 11.6- 
19.5% have been quoted (120). More recently normal reference 
ranges of 1.4-5.4% have been quoted using affinity 
chrcmatography (163, 164), raising the possibility of variable 
bonding of GSA by different methodologies.
Methods for determining glycosylated (glycated) albumin (GSA)
1 Combined Chrcmatographic/Chemical Methods
49
The original description of human GSA (155) was based on an 
in vitro experiment where albumin was initially purified from 
fresh serum by affinity chrcmatography (165), and thereafter 
incubated with radiolabelled glucose. The albumin was then 
resolved into 2 fractions by ion-exchange chromatography using 
carboxymethylcellulose. Radioactivity in one recovered peak 
isolated the GSA fraction, and this was confirmed by the 
colorimetric assay for ketoamine protein adducts. This original 
method is quite iixpractical for routine clinical assessment but 
confirmed that both the chemical and physical properties of GSA 
allow identification of the molecule. Separate affinity 
chrcmatography and colorimetric methods have since been shown to 
correlate closely with one another (157).
A more elaborate combined approach was to purify albumin by 
a one step chromatographic procedure before measurement by a 
modification of the fructosamine assay (v.i.) (166). This time 
consuming method correlated with total plasma fructosamine 
(r=0.85) but is clearly impractical for routine use.
2. Chemical (colorimetric) method
GSA can be measured after isolation of albumin, by its 
capacity to release hydroxymethylfurfural after weak acid 
hydrolysis, which in turn reacts with thiobarbituric acid to 
yield a coloured product with maximal spectrophotcmetric 
absorbance at 443nm.
This method was employed in confirming the initial 
recognition of GSA (155), and was found reliably to detect 
increased levels in diabetic subjects (156, 157). Colorimetry 
has been reported to yield about 16% more GSA than the affinity
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chrcmatography method (157), but has the disadvantage for 
clinical use in that a preliminary affinity column procedure is 
required to isolate albumin. In addition despite standardisation 
of the method by optimisation of temperature and pH, free 
glucose was found to interfere with the assay leading to 
spuriously high results (167). This could even result f ran 
carbohydrate-containing packing materials in packages of glass 
tubes, necessitating acid washing of all glassware, in addition 
to dialysis or protein precipitation with trichloro-acetic acid 
to remove free glucose (v.i.) (167). The overall effect is that 
this method is too expensive and laborious for routine monitoring 
of diabetics.
3. Affinity Chrcmatography
As with HhAx, the capacity of boronic-acid gel to bind diols 
selectively allows separation of GSA frcm non-glycosylated 
albumin. One modification of the procedure is that after 
separation of the two fractions, the albumin content of each is 
measured by a variety of procedures of varying sensitivity. The 
recognition that albumin is principally glycosylated at the 525- 
lysine residue was made by a combined approach of affinity 
chrcmatography on boronate agarose gel followed by cation- 
exchange chrcmatography (160). It was stated that 10-12% of 
human serum albumin is glycosylated. More recent reports using 
boronate affinity chrcmatography have quoted normal ranges of GSA 
of 11.6-19.5% (120), 6.8-10.3% (168), 2.0-5.4%, (163), 1.0-2.0% 
(169), 1.4-5.2% (164), 0.43-1.19% (170), 1.3-2.0% (171), and even 
0-4.5% (172). The discrepancy in normal values seems to be due
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to an accumulation of methodological factors.
The affinity column method as first described showed that 
the size of the column and the rate of transfer of the sample 
through the affinity matrix had a definite inpact on the recovery 
of the glycosylated protein (116). The suggestion that GSA 
comprised 10-12% of albumin assessed by affinity chromatography 
utilised 500mg of serum albumin on a 2.5x18 cm column of boronic 
acid gel, with flow rate of 6Gml/hour (160). However other 
studies (120, 161-165, 168-172), have utilised commercial columns 
(Glycogel B, Pierce Ltd. or Glyc-Affin, Isolab Ltd.), where no 
more than 10-20mg of albumin is passed through 1ml of boronate 
gel at a flow rate of around 30ml/hour. The lowest yield of 
0.43-1.19% reported previously (170), highlights a source of 
error in following the instructions given by the manufacturers of 
kits. It is suggested that 200pl of undiluted plasma is applied 
to the column, which means in fact that 8-lQmg of albumin is 
added, but it has been shown that when more than 3mg of albumin is 
loaded, a lower percentage of glycosylated albumin results, 
possibly due to saturation at binding sites on the affinity 
matrix (163). This observation has also been made with regard to 
measurement of total glycated plasma proteins (173), but has yet 
to be confirmed by other laboratories with regard to GSA.
Another crucial aspect is the method employed to measure 
albumin in the two fractions after they have been separated by 
affinity chrcmatography. Dye binding, immunochemical and 
radioimmunoassay procedures are described. The main dye-binding 
method, which is reccmmended by the manufacturers of one of the 
commercial methods (Glycogel B, Pierce Ltd.) is Brcmocresol
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Green. It has been suggested that BCG overestimates 1 ow levels 
of albumin or leads to precipitation of BCG-albumin precipitates, 
and is non-specific if the reaction is not timed properly (164, 
174-176). This may be partly overcome by the use of Brcmocresol 
purple dye (175), but sensitivity in low concentrations and 
poor reproducability remain a problem (176), and limit 
interpretation of those studies which have measured GSA by dye 
binding methods (120, 168, 171, 172, 177, 178).
Irrmunochemical methods may be more precise and 
nephelometric (169, 172), immunoelectrophoretic (163), and 
immunoturbidimetric (164), methods have been employed. Albumin 
overloading of columns was a feature of the study comparing 
nephelcmetry and dye binding (169), which might invalidate the 
conclusion reached, and although sensitive, nephelcmetry is not a 
facility widely available in centrifugal analysers. Rocket 
immunoelectrophoresis is sensitive but requires an overnight 
incubation which could make it unsuitable for measuring large 
numbers of samples. The use of an immunoturbidimetric assay on a 
centrifugal analyser would provide the best compromise in terms 
of accessability, economy of effort and time as well as 
sensitivity. Initial work using this method suggested this was 
indeed precise with between-run coefficients of variation 
reported between 0.7-3.2% (164), and analytical recovery of 97- 
102%. Assuming the column is not overloaded with albumin a 
precise check on recovery of albumin applied to the column would 
confirm that GSA measured by boronate affinity chrcmatography 
reliably measured all cis-diol groups, effectively the stable 
ketoamine bond of GSA. A radioimmunoassay method for GSA
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measurement has also been reported (170), and would have similar 
potential to immunoturbidimetry, although its capacity for a 
clinical service has still to be established.
i i  nFkc
An HPLC method has been developed to measure the 
glycosylated lysine residue (furosine) after isolation of albumin 
by affinity chrcmatography (179). The method has been found to 
estimate glycosylation at 27% of the 525-lysine residues, and can 
be modified to measure GSA. Whilst reproducable and specific, it 
is impractical for routine clinical evaluation of glycaemic 
control.
CLINICAL ASPECTS OF GLYCOSYLATED ALBUMIN MEASUREMENT
The half life of serum albumin is approximately 17 days. 
It is possible that glycosylation enhances catabolism of albumin; 
this would be in keeping with clinical observations of GSA in 
response to fluctuating glycaemic levels (180), and the 
observations that glycosylation may enhance catabolism of other 
serum proteins (e.g. apolipoprotein AI in HDL) (181).
As stated previously, GSA may be a sensitive indicator of 
intergrated glycaemia over relatively short periods of time, as 
suggested by clinical studies showing established falls in 
response to improved glycaemic control within 1-3 weeks but not 
by 2-3 days (182, 183), whilst a rise to a similar degree 
consequent upon insulin withdrawal, was established for total 
glycosylated proteins (60% of which is GSA) after 12 hours (161). 
A similar pattern is suggested frctn data showing a rise in GSA
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following resection of an insulinana after 17 hours of 
hyperglycaemia, maximum at 15mmol/L (182). Thus, as for Hh^, 
the glycosylation of the specific protein seems to reflect 
hyperglycaemia disproportionate to hypoglycaemia.
The suggestion that glycosylation of albumin is enhanced in 
comparison to that of haemogloblin may give GSA a further 
advantage in inproved sensitivity over HhAi with regard to 
measuring minor degrees of glucose intolerance. This is 
suggested in studies where GSA and HbAi have been measured in 
diabetics and healthy controls, and where hardly any overlap was 
noted between the 2 groups with regard to GSA whilst a degree of 
overlap was apparent for HhAx (157, 163).
The disparity between GSA and HbAx is further suggested by 
reports of a poor correlation between the two measures in 
diabetics (r=0.58-0.62) (177, 178), although other studies (163, 
164, 180, 184) have shown a much closer relationship between 
these indices (r=0.78-0.91), reflecting the selection of healthy 
controls and predominantly non-insulin-dependent diabetics with 
stable glycaemic control. GSA certainly relates closely to 
glycosylated total serum protein levels in diabetes (v.i), and 
to a lesser extent with mean daily blood glucose (r=0.38-0.72) 
(178, 180) and post-prandial glucose levels (r=0.66) (184),
although there appears to be little relationship with either 
fasting (r=0.30-0.56) (178, 180) or random blood glucose (r=0.33) 
levels (163).
One small study of stable insulin-requiring diabetics has 
suggested that GSA and HbAi gave broadly similar interchangeable 
information (178). GSA was not found to be sensitive enough in
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this situation to reflect minor glycaemic fluctuations frcm week 
to week or month to month. However this is the only study of its 
kind to date, and the low normal range of GSA quoted and lack of 
information on precise methodology raises the possibility of 
column overload thereby leading to falsely low values of GSA.
However, it is clear that GSA may be more reliable than 
HhA! in reflecting glycaemic control in conditions of altered 
red cell turnover. This may apply in pregnancy where benefits 
of effective monitoring of short term glycaemic control are 
likely to occur, although albumin kinetics are also altered. GSA 
has indeed been reported to be a reliable indicator of 
glycaemia in cross-sectional (177, 185) and longitudinal 
surveys (171) of diabetic pregnancy, and to correlate inversely 
with the birth weight ratio, although again methodological 
considerations (171, 177) limit the conclusions to be drawn frcm 
such reports. GSA may also be clinically relevant if the drug 
binding capacity of albumin is significantly affected by 
glycosylation (186).
Finally the glycosylation of serum albumin may also have an 
important role in the pathogenesis of complications; it is less 
soluble than the non-glycosylated forms (187) and has reduced 
transglcmerular permeability and reduced urinary excretion 
compared to non-glycosylated albumin in diabetics with normal 
albumin excretion rates (AER) (188), although there was no 
preferential clearance once the AER was increased. However 
another study found precisely the opposite, demonstrating 
preferential excretion of all glycated serum proteins including 
albumin in diabetics with normal AER (189). The observation
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of increased amounts of GSA in the renal substance (190) has 
led to suggestions that glycosylation of albumin may lead not 
only to enhanced urinary albumin excretion, but may also 
contribute to diabetic nephropathy by damaging the glcmerular 
and tubular basement membranes leading ultimately to hyalinosis. 
The observation of mouse glcmerular basement membrane thickening 
following repeated injections of non-enzymatically glycosylated 
plasma proteins (predominantly albumin) (191) makes this 
hypothesis quite compelling and merits further investigation.
(b) Glycosylated (Glycated) total serum proteins (GTSP)
The total serum protein pool is comprised of many different 
proteins with varying physical properties and functions, and 
half-lives that vary from several hours to 3-4 weeks. Although 
albumin has been found to account for 55-70% of the serum protein 
concentration, other large molecular weight compounds - the 
globulins- also comprise a large percentage of the pool.
When GSA was first isolated, glycosylated fractions of IgM 
and IgG were also isolated in significant amounts (155). Since 
then non-enzymatic glycosylation of fibrinogen (192), 
apolipoproteins (181, 193), and acute phase reactant proteins 
(haptoglobin and alpha 2-macroglobulin) (194) has been described. 
The GSA component has been reckoned to account for 60-70% of the 
GTSP (187). Earlier studies required intricate procedures to 
separate pure GSA and therefore assessment of GTSP was also made, 
initially showing cross-sectional and longitudinal parallelism 
with GSA (171). The lack of prior separation of albumin
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obviously makes the measure of GTSP a more attractive procedure 
for routine assessment of intermediate glycaemic control. 
However the varying half lives of the different proteins could in 
theory affect the utility of GTSP as a measure of glycaemia when 
control is changing. For example, whilst the half-life of 
albumin may not alter with glycosylation, glycosylated 
apolipoprotein B (as the major apoprotein of low density 
lipoprotein (LDL)) has been found to have a prolonged half-life, 
whilst animal studies have suggested the opposite for Apo AT, the 
predominant apoprotein of high density lipoprotein (HDL) (181, 
193). Although the conclusions of earlier studies can be 
questioned in the light of methodological problems, the 
introduction of the fructosamine assay as a measure of GTSP 
(v.i.) may clarify any differences between GSA and GTSP 
measurement in IDEM during conditions of fluctuating control.
Methods for measuring GTSP 
JL Chemical (colorimetric) method
The capacity of ketoamine bonds to release HMF after weak 
acid hydrolysis has also been employed to measure GTSP.
An initial report suggested the method was sensitive enough 
to separate fully diabetic and healthy populations and to 
correlate not only with GSA (r=0.99), but also HhAx (r=0.79) and 
fasting blood glucose (r=0.71) (187), but it later became clear 
that this relationship was artefactual. The failure to remove 
free glucose was found to interfere with the assay, accounting 
for an elevation of GTSP of 2-3 times that obtained after 
overnight dialysis of the samples of diabetic subjects (195).
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When this correction was carried out, GTSP levels in 
predominantly insulin-treated diabetics were less clearly 
separated frcm healthy controls, and less precise correlations 
were observed with Hh^ (r=0.51-0.74) (195-197), and with mean 
blood glucose levels (based on single measurements on 8 or more 
occasions over 2 years) (r=0.58) (196). An additional
significant correlation with the clinical variance of these 
glucose values and the M values suggested that GTSP might also 
reflect glycaemic instability (196).
The methodology involved in colorimetric estimation of GTSP 
has been criticised, since careful standardisation of the assay 
is required, with either dialysis (195) or precipitation with 
trichloroacetic acid (TCA) (198) being employed initially to 
remove free glucose. It is still not known however whether these 
methods are equally effective and whether the colour yield after 
incubation with TCA is similar to that achieved with dialysis 
(102). The use of a sodium borohydride blank, whilst fully 
reducing the ketoamine bond within 15 minutes, and the time and 
temperature dependent hydrolysis, are further time consuming 
components, although autoclaving at 121°C for 1 hour has been an 
effective way of shortening the latter procedure (199). The use 
of purified 5HMF as a standard allowed for variable batch 
hydrolysis or evaporation of the sample which led to a precision 
of no better than 8% within batch and 12% between batch 
variation. Later use of fructose as an alternative standard 
optimised the assay to produce intra and inter assay coefficients 
of variation of 4.3% and 8.6% respectively (199). Although 
automation of the method has been described, it is generally felt
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that the colorimetric measure of GTSP is unsuitable for routine 
use in a clinical laboratory, particularly as poisonous 
chemicals (oxalic acid and TEA) are employed in the method 
(102).
2. Protein Precipitation
This method measures both enzymatically and non 
enzymatically bound glycoproteins and involves precipitation of 
protein-bound-hexose using perchloric acid initially, with the 
precipitate then being measured colorimetrically after the 
addition of sulphuric acid (194). The levels in diabetics 
correlated with HhAx (r=0.41) but not with fasting blood glucose 
(r=0.25), and correlated with levels of haptoglobin (r=0.59), 
which was elevated in diabetics (194). The method is unsuitable 
to monitor glycaemic control as it is too time-consuming and it 
measures enzymatically derived glycoproteins in addition to non- 
enzymatic glycosylprotein.
3. Affinity Chrcmatography
As with GSA and HhAx, the m-aminophenyl-boronate gel has the 
capacity to bind selectively the cis-diol groups of all 
glycosylated serum proteins. A specific eluant then ensures 
removal and the non-glycosylated and glycosylated fractions can 
be measured separately to give an estimate of the percentage of 
GTSP. The method has been shown to distinguish between non- 
enzymatically glycosylated proteins and enzymatically linked 
glycoproteins (200).
Two ccmmercial systems (Glycogel, Pierce and Warriner and
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GlycAffin, Isolab) were used in initial assessments. It was found 
that, as with GSA, the Glycogel method was precise (within batch 
co-efficient of variation (CV) 4%, between batch CV 5.3-6.2%), 
assuming that precautions were taken to ensure the column was not 
overloaded with more than 2mg of total serum protein (201). 
Overloading eventually led to reduced yields of GTSP in diabetic 
and healthy samples, but unfortunately the direct method 
recamiended by the manufacturers of Glycogel for protein 
measurement of the glycosylated and non-glycosylated aliquots 
without a reagent is insensitive unless large amounts of protein 
(10-15mg) are applied to the gel (201). The introduction of the 
Bradford method using the Biorad protein assay reagent is 
sensitive enough to measure the small amounts of GTSP, but only 
if 2mg is added to the column (201). However several of the 
clinical reports which followed have failed to take these 
modifications into account.
The other commercial method (GlycAffin, Isolab) 
unfortunately used the Cocmassie Brilliant Blue-G-250 dye to 
measure protein which was also too insensitive to detect all the 
GTSP (120). This commercial method has been assessed further 
and it was suggested that free glucose had the capacity to 
interact with the boronic acid binding sites on the gel, 
necessitating either dialysis or a preliminary chromatographic 
phase (G25 Sephadex) to remove free glucose (168). Failure to do 
so led to a false yield of GTSP (25-30% increase) (168). Thus 
the Isolab method would appear to be unsuitable for general 
clinical use for several reasons: (1) the preliminary seperation 
of glucose by chrcmatography leads to a marked reduction of
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analytical recovery of total protein (57%) in addition to 
introducing an additional time consuming phase to this procedure. 
Overnight dialysis of free glucose is also time consuming and is 
not interchangeable with Sephadex chrcmatography. (2) the method 
was temperature dependent with poor precision (between-run CV 
18%) (3) the addition of large amounts of protein to the column 
and the consequent measurement by Coanassie Blue may have 
contributed further to the poor precision.
These two independent affinity chrcmatography methods seem 
therefore to have quite different performance characteristics 
and the suprising difference in the normal ranges of GTSP with 
Glycogel (3.0-10.3%) and GlycAffin (11.5-16.2% in one report and 
8.8-11.6% in another) would appear to confirm this.
The Glycogel affinity procedure in insulin-treated diabetics 
correlated with HhAx levels (r=0.82) but not with randan blood 
glucose values (r=0.38) (201). However the close relationship 
with the colorimetric (TBA) assay (r=0.70) (201) indicates that 
both assays measured similar glycosylated moieties although it 
was suggested that the affinity method might be more accurate. 
It was noted that unlike early claims when GTSP was measured by 
colorimetry (196), the discrimination between diabetic 
individuals and healthy controls was in fact less precise than 
for HhA-! (201). A similar degree of overlap between normal and 
diabetic GTSP ranges has since been confirmed with Glycogel 
columns, when a virtually identical correlation between HhAx and 
GTSP was observed (r=0.81), although perhaps suprisingly GTSP 
also correlated closely with fasting plasma glucose (r=0.75) 
(202). This probably reflects the predominance of non-insulin
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dependent diabetics studied confinning previous observations 
(197), and thereby reduces the relevance of the data to IDEM.
When the Glycaffin column was used (168), GTSP correlated 
with GSA. (r=0.83) although the relationship with HbAi was less 
clear (r=0.81 in one study (120) and r=0.37 in another (168)). 
No data was provided frcm these studies on the relationship 
between GTSP and random blood glucose levels.
2L HPLC
The production of furosine frcm non-enzymatically (e-N-
lysine) glycosylated proteins by acid hydrolysis can be measured 
by HPLC and has been reported by Schleicher et al (203).
Furosine (lysine-glycosylated serum protein) levels correlated 
with HhA-L (r=0.79) and with mean blood glucose (r=0.88) in a 
mixed group of insulin-dependent and non-insulin-dependent 
diabetics. A longitudinal survey of 10 insulin-dependent 
diabetics suggested that furosine was a more sensitive indicator 
of glycaemia than HbAx (203).
CLINICAL ASPECTS
The essential question about the GTSP assay is whether it
has the ability to detect short term fluctuations in glycaemia.
Using the colorimetric method, it was reported that one week of 
improved glycaemic control (mean blood glucose falling frcm 14.9 
to 10.7mmol/L) was accompanied by a 34% fall in GTSP (p<0.01) 
which was more marked after 2 weeks, when mean blood glucose 
levels fell further (204). In contradistinction, when
hyperglycaemia (22mmol/L) was induced and maintained in 4 well
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controlled subjects with IDEM, an increase of 29% in GTSP was 
noted within 12 hours which did not change thereafter (161). In 
clinical practice, the measure of a conglomerate of proteins to 
determine short term glycaemic control could be of limited use if 
glycosylation of acute phase reactants during periods of 
infection/inflamation or ketoacidosis gave a yield of GTSP 
disproportionate to the overall ambient glycaemia. This has been 
demonstrated in one study where marked rises in GTSP (measured by 
colorimetry) were apparent after 3 days in diabetics with minor 
intercurrent infection (205).
However the opportunity to reflect short term changes in 
glycaemia over a period of 12 hours to 1 week is likely to be a 
useful addition to direct glycaemic measures and the use of HhAx 
in the assessment of carbohydrate metabolism in IDEM. The 
colorimetric method has even been shown to be effective in 
measuring GTSP in stored filter paper (v.i.) (206), which has 
obvious potential for validation of glycaemic control at heme, 
particularly when diabetics live in remote areas. The filter 
papers could then be posted to the hospital for assessment either 
prior to patients' visits or with a view to suggested 
modifications in treatment being made by phone without direct 
patient contact.
As was the case for GSA, the GTSP assay should have 
advantages over HhAi in reflecting glycaemic control under 
conditions of disordered red cell turnover. The most obvious 
example is in diabetic pregnancy where GTSP has been shown to 
correlate with maternal glycaemic control and fetal birth weight 
(177). Longitudinal assessment in gestational diabetic pregnancy
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showed the capacity of GTSP to differentiate normal pregnancies 
frcm those who later developed gestational diabetes by 11-14 
weeks, although thereafter GTSP levels decreased to early 
pregnancy values (207). In diabetic pregnancies, improved 
glycaemic control has been demonstrated to lead to a 50% 
reduction in GTSP after 4 weeks, whilst it took 12 weeks for 
similar changes to occur in HhAx (171). Unfortunately these 
studies followed the manufacturer's (Pierce) instructions, 
thereby inadvertantly overloading the affinity column with 
protein, which limits interpretation of these data.
In addition to the use of GTSP measures to reflect glycaemia, 
interest has focussed on a potential pathophysiological role of 
GTSP in the development and progression of diabetic nephropathy. 
This was first suggested when repeated intravenous injections of 
GTSP were found to produce pseudodiabetic renal glcmerular 
changes in mice (191). Glycosylated proteins and peptides have 
been detected in renal tissues frcm humans with diabetic 
nephropathy (190) and also in their urine (188, 189, 208). The 
suggestion has been made that GTSP excretion is enhanced in 
diabetics without incipient or established nephropathy (189). 
The loss of selectivity of GTSP excretion with the development of 
microproteinuria suggested that the early changes could be related 
to the development of nephropathy. These findings have recently 
been challenged, and in fact when urinary GSA was measured by a 
highly specific method, exactly the opposite finding was recorded 
in diabetics with normal albumin excretion rates (AER) (188). 
However both these reports (188, 189) suggested that early changes 
in ionic change following glycosylation of either the renal
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basement membrane or filtered macrcmolecules may be implicated in 
the development of nephropathy.
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(C). FRUCTOSAMINE
Serum fructosamine measurement is a further colorimetric 
method designed to estimate all ketoamine bonds and therefore is 
also a measure of GTSP. I will discuss it separately as its 
development has superseded that of CTSP and it has now become 
widely used, perhaps prematurely, because of it’s simplicity 
rather than its clinical utility.
The assay is based on the capacity of stable ketoamine 
bonds to act as a reducing agent in an alkaline solution. The 
method was first described in 1982 (209) and is a colorimetric 
procedure where the colour development secondary to reduction of 
the dye NET (nitroblue tetrazolium) is measured 
spectrophotcmetrically. Although the method has now become 
automated (210, 211) and widely used (212), the actual mechanism 
of the reducing activity has remained obscure and the nature of 
the active species involved in dye reduction conjectural. It 
has been suggested that superoxide free radical autoxidation frcm 
ketoamine bound glucose is involved in the reduction of NET and 
this has been supported by the observation of a diminution in 
fructosamine levels if the assay was carried out in the presence 
of superoxide dismutase (SOD), a potent inhibitor of superoxide 
activity (213). If this hypothesis is sustained then the 
fructosamine assay may be subject to modification in the 
presence of substances which can alter the serum oxidant 
activity, such as serum caeruloplasmin, which acts as a scavenger 
for SOD (214), and which may increase during pregnancy or with 
the oral contraceptive (215). The suggestion that
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microangiopathy leads to the production of free radicals (213) 
would also increase the potential for excessive reduction. 
Other low molecular mass compounds such as glutathione and 
ascorbic acid in significant amounts have been reported to 
elevate fructosamine levels falsely (209), and the preservatives 
fluoride and EDTA can reduce the yield, thereby making serum 
rather than whole blood necessary for fructosamine estimation in 
clinical practice (216).
It has only recently been demonstrated that fructosamine 
measures all serum glycated proteins (217), although fructosamine 
activity was greater after in vitro incubation of glucose with 
albumin when compared to alpha, f3 or gamma globulin protein 
fractions (218). This suggests that albumin glycosylates more 
freely. Albumin has a longer half life than the other protein 
fractions and GSA may therefore give disproportionate weighting 
over the other proteins in the fructosamine assay. However it is 
now quite likely that the fructosamine assay does not measure 
labile (Schiff base) glycated products, as evidenced by the lack 
of NET reduction by glucosylpiperidine, the Schiff base of 
glucose and piperidine (209), and the failure for frtictosamine 
levels to rise after a test meal in diabetics or following the 
induction of hyperglycaemia in vitro (219). Earlier work 
demonstrated that the fructosamine colorimetric reaction was not 
linear at higher concentrations of the standard 
(deoxymorpholinofructose) (211), suggesting the system was either 
saturated or less sensitive in response to severe hyperglycaemia.
The majority of these previous considerations are 
theoretical. In practical terms the method also has
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limitations. It currently relies on the use of the synthetic 
ketoamine IMF (1-deoxy-morpholino-D-fructose) in an albumin 
solution for standardisation. Variable batch activity of the 
standard has been reported leading to vastly different normal 
ranges (220). These have varied frcm as lew as 0.96 - 1.12mmol/L 
(211) to as high as 2.37-4.05mmol/L (219) and one laboratory has 
quoted a wide reference range of 1.23+0.62mmol/L (166). The use 
of pooled human serum has been suggested as an alternative 
standard (220), but it would seen prudent that both IMF and 
individual laboratory generated serum pools are measured in each 
assay run to assess reproducability, which the ccmmercial 
method currently available (Roche Products, Switzerland) quotes 
at around 3% . One further modification is to use a pH of 10.3 
rather than 10.8 for NBT reduction as originally suggested (209) 
since the lower pH has been found to increase the yield of 
fructosamine (221-224).
There is still controversy as to whether the clinical status 
of the diabetic patient can affect the fructosamine level, and 
most debate has centred around the effects of differing levels 
of serum albumin. Whilst most early studies did report a 
correlation between serum fructosamine and albumin levels (210, 
211, 225), clinically relevant significant reductions in
fructosamine levels were only encountered in hypoalbuminaemic 
subjects, in whom a correction factor was suggested to be 
appropriate (226). Since then there have been reports of a
diurnal variation in serum fructosamine and albumin (227), and a 
routine correction for the serum protein concentration has been 
advocated (226-229). An additional component to the diurnal
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variation in fructosamine independent of changes in serum 
proteins has also been demonstrated (227), which might imply the 
need for accurate timing of repeated estimations, although most 
recently it has been clearly shown that up to 50% of the NBT 
reduction is due to an as yet unidentified substrate, independent 
of glycosylated proteins (230). These criticisms are still 
refuted by the original proponents of the method who have 
reaffirmed that clinically relevant alterations in fructosamine 
are not apparent in diabetics who were normoalbuminaemic or who 
had proteinuria less than lg/L (231). However it is recognised 
that other pathological states leading to disturbed protein 
turnover such as thyroid disease or parenteral nutrition, do 
modify fructosamine levels (232, 233). Uraemia, per se, does not 
contribute to significant alterations in fructosamine in the 
absence of hypoalbuminaemia (211, 225). Likewise, moderate 
hyperlipidaemia is said to have little impact on the assay 
(234), although the estimation of fructosamine in frankly 
lipaemic sera may benefit frcm prior delipidation (209, 227).
Clinical Utility
As a measure of all glycated total serum proteins (GTSP), 
the length of time over which fructosamine gives an integrated 
measure of glycaemic control cannot be stated with certainty, 
although the average half life of GTSP is probably around 20-30 
days (187), and it has been proposed that fructosamine levels 
provide an index of glucose control over the prevailing 1-3 weeks 
(225).
Currently, fructosamine tends to be canpared with HBAi, and
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has been found to correlate fairly well (r ranging frcm 0.70- 
0.79) in independent studies of healthy controls and mixed groups 
of diabetics (166, 202, 211, 225, 233), although variable
correlations with stable HbAx of r=0.37 (219), r=0.61 (210) and 
r=0.82 (235) have been described when only insulin dependent 
diabetics were studied. The manufacturers of the ccmmercial 
fructosamine kit quote a correlation coefficient as low as 
r=0.60 (216) if Hh^ is measured by HPLC (high pressure liquid 
chrcmatography) and as high as r=0.90 if ion exchange 
chrcmatography was used to determine HbAx . Perhaps surprisingly, 
the correlations with GTSP measured by the TEA. colorimetric 
method has been reported to be as low as r=0.58 (209), although 
this was attributed to extreme imprecision of the 
thiobarbituric acid (TEA) method, as evidenced by a small poorly 
defined difference between duplicate test and blank specimens. 
More recently correlation coefficients between fructosamine and 
GTSP have been reported to range between 0.82 and 0.92 (202, 216, 
219, 233), when GTSP was measured by either colorimetric or 
affinity methods. The relationship between fructosamine and GSA 
has also been reported to be a close one with correlation co­
efficients quoted between 0.85 and 0.90 (202, 219, 233, 236), 
although it should be stressed that normal subjects and 
predominantly type II diabetic data were used in these analyses.
A close relationship with fasting blood glucose has been 
reported with correlation coefficients ranging between 0.74-0.82 
in mixed groups of diabetics and healthy controls (202, 209, 216, 
225), although as low as r=0.38 in a study of 45 insulin-treated 
diabetics (219). The correlation coefficient of r=0.73 between
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fructosamine and the 2-hour post-prandial blood glucose values in 
a study of type II diabetics and healthy controls (225), 
effectively reflects the fasting blood glucose values in these 
individuals, and subsequent reports have confirmed the relative 
insensitivity of fructosamine (235) to reflect the more marked 
post-prandial glycaemic excursions seen in IDEM, as gauged by the 
mean amplitude of glycaemic excursions (MAGE). A closer 
correlation with mean blood glucose and fructosamine values in 
insulin-dependent diabetics has however, been recorded (235).
Longitudinal studies designed to assess the temporal 
response of fructosamine to differing glycaemic levels are few 
and far between. An initial report on 6 insulin-treated diabetics 
suggested that despite a 48% fall in mean blood glucose and a 38% 
fall in fasting blood glucose, fructosamine levels only fell 
by 8% in the first week and that a 16 day lag was observed in one 
subject before the normoglycaemic levels attained by 3 days were 
paralleled by normal levels of serum fructosamine (225). In fact, 
when glycaemic control was inproved over 3 weeks in a group of 7 
non-insulin dependent diabetics, fructosamine was found to be 
insensitive as a marker of this (p=0.27) (237), with no
significant change developing till at least 4 weeks, suggesting 
that in practice fructosamine does not have the capacity to 
reflects accurately improved glycaemic over a period of less than 
3 weeks. However as with other measures of glycosylated 
proteins, a hyperglycaemic episode of abrupt onset is 
accompanied by a significant (p=0.001) rise in fructosamine after 
1 week (237). An anecdotal report of the response to effective
insulin treatment suggesting that fructosamine falls by 1-3
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weeks in response to improved glycaemic control (202) has yet to 
be confirmed in properly designed studies.
Fructosamine has also been studied as a screening test, for 
gestational diabetes (238) and as an alternative to glucose 
tolerance tests (225). A reasonable sensitivity for these 
diagnoses (85-89%) was reported with high specificity (5-9% false 
positives) but further assessment is needed.
At present therefore fructosamine appears an attractive 
cheaper quicker alternative to glycosylated haemoglobin with 
which it compares closely both in cross-sectional and 
longitudinal evaluations. Despite claims that it measures all 
the GTSP, variable correlations with GSA and GTSP and the lacik of 
a clear temporal relationship of the time span seen with GSA in 
response both to hyperglycaemic and hypoglycaemic excursions 
suggests that it gives complementary rather than equivalent 
information to GSA as an indicator of prevailing glycaemic 
control. Longitudinal studies of GSA, HtAx, and fructosamine in 
IDEM are needed to clarify these points. In addition
methodological considerations, in particular the need to correct 
for the prevailing serum protein concentration, and 
identification of all substances contributing to NBT reduction, 
must be taken into account if the assay is to be used to assist 
in the clinical management of IDEM.
1:2 LIPID METABOLISM
Disordered lipid metabolism is a constant feature of both 
insulin-dependent and non-insulin-dependent diabetes mellitus.
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The excess of cardiovascular mortality in all forms of diabetes 
is often attributed to hyperlipidaemia although epidemiological 
studies do not in fact bear this out. Although it is possible 
that lipids accelerate the development of atherosclerosis by 
virtually the same mechanism in IDEM and NIDEM, clear differences 
in the pattern of lipid and lipoprotein abnormalities are 
apparent between the two. Unfortunately most epidemiological and 
clinical studies of lipids in diabetes have pooled all diabetics 
regardless of their endogenous insulin status. Other factors 
such as age, gender, tobacco and alcohol consumption, relative 
amounts of exogenous and endogenous insulin, the degree of 
insulin resistance, body mass index, diet, ambient glycaemic 
control, the extent of diabetic renal disease and genetic 
influences all have a bearing on lipid metabolism and should be 
taken into account.
Although hyperlipidaemia may accompany IDEM, it is becoming 
clearer that diabetes may also exert a more subtle qualitative 
influence on lipids and lipoproteins. Prior to reviewing the 
published work on the quantitative and structural alterations of 
lipoproteins and their relevance to atheromatous disease in IDEM 
it is worth outlining current knowledge about normal lipid 
metabolism to put these changes in IDEM into perspective.
Lipid Metabolism in health
Lipids are a heterogeneous group of compounds which are 
grouped together by virtue of their solubility in organic solvents 
and their insolubility in aqueous media. They can be divided 
into two broad groups: the small rapidly-turning over molecules
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involved in immediate fuel supply and the larger molecules 
involved in lipid transport and storage.
The small lipid molecules are non-esterified (free) fatty 
acids (FFA), glycerol and ketone bodies. FFA are produced by 
hydrolysis of triglyceride in adipose tissue and circulate as an 
energy source for liver and muscle. Glycerol is also formed by 
lipolysis in adipose tissue. It cannot be re-esterified and more 
than 90% is taken up for hepatic metabolism. Ketone bodies are 
formed as by-products of the Kreb's cycle in the liver and 
circulate to be available as a minor energy source for muscle 
after oxidation. Levels of all these molecules are increased in 
the circulation in conditions of enhanced lipolysis, and their 
half lives can be measured in minutes.
The larger lipid molecules are cholesterol, phospholipid and 
triglycerides. Half-lives of triglycerides vary frcm 6-12 hours 
whilst cholesterol has a half life varying between three and a 
half and six and a half days. Free cholesterol is the form of 
sterol relevant to membrane formation and hormone and bile acid 
synthesis whereas cholesterol ester predominates in the 
transport and storage forms of cholesterol. These larger lipid 
molecules are derived from either a dietary source or arise de 
novo from synthesis at the intestinal, hepatic or adipose tissue 
level. Lipoproteins have evolved to facilitate transport of 
these water-insoluble lipids in an aqueous medium (plasma).
Plasma Lipoproteins
Four major classes of lipoproteins are defined, based on 
either their electrophoretic mobility or their physical 
characteristics (flotation density determined by either ultra-
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centrifugation or precipitation methods) (Table 1). All 
lipoproteins originate in the liver and/or intestine and appear to 
have a pseudcmicellar structure. Cholesterol esters and 
triglycerides are neutral but maintained in a soluble stable form 
by their interaction with the more polar apolipoproteins and 
phospholipids. Unesterified cholesterol is also present and is 
intermediate in polarity. The outer surface of lipoproteins is 
composed of the more polar apolipoproteins, unesterified 
cholesterol and phospholipids, thereby protecting the polar 
constituents from the aqueous environment.
Chylomicrons
These molecules have been characterised as large and small 
triglyceride - rich particles secreted by the intestine, and are 
the major transport form of dietary fat. Digested dietary fat is 
presented to the intestinal mucosa as monoglycerides and fatty 
acids which serve as precursors for triglyceride synthesis. The 
chylomicron molecule is formed by the combination of resynthesised 
triglycerides with phospholipids (synthesised de novo or formed 
from reacylation of absorbed lysolecithin), specific apoproteins 
synthesised during fat absorption or acquired in the lymph (apo B, 
apo A I, apo A IV, apo C and apo E) and cholesterol. The 
cholesterol is derived from absorption of sterol from the
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TABLE 1
Composition and classification of the major human plasma 
lipoproteins (Percent of Dry Weight)
Chylomicrons VLDL LDL* HDL
Density (g/ml) <1.006 <1.006 1.006-1.063 1.063-1.21
Electrophoretic 
Mobility Origin
Triglyceride (%) 85-90
Cholesterol 
Ester (%) 3-4
Cholesterol (%) 2-3
Phospholipid (%) 6-8
Protein (%) 1-2
* LDL is often subclassified: IDL 
and LDL2 1.019-1.063g/ml.
PRE BETA BETA ALPHA
50-55 6-10 3-6
14-16 35-45 12-18
6-8 8-12 2-4
16-20 20-25 25-30
8-10 18-22 47-52
(11^ ) density 1.006-1.019g/ml
(Frcm: Simmons LA and Gibson JC (239))
intestinal lumen, de novo mucosal synthesis and from circulating 
lipoproteins. Chylomicron molecules are then released into the 
mesenteric lymph and thereafter into the general circulation 
where they acquire apo E and apo C frcm HDL (high density 
lipoprotein). This enriches the chylomicron with apo C II, the 
co-factor for enzymatic removal of triglyceride.
Very low density lipoproteins (VLDL) : These molecules have a 
transport function for endogenous triglycerides, principally 
derived frcm the liver, although an intestinal derived VLDL is 
apparent in post-absorptive and fasting states. The predominant 
hepatic VLDL contains apo B and apo E derived frcm the liver 
whilst apo C and to a lesser extent apo A I are acquired in the 
circulation.
Low density lipoproteins (LDL): These molecules are the major 
lipoproteins for cholesterol transport to tissues and in general 
contain about 80% lipid and 20% protein. The more lipid rich 
class, IDL (intermediate density lipoprotein), is generated 
through progressive metabolism of the core triglycerides of VLDL. 
Cholesterol esters and triglycerides are the major lipid 
components, whilst apo B and to a lesser extent apo C and apo E 
make up the protein content of IDL. . The turnover of apo B in 
VLDL and LDL is identical which suggests that both VLDL and IDL 
are quantitatively converted to LDL, although there may be a 
capacity for independent clearance of VLDL and IDL and for de 
novo hepatic synthesis of IDL and LDL in certain circumstances. 
LDL2 comprises less triglycerides, apo C and apoE than IDL and is
78
therefore a smaller denser molecule.
High density lipoproteins (HDL): High density lipoprotein is
likely to be responsible for reverse cholesterol transport frcm 
peripheral sites to the liver and to other sites of degradation 
and excretion. At present this has not yet been conclusively 
established in man. HDL is synthesised both in the liver and the 
intestine in the form of disc shaped particles (nascent HDL). 
The molecule contains about 50% lipid (predominantly cholesterol) 
and 50% protein. The major apoproteins apo A I and apo A II are 
synthesised by both liver and intestine, although predominantly 
for the HDL found in the mesenteric-lymph, whilst nascent 
hepatic HDL in seme species contains primarily apoE. Compared 
to plasma HDL both intestinal and hepatic nascent HDL are 
enriched with phospholipid and unesterified cholesterol. The 
major phospholipid species is phosphatidylcholine (lecithin) and 
as a reactant in the enzymatic reaction catalysed by lecithin 
cholesterol acyl transferase (LCAT), is involved in plasma 
cholesterol esterification. Apo A I in HDL has been found to 
activate the LCAT reaction. HDL has been separated into 2 
subclasses, HDL2 (1.063-1.120g/ml) and HDL3 (1.120-1.210g/ml). 
HDL2 accounts for much of the interindividual variance in HDL 
cholesterol levels, and particles are larger and contain more 
unesterified cholesterol and triglyceride than HDL3. In 
addition the Apo AI/A II ratio and apo C content may be greater 
in HDL2 than HDL3. The Apo C is transferred frcm HDL to 
triglyceride rich lipoproteins to control their rate of lipolysis
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and possibly hepatic uptake.
L(p)a Lipoprotein: This lipoprotein class contains predcminately
apo B in addition to albumin and apo L(p)a. It's density (1.05- 
l.lOg/ml) means that it floats partly in the LDL2 and partly in 
HDL2 range. Its function is unknown but its presence has been 
related to the development of coronary heart disease.
Lp-X lipoprotein: This lipoprotein has a flotation density
similar to LDL, and is characterised by a high proportion of 
unesterified cholesterol and phospholipid and a low protein 
content of apo B, apo C and albumin. It is found in patients 
with biliary obstruction and may arise due to incomplete 
modification of nascent HDL by LCAT.
The Apolipoproteins: These are the lipid-free protein components
of plasma lipoproteins, obtained after treatment with organic 
solvents or detergents. Not all proteins contained within 
lipoproteins necessarily have a role in lipid transport, as 
evidenced by serum amyloid A proteins which are acute phase 
reactants, and are detected bound to plasma HDL. The airphipathic 
structure of the apoproteins with water soluble and insoluble 
amino acids situated on different regions permits the 
apoprotein to act as soluble stable structures. Their 
distribution varies through the lipoprotein classes (Table 2).
80
TABLE 2
Apolipoprotein canposition of the lipoprotein classes
Apolipoprotein* Chylomicrons VLDL LDL HDL
AI <5% <5% Trace >15%
All <5% <5% Trace >15%
AIV <5% Trace Absent > 5%
B >15% >15% 90% < 5%
Cl 10% 10% Trace < 5%
CII 15% 10% Trace < 5%
cm 15% 50% Trace < 5%
D Unknown Minor if 
present
Trace < 5%
E 5% >10% < 5% 40%
* Refers to % of total protein
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Apolipoprotein AI: This is the major protein carponent of HDL. It 
is composed of a single chain of 243 amino acid residues, and 
exists in several isoforms. Apo AI is a potent activator of LCAT, 
the enzyme responsible for cholesterol ester formation. The 
relative contributions of the hepatic and intestinal sources of 
apo AI are ill-defined. More than 90% of plasma apo AI is 
associated with HDL, less than 1% with VLDL, and no more than 10% 
with the lipoprotein free plasma fraction.
Apolipoprotein All: This is also a major constituent of human 
HDL, accounting for about one third of the total protein and 15% 
of HDL mass. It exists as a dimer of two identical chains of 77 
amino acid residues. The specific role of apo A II in lipid 
transport is unclear.
Minor HDL Apolipoproteins: The designation apo A III or apo D has
been applied to a protein which comprises less than 5% of the HDL 
apoprotein. It was originally though to activate LCAT but this 
has not been confirmed. Apo A IV is present in the HDL of seme 
species, but is found predominately in the lipoprotein free 
fraction of plasma. It is synthesised by both liver and 
intestine and may be cyclically reincorporated into chylomicrons. 
Other proteins provisionally called apo F and D-2 have been 
identified in human plasma HDL but their function is still 
uncertain.
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Apolipoprotein B: Apo B is a major constituent of chylomicrons, 
VLDL and LDL, comprising more than 90% of the protein of LDL. 
Two different molecular weight structures of apo B . are 
identified: apoB 100 is synthesised primarily in the liver whilst 
the smaller fom apo B 48 originates frcm the small intestine. 
Immunological differences between these large and small varieties 
of apo B probably exist. In addition to a role in chylomicron and 
VLDL synthesis, apo B is critical for receptor-mediated LDL 
uptake. L(p)a, VLDL and chylomicrons together account for no
more than 10% of plasma apo B in health.
Apolipoprotein C I: Apo C I ccnprises 10% of VLDL and 2% of HDL
protein, binds phospholipid and activates LCAT. It is a single 
chain of 55 amino acid residues.
Apolipoprotein C II: Apo C II activates lipoprotein lipase, and 
accounts for 10% of VLDL, 1-2% of HDL2 and less than 1% of HDL3 
protein. It is a single chain protein of 78 amino acid residues, 
and isoelectric heterogeneity of apo C II has been noted.
Apolipoprotein C III: This accounts for 50% of the protein in 
VLDL and 2% of that in HDL. It is a single chain 79 amino acid 
residue structure, occurring in at least three polymorphic forms 
according to the number of sialic acid residues at the end of the
carbohydrate chain. About 25% of the Apo C III is in VLDL and 60%
in HDL. Whilst lipoprotein lipase activity is diminished in 
vitro it is doubtful whether this is a physiological property of
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Apo C III in vivo.
Apolipoprotein E: This is a component primarily of HDL, IDL .and
LDL, and it comprises 10-20% of VLDL protein. It usually arises 
as a single chain and extensive heterogeneity has been defined by 
isoelectric focussing. Its structure is coded for by three 
codcminant alleles (e2, 63 and 64), located on chromosome 19. 
Six potential phenotypes are therefore described (Apo E2/2, E2/3, 
E3/3, E3/4, E4/4, E2/4) and differences in sialic acid content 
may affect the isoelectric detection. A specific hepatic 
receptor for Apo E which preferentially binds the more basic 
isoforms (expression of 63 and 64 alleles) has been identified, 
and their recognition may provide a link in the normal conversion 
of VLDL remnants to LDL. Apo E is synthesised by the liver and 
levels correlate closely with those of serum triglycerides. 
Variable expression of the apo E phenotype accounts for up to 10% 
of interindividual variation in levels of cholesterol, 
predominately LDL cholesterol, with expression of an 62 allele 
associated with low levels, and correspondingly higher levels in 
those who express the 64 allele.
Lipoprotein Metabolism
Anabolism: Absorption:- Dietary triglyceride leads to a post­
prandial plasma peak 3-5 hours after a meal. The chylanicron 
triglyceride generated is normally rapidly metabolised within 15 
minutes of absorption. If dietary fat constitutes 22-40% of the 
total calorie load, plasma cholesterol levels are unlikely to be 
affected, although the quality of dietary fat may exert an effect
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on both cholesterol and triglyceride levels. Dietary 
polysaturated fats have been reported to decrease plasma lipids 
possibly secondary to altered intestinal lipoprotein 
degradation. Although plasma cholesterol levels are relatively 
stable and do not reflect the post-prandial chylomicron tide, 
dietary cholesterol is absorbed in chylomicrons and may exert 
sustained effects on cholesterol via regulation of endogenous 
cholesterol synthesis. Dietary cholesterol is comprised of both 
free and esterified components, the free cholesterol is absorbed 
as a mixed micelle with dietary triglyceride, and 50% is re- 
esterified with endogenous and exogenous fatty acids in the 
intestinal mucosa and packaged into chylomicrons. Although only 
30-50% of ingested cholesterol is absorbed, the cholesterol 
content of the diet will have a clear bearing on the plasma 
concentration of cholesterol for the population studied.
Hepatic Synthesis: - The major stimulus to hepatic VLDL 
synthesis is the demand for triglyceride transport determined by 
the availability of the precursors FFA and glycerol. In the
absorptive state glucose and residual chylomicron triglyceride 
fatty acids are used for FFA synthesis while in the post- 
absorptive state the source is mainly adipose tissue.
The secondary post-prandial triglyceride rise 4-6 hours 
after a meal represents hepatic VLDL triglyceride synthesis, and 
varies depending on the dietary carbohydrate and fat load. For 
example institution of a high carbohydrate diet can lead to 
hypertriglyceridaemia by the following mechanism. Glucose 
hepatocyte flux is in excess both of energy demands and glycogen 
storage capacity. Acetyl Co A and dihydroxy acetone phosphate
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are then respectively shunted into fatty acid and glycerol 
synthesis which primes the system for triglyceride synthesis.
Cholesterol synthesis likewise is related to the demand* for 
triglyceride transport, and is initiated frcm intrahepatic 
acetate, and limited by the enzyme HMG Co A reductase, which in 
turn is regulated by dietary cholesterol and the enterohepatic 
circulation of bile salts. Therefore the rate of hepatic 
cholesterol synthesis appears to be inversely related to hepatic 
cholesterol uptake frcm chylomicrons and intestinal VLDL. 
Nascent VLDL requires Apo B and also Apo C and Apo E for its 
secretion frcm the liver. LDL formation is thought to be 
predominantly due to catabolism of VLDL in health, although a 
minor independent synthetic pathway may be present. Nascent HDL 
is synthesised in hepatocytes and intestinal mucosal cells but 
regulating factors have not been identified. After the disc­
like nascent HDL structures form with apoproteins combining with 
phospholipid and free cholesterol, extensive structural and 
compositional modification takes place after secretion. The most 
important is the esterification of free cholesterol to form 
cholesterol ester after LCAT activation, leading to a change in 
the HDL molecule, which becomes spherical in structure. 
Cholesterol ester is then transfered to VLDL during catabolism. 
In addition, apoprotein content varies such that nascent HDL is 
composed predominantly of apo E relative to Apo A and Apo C, 
whilst plasma HDL is characterised by a predominance of Apo A. 
This might be relevant to the LCAT reaction which is facilitated 
by Apo AI.
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Catabolism: The initial step in chylomicron and VLDL catabolism 
is the acquisition of Apo C-II frcm HDL which catalyses 
lipoprotein triglyceride lipolysis by lipoprotein lipase. This 
enzyme is present on the luminal aspects of capillary 
endothelium and is released into the circulation by heparin. 
It's activation results in progressive triglyceride depletion 
via the IDL intermediate. The lipoprotein structure is 
maintained by simultaneous removal of phospholipid, unesterified 
cholesterol and Apo C peptides frcm the lipoprotein surface to 
HDL, whilst reciprocal transfer of cholesterol frcm HDL takes 
place. VLDL in man is the main determinant of LDL levels, and 
normally a constant amount of Apo B is maintained per particle, 
demonstrating that Apo B is a fundamental structural unit of 
chylcmicrons, VLDL, IDL and LDL. LDL circulates as the source 
of cholesterol for tissue membrane synthesis, and its 
catabolism is dependent on the expression by the cell of a 
specific high affinity LDL receptor. Lysoscmal uptake is 
followed by hydrolysis of the LDL protein and cholesterol 
ester. Free cholesterol is then available for intracellular 
metabolism. Intracellular cholesterol is involved in a negative 
feedback process controlling LDL receptor expression: the
molecule regulates cholesterol synthesis via its effects on the 
enzyme HMG-Co A reductase, and in excess leads to ACAT (acyl-CoA 
transferase) activation, resulting in intracellular cholesterol 
ester storage. The LDL receptor is in addition involved in 
specific uptake of Apo E containing lipoproteins as well as Apo 
B.
The role of HDL in ' reverse cholesterol transport', whereby
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it mediates cholesterol removal to degradative and secretory 
sites, remains speculative in man. However, the kidney is likely 
to be an important site of HDL catabolism. Apoproteins AI .and 
All have been demonstrated in the urine of healthy subjects (240) 
and rat proximal convoluted tubules have been found to degrade 
Apo A I entering the urine space (241). In addition, of course, 
cholesterol is excreted and degraded via the hepatobiliary 
system as faecal sterols, and bile acids frcm the same source are 
also critical in the phase of fat absorption.
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LIPID METABOLISM IN INSULIN DEPENDENT DIABETES MELLLTUS
Disturbed lipid metabolism in insulin-dependent diabetes was 
probably first recognised by Frederick Allen in 1916 (242).
Before the discovery of insulin, it was he who championed a low 
fat intake to retard the development of ketoacidosis (242). In 
the 1930's with the wider use of insulin, high fat, low 
carbohydrate diets were in vogue, and diabetic hyperlipidaemia 
was quantified and found to be predcminatly due to 
hypertriglyceridaemia (243) and inadequate metabolic control. 
The increasing use of the liberal carbohydrate intake with 
correspondingly less fat intake practiced till the early 1970's 
has been found to be associated with an increased prevalence of 
macrovascular complications and serum triglyceride 
concentrations, whilst there was little change noted in 
microvascular disease and levels of serum cholesterol (244). 
Since fibre rich, high polyunsaturated: saturated fat ratio diets 
were advocated for insulin dependent diabetes, further changes in 
the patterns of lipids and vascular disease are likely to have 
developed.
Many other factors are also involved in the disturbances of 
lipid metabolism in IDEM. It is also now clear that lipid
metabolism is appreciably different in NIDEM and IDEM. This is 
due in part to differences in absolute and relative degrees of 
peripheral and portal insulinaemia and insulin resistance in the 
two conditions. By the same principle the extent of insulin
repletion in IDEM clearly has an important bearing on the pattern
of lipid abnormalities. Unfortunately many earlier studies with 
potentially relevant findings in IDEM tended to merge all
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diabetics irrespective of their mode of treatment. However it is 
still quite feasable that these data as well as that obtained 
frcm studies purely on patients with NIDDM could have seme 
bearing on lipid metabolism in IDEM.
In the next section I will summarise published work 
primarily on IDEM but in addition where pertinent, refer to 
studies of NIDEM alone, NIDEM and IDEM together, or studies on 
animal models of insulin-dependent diabetes.
1. Abnormalities of Lipoproteins in IDEM
(a) Chylomicrons and intestinal VLDL
Virtually no studies have been carried out to examine 
chylcmicron or intestinal VLDL synthesis and turnover in IDEM. 
However the rare chylcmicronaemia syndrcme associated with 
massive hypertriglyceridaemia is frequently associated with 
diabetes, usually IDEM (245). Severe insulin deficiency alone 
does not lead to the disorder and additional familial forms of 
hypertriglycerdaemia are required for expression of the condition 
(246).
Animal models of insulin-dependent diabetes have demonstrated 
both elevated intestinal cholesterol synthesis and fasting 
triglyceride production (247, 248), which may provide part of the 
explanation for the increased whole body cholesterol synthetic 
rate observed in human insulin-dependent diabetes mellitus (249). 
In addition exogenous triglyceride clearance assessed by the 
intralipid tolerance test has been reported to be reduced in 
untreated IDDM (250), although this was not confirmed by a later 
report which suggested that removal of exogenous fat depended
90
solely on the pre-existing fasting triglyceride level (251).
(b) Hepatic very low density lipoprotein (VLDL)
Elevated levels of VLDL triglyceride and cholesterol 
accompany diabetic ketoacidosis (252), although if IDEM patients 
receive adequate insulin repletion VLDL concentration is often 
normal (253). VLDL triglyceride in particular correlates closely 
with the degree of glycaemic control in IDEM (253a, 254). A 
decreased fractional catabolic rate of endogenous VLDL is found 
in poorly controlled IDDM (251, 255). This has been attributed 
to the lipoprotein lipase deficiency which accompanies insulin 
deficiency (256, 257), although the increased VLDL production 
which accompanies moderate insulin deficiency due to increased 
fatty acid mobilisation also contributes to the 
hypertriglyceridaemia (255, 258). However, in
normotriglyceridaemic IDEM patients with stable but suboptimal 
glycaemic control on conventional insulin therapy, VLDL 
triglyceride production and catabolism rates were found to be 
normal (259). Intensified insulin therapy by either CSII (259) 
or the artifical B cell (Biostator) (260), even led to subnormal 
VLDL triglyceride production rates and to a lesser extent in the 
fractional catabolic rate (FCR). A fall in VLDL cholesterol also 
accompanies improved glycaemic control with CSII in IDEM (259). 
Conformational changes in VLDL are a feature of NIDEM (256), but 
it is likely that in IDDM there is also lipid enrichment relative 
to the protein content of VLDL, in addition to the increased VLDL 
cholesterol: triglyceride ratio previously reported (259). This 
latter finding might be due to accumulation of VLDL remnants
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(intermediate density lipoproteins) in IDDM. Finally, it has
been suggested that the lipid metabolism in IDEM may vary with 
the route of insulin delivery and one unconfirmed report .has 
suggested that intraperitoneal insulin leads to increased VLDL 
triglyceride levels despite lowering blood glucose (261).
The apolipoproteins Cl, CII and CIII are found predominantly 
in VLDL and to a lesser extent in HDL. Apo C III and CII inhibit 
and activate lipoprotein lipase respectively, and marginal 
elevations of both are described in IDEM, with a close correlation 
with levels of serum triglycerides (262). It is uncertain
whether there are functional consequences of glycosylation of Apo 
Cl, described in hyperglycaemic diabetics (263). Apo E is 
likewise glycosylated in diabetes (263). Although levels are 
reported to be higher in non-insulin- dependent diabetes mellitus 
(264), levels of Apo E relative to Apo B were no different, and 
ApoE was reduced in proportion to VLDL triglyceride in another 
report (265). Such studies are not available in IDEM, although 
there is preliminary evidence of reduced levels of Apo E 
following CSII therapy (266) and reduced levels are found in 
insulin-dependent diabetic rats (267). Phenotypic variation in 
ApoE in IDEM has still to be investigated, although in Japanese 
non-insulin-dependent diabetics the phenotypic frequency was 
similar to that of non-diabetics (268). However Eto et al (268) 
did find that the E2/E3 phenotype was the commonest finding in 
hyperlipidaemic diabetics and non-diabetics.
(c) Low Density Lipoprotein (LDL)
Low density lipoprotein measurements in IDEM reflect
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lipoproteins within the density of both LD!^  (IDL) (1.006- 
1.019g/ml) and LDL2 (1.019-1.063g/ml). As yet it is not clear if 
there are alterations in both these subclasses, although IDL-may 
be increased in IDEM (269). A methodological problem is that in 
virtually all large studies, the value of LDL cholesterol is 
calculated indirectly by the Friedewald formula (270), where 
LDL cholesterol = Total cholesterol - (Total
triglycerides/2.2 + HDL). However to my knowledge this ratio 
has not yet been validated in IDDM.
LDL cholesterol concentrations have been found to vary with 
the extent of hyperglycaemia, showing a correlation with HhAi, 
ranging frcm r=0.17 (271) to r=0.35 (253a), with closer matching 
reported in IDEM subjects with levels greater than 13%
(253a, 254). In addition inproved glycaemic control has led to 
significant falls in LiDL cholesterol in most studies of poorly 
controlled IDDM treated by CSII, (48, 50-52) and on occasion to 
levels less than healthy controls (272). However the relatively 
poor correlation between HbAi and LDL cholesterol and the 
observation frcm several studies demonstrating similar LDL 
cholesterol levels in IDEM compared to healthy age and weight 
matched controls (253), confirms that quantitative alterations 
are not inevitable in IDEM.
LDL triglyceride levels have been found to be higher than 
in healthy controls and to be proportional to the degree of 
hyperglycaemia in IDDM (253). Apo B is the major apoprotein of 
IDL and has been demonstrated to be a stronger positive risk 
factor for coronary heart disease in non-diabetics than LDL 
cholesterol (273). Levels of apoB in IDDM are also related to
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glycaemia with a strong correlation (r=0.57) reported with HbAx 
in one study (54), and significant falls in levels accompanying 
inproved glycaemic control (47, 54). However cross sectional 
comparison of white males with and without IDDM, matched for age, 
has suggested a quite clear reduction of apoB levels in the IDEM 
group (54), although no difference was reported in either males 
or females in another study (274). Thus it would appear that 
whilst metabolic control may affect levels of LDL, residual 
qualitative differences could be a feature of IDEM. Both 
cholesterol and triglyceride saturation of LDL relative to the 
protein content have been reported in IDEM (54, 56, 275).
Very little work on LDL turnover has been performed in IDEM, 
but the fractional catabolic rate has been reported to be similar 
to non-diabetic controls irrespective of the mode of insulin 
delivery, although improved glycaemic control did lead to 
decreased LDL apo B production rates to levels less than healthy 
controls (272).
Studies of LDL metabolism in IDEM have otherwise been 
confined to predominantly in vitro experiments of LDL receptor 
activity and have tried to elucidate the cause of the previously 
described abnormalities of LDL. Although LDL receptor activity 
in cultured human skin fibroblasts has been shown to be insulin 
sensitive and LDL degradation sensitive to insulin administration 
in vivo (276, 277), intrinsic abnormalities in diabetic LDL 
receptors in vitro were not apparent in one elegant study (278). 
The demonstration that LDL could be glycosylated in vitro (279) 
raised the possibility that post-translational modification of 
the LDL molecule secondary to hyperglycaemia could affect it's
function, and glycosylated LDL has been reported to be 
internalised and degraded by the LDL receptor to a lesser degree 
(275, 279, 280) in addition to being a less effective stimulator 
of cholesterol ester synthesis by cultured fibroblasts (279). 
The inhibition of LDL catabolism by glycosylation may lead to 
increased LDL levels in plasma. As expected, therefore, 
inproved metabolic control leads not only to reduced levels of 
glycosylated LDL, but also to a fall in the triglyceride content 
of LDL which may in addition enhance LDL catabolism (275). LDL 
glycosylation has been shown to be closely correlated with Hh^ 
(281), which suggests that it is in a dynamic state whereby poor 
metabolic control in addition to modifying the LDL structure may 
also affect LDL function. A further intriguing feature of LDL 
in diabetes is the observation of specific autoantibodies to 
glycosylated LDL developing in human diabetic subjects (282). 
The consequent development of LDL immune complexes may prove to 
be relevant to the development of diabetic vascular 
complications.
(d) High Density Lipoproteins (HDL)
As with LDL, methodological considerations have been cited 
to account in part for the disparity in HDL levels reported in 
IDEM. "When comparisons were made, higher levels of cholesterol 
were measured in the serum high density, lipoprotein (HDL) 
fraction isolated by heparin-manganese chloride precipitation in 
comparison to ultra-centrifugation, which in turn measured higher 
levels of HDL than did sodium phosphotungstate-magnesium chloride 
precipitation (283). It has been suggested that
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ultracentrifugation derived HDL in addition isolates Lp(a), 
present in the density range 1.055-1. 085g/ml, whilst the presence 
of positively charged groups such as on apolipoprotein Ef which 
has disulphide links with apo A II, may contribute to higher HDL 
levels using the heparin-manganese chloride precipitation method 
(283).
HDL levels are higher in wanen than men and may also be 
increased by alcohol ingestion (284) and training (285), and 
reduced by smoking (286). There is controversy as to whether 
ageing is associated with reduced HDL levels. A direct 
correlation with age and HDL cholesterol has been reported in 
females with or without (287) and in men with IDEM (288) but 
this is not apparent in other reports (289, 290). Age related 
increases in Apo A I are also reported in non diabetics (291). 
However, body mass does not appear to exert any influence on HDL 
cholesterol in insulin treated diabetics (292, 293).
Despite such uncertainty there appears to be a general 
consensus that HDL cholesterol and triglyceride levels are lew 
in poorly controlled hyperglycaemic insulin dependent- diabetics 
(253a, 254, 256, 289). Otherwise HDL cholesterol and
triglyceride levels increase in parallel with improved glycaemic 
control (254, 256), and HDL tends to be similar (294, 295), or 
even higher (287, 288, 292, 293, 296) than in non-diabetics 
matched for age, sex and weight.
Significant increases in HDL cholesterol in patients with 
suboptimal control of IDEM treated with CSII are well established 
observations, but were not apparent till at least 8 weeks in most 
studies (46-48, 51, 52, 54). In a study reporting significant
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increases in HDL cholesterol after 2 weeks of intensified 
conventional insulin therapy, the patients had acute metabolic 
decompensation (47) thereby accounting for lower than expected 
baseline values of HDL cholesterol. The complexities of HDL 
metabolism are such that to date no studies have set out to 
determine the exact nature of the abnormalities in IDDM. 
Although improved glycaemic control in individuals has been 
associated with rising levels of HDL cholesterol, there is with 
one exception (294) a poor correlation between levels of HDL 
cholesterol and glucose and HbAx in most studies (262, 283, 290, 
292, 293, 295, 296), although multivariate analysis has
demonstrated an independent relationship between HhAx and HDL 
cholesterol (288). One explanation is the role of VLDL and 
insulin in HDL metabolism. An inverse relationship between VLDL 
and HDL cholesterol has been reported (253, 287, 292) and may 
reflect transfer of esterified cholesterol and triglyceride 
between these molecules in IDDM. In addition the catabolic 
pathway which leads to the formation of HDL is dependent on 
cholesterol enhancement of nascent HDL, which in turn reflects 
lipoprotein lipase activity. Tissue lipoprotein lipase is 
activated by insulin and there inevitably is relative peripheral 
hyperinsulinaemia in well controlled IDDM which would of course 
activate lipoprotein lipase. For these reasons a relationship 
between glycaemia and HDL cholesterol in IDDM is apparent 
although not causal in well controlled insulin replete IDDM with 
reduced, often low levels of VLDL triglyceride. One further 
hypothesis is that the state of insulin resistance in IDDM leads 
to enhanced hepatic output of nascent HDL ultimately leading to
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high levels of cholesterol replete HDL (293).
The apparent increase in HDL cholesterol in stable IDEM is 
contrary to a naive concept that as a 1 cardioprotective 
lipoprotein1, HDL levels should lew in a population where 
atherosclerosis is accelerated. This has led to several studies 
where conformational changes in HDL have been sought. 
Triglyceride enrichment of HDL in IDDM has been reported (293) 
although this was not confirmed in another report (292). HDL 
phospholipid content appears to parallel the cholesterol 
saturation of the molecule (287). The apoproteins AI and All 
have been measured in IDDM with conflicting results. Levels of 
'apolipoprotein A1 in HDL are no different between IDDM and 
healthy controls when antisera were used which recognised both 
apo AI and apo All (289). More specific analyses have suggested 
that apo AI levels are increased in IDDM, and an elevated apo 
AI/AII ratio is described (274, 295, 297). In one of these 
reports, it was concluded that this reflected an increase in the 
HDL2/HDL3 cholesterol subfraction ratio (295) although this was 
based on a close correlation between Apo A I and All in only 4 
individuals. Other reports have shown precisely the opposite 
finding with reduced levels of apoA I and reduced or normal apo 
All levels in IDDM (262, 274) although that glycaemic control was 
poorer in these latter studies. A strong positive correlation 
between total daily insulin dose and both apoAI and apo All has 
been reported, and may help to explain these disparities (274).
The distribution of cholesterol in the HDL2 and the smaller 
HDL3 subfractions may prove to be the most relevant to a 
pathophysiological role for HDL in atherosclerosis in IDDM, since
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HDL2 cholesterol in non-diabetics is thought to be the fraction 
involved in cardioprotection. There is disagreement as to whether 
the HDL2 (287, 293, 298) or the HDL3 (299, 300) cholesterol 
subfraction contributes most to the high HDL cholesterol of IDEM. 
As HDL 3 is the precursor of HDL2, a rise in the former might 
reflect enhanced catabolism prior to its conversion to HDL2. 
Support for this hypothesis ccrnes fran observations that 
glycosylation of apoAI and apo All has been demonstrated in vivo 
(263) and that catabolism of glycosylated HDL is increased at 
least in animal models (181). HDL3 has also been reported to be 
enriched in triglyceride with reduced particle size in poorly 
controlled IDEM (256).
The close correlation between post-heparin lipoprotein 
lipase activity and HDL cholesterol (primarily HDL2) and 
phospholipids, and an inverse relationship between HDL and 
hepatic lipase activity in well controlled IDEM has suggested 
that exogenous insulin administration may have a key role in 
determining HDL levels (298). However this hypothesis has been 
challenged by a report where despite no difference in exogenous 
insulin dosage, the highest levels of HDL and HDL2 cholesterol 
were observed in IDEM without residual endogenous insulin 
secretion, suggesting that peripheral hyperinsulinaemia leading 
to enzyme activation and HDL production was not the cause of 
elevated HDL in IDEM (293).
(e) Lp (a) Lipoprotein
In non-diabetics, this cholesterol-rich, apoprotein B 
containing lipoprotein is found within the density distribution
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of HDL, and high concentrations have been correlated with 
coronary heart disease (301). In the only study of Lp(a) in IDEM 
to date, although mean and median values did not differ 
significantly frcm controls, elevated levels higher than 2Qmg/dL 
were found in 14% of a group of diabetics without retinopathy or 
nephropathy compared to 5% of controls. Levels did not appear to 
be influenced by gender, age or glycaemic control (274).
2 Enzymatic regulation of Lipid Metabolism in IDEM
(a) Lipoprotein Lipase
This enzyme is present in a variety of tissues, plays a 
major role in peripheral removal of plasma triglyceride in man, 
and it's activity is said to be regulated by insulin. Tissue 
activity can be indirectly estimated by measuring the post­
heparin lipolytic activity (PHLA), a measure of triglyceride 
hydrolysis after a small dose of intravenous heparin. Levels of 
PHLA may be low in sane uncontrolled hypertriglyceridaemic 
insulin-dependent diabetics (302-303) although normal PHLA is 
frequently a finding in such patients (304). Chronic stable 
IDEM patients tend to have high levels of PHLA (303). PHLA also 
reflects lipolytic activity frcm sources other than adipose 
tissue, including the liver (305), and this may explain why this 
supposedly insulin-sensitive enzyme activity is not always 
abnormal in untreated IDEM. However liproprotein lipase activity 
in adipose tissue and skeletal muscle biopsies is uniformly low 
in insulin-deficient IDEM, and levels increase in response to 
insulin treatment (306, 307). Hepatic lipase is also an
insulin-sensitive enzyme. Activity has not been found to be
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altered in ketoacidotic or stable longstanding insulin-dependent 
diabetes, although it is elevated in hyperlipidaemic non-insulin 
dependent diabetes (303). A preliminary observation of reduced 
activity in well controlled IDDM and an association with a higher 
HDL2/HDL3 ratio (298) suggests that it may be involved in 
regulation of HDL as well as VLDL.
(b) Lecithin: cholesterol Acyltransferase (LCAT) and 
cholesterol ester transfer
LCAT catalyses the transfer of an unsaturated fatty acid 
residue frcm lecithin to cholesterol with the formation of 
cholesterol ester and lysolecithin. HDL lipids are the preferred 
substrate, and this might reflect the capacity of apolipoprotein 
AI in HDL to activate LCAT. LCAT may have a role in the 
catabolism of VLDL in addition to structural modification of HDL. 
In suboptimally controlled IDDM, although the fractional rate of 
cholesterol esterification was not different, significantly 
higher mean free cholesterol concentration and mean LCAT activity 
has been reported in one study when compared to healthy controls
(308), although LCAT activity was found to be unaltered in 
another report in IDEM patients with virtually identical 
glycaemic control (274) and reduced in diabetic ketoacidosis
(309). LCAT activity positively correlated with plasma free 
cholesterol but not with gender, age, body mass index or 
glycaemic control (274, 308). The discrepancy with regard to 
LCAT activity reflects the different methodology employed, but 
perhaps the report by Mattock et al (308) is most valid in that 
it gives a measure of the combined effects of enzyme
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concentration and substrate characterised in the assayed plasma 
and may therefore be a more physiological approach to assessing 
LCAT activity in vivo. The increased plasma phospholipid levels 
reported in diabetics may enhance LCAT activity to account for 
these findings (308).
In non-insulin dependent diabetes an increase in the free 
cholesterol content of VLDL and LDL relative to cholesterol ester 
and phospholipid has also been reported and may be due to 
inhibition of cholesterol ester transfer (310, 311). If the same 
abnormality is present in IDEM then the increased LCAT activity 
is presumably a secondary compensatory phenomenon to try to 
catabolise the free cholesterol rich VLDL.
3. Additional factors which exert an influence on lipid metabolism 
in IDEM
i) Diet: Frederick Allen published his work 1 Total dietary 
regulation in the treatment of Diabetes' in 1919 (242); he
recognised that diabetes affected lipid and protein as well as 
carbohydrate metabolism and suggested that all 3 components of 
the diet overburdened the system. His radical solution of near­
starvation helped to prolong life, in seme cases till insulin 
therapy was available. Although this ruthless regime is now 
clearly seen as ill conceived in its approach, quantitative and 
qualitative dietary modification of carbohydrate and fat intake 
is now widely practised. Indeed, a reciprocal relationship was 
noted between plasma cholesterol and carbohydrate intake in 
diabetes as early as 1930 (312).
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Consumption of a diet high in polyunsaturated fats (the 
'com-oil' diet) was reported to reduce serum lipids in young 
diabetics as early as 1955 (313). However longer term follow-up 
of patients treated in this way demonstrated the development of 
'hyperbetalipoproteinaemia1, effectively an increase in serum 
cholesterol levels. These unexpected findings were attributed 
to an increase in dietary carbohydrate with respect to protein, 
despite a continued high intake of polyunsaturated fat (314). 
The observation that a high refined carbohydrate intake can lead 
to hypertriglyceridaemia had previously been made in normal 
subjects (315, 316) and has recently been confirmed (317). Whilst 
this supports the concept that glucose is utilised by the liver 
as a substrate for VLDL production, such findings are not 
apparent in studies of diabetes, possibly due to the substitution 
of sugar by fibre (318, 319). A reduction in HDL cholesterol is 
also reported to accompany high carbohydrate, low fat diets (318, 
320). Therefore it would appear that dietary balance of 
carbohydrate and lipid is essential to achieve the optimum lipid 
profile in IDEM. The British Diabetic Association currently 
recommends an avoidance of saturated fat and its replacement by 
fibre-rich carbohydrate and polyunsaturated fat containing foods. 
The relative proportions of the dietary calorie intake suggested 
are total protein intake 15%, fat 35% and carbohydrate 50% (321).
When such an approach has been put to the test, the effects 
on lipids and lipoproteins have been rather variable. High fibre 
diets in diabetics have not led to increases in triglycerides 
although a reduction in HDL is reported, but concomitant changes 
in the cholestrol content and the polyunsaturated‘.saturated (P:S)
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fat ratio has made it difficult to assess the independent role of 
dietary carbohydrate in IDEM (320, 322). Taskinen et al (319) 
reported that total, VLDL, LDL and HDL triglyceride levels were 
unchanged, although the HDL2 triglyceride content increased, in 
response to a diet rich in fibre (55g/day), with a P:S ratio of 
0.4 composed of 60% carbohydrate and 20% fat. Significant 
reductions in total, LDL and HDL (solely HDL3) cholesterol were 
apparent by 2 weeks whilst hospitalised on a metabolic ward, but 
these alterations were reversed 4 weeks after returning heme, 
suggesting that compliance to such dietary restrictions is poor. 
In addition adipose tissue lipoprotein lipase activity did not 
alter during the study, nor did levels of apolipoprotein A I or 
II in either the HDL2 or HDL3 subfractions, although a 
presumptive transfer of the apo Cs frcm HDL3 to HDL2 developed, 
as judged by a rise in total protein content in HDL2 after the 
diet.
In a report on 6 female insulin-dependent diabetics treated 
with a more cholesterol restricted, higher P:S fat ratio diet, 
significant reductions in total, LDL and HDL cholesterol and in 
levels of apolipoproteins AI, B and CIII were observed (323). 
Levels of LDL and HDL triglyceride and of the apolipoproteins All 
and E were unchanged. However both total and VLDL triglycerides 
and VLDL cholesterol levels rose significantly (323).
In addition such restricted diets are most unlikely to be 
palatable enough for routine use and it has even been suggested 
that a more modest high carbohydrate/high fibre/low fat diet may 
lead to a deterioration in glycaemic control (324).
More recent alternative dietary strategies in non-diabetics
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have employed the use of diets rich in fish oil containing 
eicosapentaenoic acid (EPA 20: 5W3), or catimercially available 
fish oil supplements (Maxepa) to reduce VLDL triglyceride 
synthesis and also to modulate haemostatic and platelet function. 
However in a study of normotriglyceridaemic insulin dependent 
diabetes, 15gm/day of Maxepa led to a significant increase in 
levels of total and LDL cholesterol and fibrinogen (325) which 
would outweigh any additional triglyceride lowering effect in 
hypertriglyceridaemic IDEM.
(ii) Renal Function Diabetic nephropathy characterised by 
persistent proteinuria and a consequent decline in renal 
function, ultimately affects up to 45% of patients with IDEM 
(326). Renal failure and the nephrotic syndrome complicating 
IDEM can independently lead to disordered lipid metabolism (327- 
328), a fact often neglected in discussions of lipid metabolism 
in IDEM.
Previous reports have demonstrated significant elevations of 
serum triglycerides, total and LDL cholesterol and 
apolipoprotein B, and reductions in levels of HDL cholesterol and 
the ratio of apolipoprotein A/apolipoprotein B in IDEM 
complicated by albuminuria greater than 150pg/minute (329- 331). 
Progression to renal failure is associated with a more marked 
reduction in HDL cholesterol levels (330). Abnormalities of 
lipoproteins may even be apparent prior to the development of 
proteinuria, and subjects with IDEM and subclinical (incipient) 
nephropathy (albuminuria excretion rate 20-15Opg/minute) have 
been found to have higher concentrations of apolipoprotein B and 
a reduced apoA/apoB ratio compared to those with normal
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albuminuria excretion rate (less than 20pg/minute) (331).
iii) Genetic: Both diabetes and hyperlipidaemia are
heterogeneous conditions and do not segregate according to simple 
Mendelian principles, but polygenic inheritance of both 
conditions is a possibility (332).
The insulin gene is located on chranoscme 11, and a highly 
polymorphic locus flanking it has been identified and associated 
independently with hypertriglyceridaemia (333) and 
atherosclerosis (334) in NIDEM. Whether such relationships are 
also apparent in IDEM is unknown, although it is of interest that 
the genes for the apolipoproteins AI and CIII are also located on 
chranoscme 11 (332), but an uncommon apoA I polymorphism was not 
found with increased frequency in one study of 
hypertriglyceridaemic non-insulin dependent diabetic and non­
diabetic individuals (335).
An alternative approach designed to examine whether 
individuals with inherited hypertriglyceridaemia (type IV and V 
hyperlipidaemia) and diabetes mellitus developed familial 
diabetes mellitus as a genetic syndrcme, failed to demonstrate a 
dependent inheritance of the two conditions (336). In a survey 
of 157 insulin-dependent diabetic children, hyperlipidaemia was 
designated as genetic in source in only 3 of the 14 subjects in 
whcm it was identified (337). However the lack of correlation 
between measures of glycaemic control and the elevated total 
serum cholesterol levels in this study raises the possibility of 
more subtle genetic influences determining lipid levels in IDEM.
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It is of interest that in addition to coding for the C3 
complement and apolipoprotein E phenotypes (332), chranoscme 19 
also contains a gene sequence for the insulin receptor (338). 
Variants of the C3 complement phenotype are associated with 
familial hypercholesterolaemia (332) whilst structural 
modification of apolipoprotein E as a consequence of expression 
of E2/E2 homozygosity confers susceptability to the development 
of type III hyperlipoproteinaemia (339), which in turn is often 
associated with glucose intolerance (340). Whilst linkage 
disequilibrium of the insulin receptor gene and the apoE and/or 
C3 complement genes is unlikely owing to the location of these 
genes on chranoscme 19, there is still the exciting possibility 
of a combined genetic defect leading to expression of IDEM and 
hyperlipidaemia in a homogeneous subset of individuals.
(iv) Demographic variables: Levels of total and low density
lipoprotein plasma cholesterol and triglycerides have been found 
to increase with age both in diabetic (341) and in healthy 
subjects (342).
Gender has been confirmed to have a bearing on lipoprotein levels 
in IDEM, and females have been found to have consistently higher 
levels of total VLDL and LDL triglycerides and total and LDL 
cholesterol, with correspondingly lower levels of total HDL and 
HDL2 cholesterol, in comparison to males with IDEM of similar age 
and body mass index (287, 343). Similar differences were not 
apparent between non-diabetic men and women (343).
Diurnal variations in levels of total, HDL and LDL plasma 
cholesterol (344) have been reported in both normals and insulin-
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dependent diabetes but this finding remains unconfirmed, although 
a post-prandial triglyceride rise is clearly recognised in health 
and in diabetes (345), in whan subtle abnormalities may prove to 
be relevant to the pathogenesis of atherosclerosis.
(v) Pharmacological: The management of hyperlipidaemia in IDEM is 
not stated to differ frcm that in non-diabetics, although to my 
knowledge very few if any studies have demonstrated the efficacy 
of ion-exchange resins, fibric acid derivatives or drugs such as 
nicotinic acid or probucol in hyperlipidaemia associated with 
IDEM.
Perhaps more pertinent in practical terms is the potential 
for agents commonly used in IDEM for associated problems, such as 
hypertension,to modify lipid metabolism. For example p blockers 
have been clearly demonstrated to increase plasma triglycerides 
and VEDL cholesterol, whilst reducing HDL cholesterol levels in 
normolipidaemic individuals (346, 347), and alpha-adrenergic
blockers such as prazosin and doxazosin lead to reductions in 
triglyceride and cholesterol concentrations (348, 349) in non­
diabetic hypertensive patients. In a randomised double blind 
study of hypertensive insulin-dependent hypertensive diabetics, 
oxyprenolol surprisingly did not lead to alterations in 
triglycerides, cholesterol or HDL, although free fatty acids 
levels fell (350). In distinction methyldopa treatment led to 
significant increases in levels of triglycerides and reductions 
in free fatty acids, without affecting HDL or total cholesterol 
(350).
Other agents have been employed to see whether they had a
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specific role to play in treatment of diabetic hyperlipidaemia. 
Whilst ascorbic acid was not found to modify hyperlipidaemia in a 
double-blind cross-over study in IDEM and NIDEM (351), an 
independent role for chlorpropamide in lowering total, LDL, HDL 
and HDL3 cholesterol has been observed in IDEM (352). In 
contrast, despite lowering triglyceride levels, cholesterol 
levels rose following treatment of IDDM with MaxEpa (325).
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1:3 PROTEIN METABOLISM
IDEM is a disorder of protein metabolism, characterised by 
protein intolerance and the consequence of reduced synthesis of, 
and altered sensitivity to insulin, which acts as a major 
anabolic hormone. Although defects of protein metabolism are 
often reported in associated with hyperglycaemia, it is likely 
that they both reflect deficient insulin action and therefore are 
only indirectly linked with one another.
Amino acids, as the substrates for protein synthesis, are 
often present in abnormal amounts in IDDM. Insulin deficiency is 
associated with accelerated amino acid oxidation, decreased 
uptake of exogenous amino acids and repletion of nitrogen in 
muscle (353). Hyperglycaemia is associated with decreased serum 
levels of alanine, attributed to a reduction in pyruvate derived 
frcm glucose, which in turn usually leads to alanine synthesis. 
In contrast, the branched-chain (exogenous) amino acids derived 
frcm the diet - valine, leucine and isoleucine - are found in 
increased amounts, probably the consequence of diminished 
peripheral metabolism as opposed to reduced hepatic release 
(353). In addition, amino acids serve as precursors for 
gluconegenesis in IDEM after high protein intake, which further 
contributes to the hyperglycaemia. Therefore it is not 
surprising to find that CSII and improved glycaemic control, 
whilst not associated with significant alterations in serum 
alanine levels (42, 50), can lead to significant reductions in 
both fasting and post-prandial levels of the branched chain amino 
acids (43, 44).
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It has also been established in nonnal subjects and in 
diabetics with and without established nephropathy that diets low 
in protein content have the capacity to alter renal haemodynamics 
and reduce urinary albumin excretion (354-356). However, it 
could be argued whether quantitation of urinary albumin excretion 
provides a useful measure of the eff icency of protein metabolism 
in IDEM, as it is undoubtedly sensitive to other factors. Both 
systolic and diastolic hypertension (357, 358) as well as
exercise (359, 360) and the infusion of dibasic amino acids (361) 
have been found to influence AER. Whilst genetic factors have 
not yet been found to be important (362), there are sound 
theoretical reasons why other factors, such as coexistent 
autonomic dysfunction may affect glcmerular and tubular handling 
of albumin (363) (v.i.). The recognition that elevated urinary 
albumin excretion might serve as a functional marker of 
underlying morphological damage to the diabetic kidney and 
predict ultimate clinical nephopathy (364-366), strengthens the 
concept of albumin excretion rate measurement as a marker of 
underlying disease rather than reflecting protein metabolism.
However urinary albumin loss can be regarded as a marker of 
enhanced catabolism secondary to insulin deficiency in the early 
stages of diabetic ketoacidosis, and there is clear evidence that 
poor glycaemic control independently increases the AER (357, 
358). The use of CSII to improve glycaemic control is also 
reported by seme (24, 31, 35), although not all (25, 32-34) 
groups to lead to a reduction in AER. More recent studies have 
demonstrated that infusions of ketone bodies at a low 
concentration led to a more marked increase in total urinary
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protein excretion than did elevated blood glucose levels (367).
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2. DETERMINANTS OF METABOLIC CONTROL
For practical purposes, the management of IDEM is aimed at 
achieving near-normoglycaemia without excessive hypoglycaemia. 
Several variables have a bearing on the ability of each patient 
with IDEM to approximate to ideal metabolic control. Those 
factors which continue to affect outcome of intensive therapeutic 
programmes are: (a) type and dose of insulin and its mode of 
delivery (b) balancing of diet and daily activity (c) self- 
monitoring of metabolic control (d) patient education, motivation 
and behaviourial characteristics (e) specific clinical (e.g. 
blindness) or biochemical (e.g. extent of endogenous insulin 
reserve) features and (f) flexible modification of factors (a) 
and (b) based on the information frcm factor (c).
2:1 INSULIN THERAPY
(i) Formulation and species: After the initial clinical use of 
the 'pancreatic extract1 in IDEM, modification by acidification 
and later crystallation (368) of insulin led to a sterile short 
acting insulin of bovine or porcine origin, similar to modem 
regular (soluble) insulin. In 1936 the fish protein protamine, 
was ccmplexed with zinc and insulin as PZI (protamine zinc 
insulin) to retard its absorption and a to prolong its action 
(369). Modification of PZI by combining insulin and protamine 
in equal quantities led to the introduction of 'Isophane' insulin 
in 1950, and this in turn was followed by a formulation whereby 
insulin was crystallised in an acetate buffer and an excess of 
free zinc to yield slow acting (1 lente1) insulins. By careful 
adjustment of pH, insoluble crystalline (ultralente) and
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amorphous (semilente) forms were made available (370). Since the 
1950’s, the use of bacteriacidal preservatives and availability 
of neutral (nonacidic) preparations lessened the incidence of 
bacterial or chemical irritation at injection sites. In the 
early 1970's the use of purification techniques to remove peptide 
contaminants such as gluagon and sanatostatin, resulted in 
availability of the so- called 'monocanponent' insulins (371). 
These purified insulins contained less than 10 parts per million 
(ppm) of proinsulin and were of bovine or porcine origin (371). 
The antigenicity of animal- derived insulins leads to the 
production of antibodies which affect bioavailability of 
circulating insulin. Even now there is uncertainty as to whether 
the resultant insulin-antibody immune complexes have a potential 
pathogenic role in microvascular complications (372, 373), or 
whether such complexes act as a reservoir for the release of 
insulin, and consequently a smoother peripheral insulinaemic 
profile (374, 375). A role for insulin antigenicity in antibody- 
mediated local cutaneous responses may also influence insulin 
absorption (376, 377).
Animal insulins have been superceded by the introduction in 
1980 of human insulin derived frcm two different sources. The 
advent of recombinant DNA technology led to genetic manipulation 
of organisms such as E. Coli to code for insulin A and B chain 
production which could then be combined chemically (378). An 
alternative less economical approach has been the production of 
semi-synthetic human insulin by enzymatic conversion of porcine 
to human insulin (379). Both synthetic human insulins and native 
human insulin have identical composition, although the physico­
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chemical structure may differ slightly, but the significance of 
this is not known (379, 380).
Human insulin would appear to be less antigenic and 
consequently may have different pharmacokinetic characteristics, 
with a faster absorption and consequently faster onset and 
shorter duration of action (381). It has recently been suggested 
that hypoglycaemic awareness may differ between insulin species 
(382), perhaps due to altered counter-regulatory responses (383), 
but reduced antigenicity may confer a further potential benefit 
for human insulins in the management of cases of insulin 
resistance or allergy developing whilst on animal insulin (384, 
385). It should be stressed however that cross- reactivity 
between animal insulin antibodies and human insulin is well 
described (386), and persistent local or systemic allergies to 
human insulin are also recognised (376, 387).
(ii) Absorption: Factors other than species and formulation are 
known to affect insulin absorption after subcutaneous 
administration. The injection site and concentration and volume 
of injected insulin have all been demonstrated in radiolabelled 
pharmacokinetic studies to affect bioavailability of insulin 
(388): subcutaneous abdcminal administration produces more rapid 
and predictable absorption than does injection into the upper or 
lower limbs (389), the latter of which is also more susceptable 
to variation during exercise (389, 390). Likewise limb massage 
(391) or local heating frcm saunas (392) leads to accelerated 
rates of absorption secondary to increased subcutaneous blood 
flow, whilst smoking has the opposite effect (393). It has also
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been demonstrated that subcutaneous blood flow is disturbed in 
diabetic microangiopathy which could lead to erratic absorption 
(394).
(iii) Frequency and mode of delivery; Virtually all insulin- 
dependent diabetics administer subcutaneous insulin for control 
on a day to day basis, although this inevitably produces 
peripheral hyperinsulinaemia with a peripheral to portal insulin 
gradient. Other routes of administration may offer a selective 
advantage in specific circumstances, but are impractical for 
widespread use.
Peripheral intravenous insulin delivery is the preferred 
route for treatment of diabetic ketoacidosis (395) and the rare 
syndrome of subcutaneous insulin resistance (396). However there 
are difficulties with venous access and thrombosis which result 
with long term use. The short half-life of intravenous insulin 
means that interruption of the infusion rapidly leads to insulin 
deficiency, unlike subcutaneous intermediate acting insulin 
where a depot of insulin is present. In addition studies have 
suggested that mealtime hyperinsulinaemia is necessary to achieve 
normoglycaemia with intravenous insulin (397)
Insulin is absorbed more promptly frcm the intramuscular 
than the subcutaneous route (398). It is an effective means by 
which to treat diabetic ketoacidosis (399). Whilst intramuscular 
infusion may achieve a better metabolic response in individuals 
with subcutaneous insulin resistance, haematcma formation and 
fibrosis at the site of the catheter (400) limit application of 
this route.
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Intraperitoneal insulin is an effective way to control IDEM 
subjects with nephropathy on chronic ambulatory peritoneal 
dialysis (CAPD) (401). Direct absorption frcm the peritoneal 
cavity to the hepatic portal vein produces excellent control of 
meal-induced hyperglycaemic excursions and less peripheral 
hyperinsulinaemia (402). Implantable insulin pumps with 
peritoneal access have also been used successfully (403), but 
peritonitis is unfortunately still a frequent complication, 
although the recent introduction of a subcutaneous implantable 
reservoir allows peritoneal absorption with less risk of 
infection (404).
Rapid degradation of insulin by gastointestinal proteolytic 
enzymes would prevent orally administered insulin frcm being 
effective. However if this problem could be circumvented it 
would become an attractive delivery route as all absorbed insulin 
would enter the portal vein. Entrapment of insulin in liposcmal 
particles may reduce degration (405) but the delay in absorption 
inherent in all orally administered drugs make it doubtful 
whether oral insulin could control acute episodes of 
hyperglycaemia.
Rectal insulin, however, would be free of such limitations 
and rapid insulin absorption and hypoglycaemic activity has been 
reported (406), although the frequent administration necessary to 
maintain normoglycaemia would be likely to be socially 
unacceptable.
Nasal administration of insulin produces a rapid 
hypoglycaemic effect but variable absorption (407) and lack of a 
stable aerosol formulation has inhibited widespread acceptance of
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this approach.
The intraportal route of insulin administration would 
nearly duplicate the normal pancreatic source of insulin and 
normalisation of glucose recycling has been demonstrated in
animal studies (408), although difficulty with access and the 
risk of hepatic vein thrombosis make this method of delivery 
unacceptable for practical diabetes care.
Modification of the frequency and duration of subcutaneous 
insulin delivery has been found to influence glycaemic control. 
Once daily acting (Lente or Ultralente) insulins are ineffective 
in achieving glycaemic control in genuinely insulin-dependent 
diabetes, and most conventional regimes employ a mixture of
soluble and isophane insulin administered twice daily, or split 
the evening dose, covering the main meal with soluble and 
administering isophane insulin at bed-time to reduce levels of
fasting hyperglycaemia. Intensified conventional therapy is 
effectively a modification of this regime using multiple insulin 
injections as necessary to lower post-prandial hyperglycaemia. 
Alternative approaches to achieving near-nonoglycaemia are the 
use of pen devices, where after a nocturnal dose of subcutaneous 
ultralente insulin to achieve background insulinaemia, injections 
of soluble insulin can be administered subcutaneously to prevent 
post-prandial hyperglycaemia, titrating the dose to the
anticipated carbohydrate load. This approach more closely mimics 
the pulsatility of physiological insulin delivery, although as 
with CSII, which also ensures continuous background insulin with 
meal-time boluses, peripheral hyperinsulinaemia is required 
to achieve near-normoglycaemia (409). There is little doubt that
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such regimes may be extremely suitable for a small minority of 
highly motivated individuals who wish more flexability with their 
insulin regime. However, studies of both hospitalized patients 
(410, 411) and outpatients (412, 413) have failed to demonstrate 
a significant advantage of CSII over intensified conventional 
therapy, and the high incidence of ketoacidosis and acute 
metabolic decanpensation reported with CSII (41), and excessive 
weight gain reported with intermittent insulin administered by 
pen devices (414) will inhibit more widespread usage of these 
systems. Insulin absorption from repeated injections may be 
enhanced by the use of a sprinkler needle (415), but this 
innovation has yet to be subjected to careful scrutiny in 
controlled studies.
2:2 DIET AND EXERCISE
The acknowledgement that glycaemic control is determined in 
IDEM by a balance of dietary intake, physical activity and 
insulin therapy, makes it vital to individualise each patient's 
meal plan, and in particular to ensure dietary compliance by 
making the diet realistic.
The precise details of meal times will be dependent to seme 
extent on the type of insulin regime, but in general terms the 
daily food intake should be reasonably consistent with regard to 
the calorific intake and balance of the major nutrients. This 
basic programme should have the capacity to be flexible both with 
regard to insulin dosage, and the quantity and timing of meals, 
taking account of variation over week-ends, during holidays, or 
during the menses. It is more relevant on a day to day basis to
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ensure that all patients are encouraged to modify their diet at 
times of increased energy expenditure (v.i.) • Extra 
carbohydrate, or alternatively, reduced preprandial soluble 
insulin prior to exercise, should ensure freedom frcm immediate 
hypoglycaemia, and it has been suggested that an extra 10-15g of 
carbohydrate should be provided for every 30-45min of increased 
activity (416). In my own experience, requirements of additional 
carbohydrate varies frcm patient to patient and should be 
tailored to individual needs. However one frequent observation 
which is often not stressed is the capacity for delayed (often 
nocturnal) hypoglycaemia, developing up to 12 hours after the 
exercise. It is uncertain whether this reflects altered insulin 
absorption in addition to delayed supression of hepatic glucose 
output, secondary to depletion of glycogen stores (416). Even 
without extra physical activity, conventional insulin therapy 
often predisposes diabetics to preprandial hypoglycaemia, 
particularly before lunch, following administration of soluble 
and isophane insulin with breakfast. The principals of regular 
snacks between meals and at bedtime, and minimal delay with main 
meals, should be reinforced to minimise this problem. In 
addition the widespread practice of carrying rapidly absorbed 
refined carbohydrates at all times is to be encouraged. On the 
other hand, ingestion of rapidly absorbed simple sugars (glucose, 
sucrose and maltose) should be discouraged at regular meal times, 
particularly in those insulin-treated diabetics with residual C- 
peptide secretion, since dietary glucose alone does not normally 
mediate insulin secretion and hyperglycaemia could result (416). 
In general, a diet high in fibre and in polyunsaturated fat which
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fulfills the requirements for total energy intake and contains an 
appropriate distribution of nutrients is to be encouraged.
Total energy intake should vary according to age, sex, body 
mass index and the degree of physical activity. The Exchange 
Group System devised by the American Diabetes Association (416) 
or the British Diabetic Association 'Lines’ system, ensure that 
both the caloric load and nutrient distribution of foods are 
known, which affords patients flexibility with what they consume. 
However such concepts have recently been challenged, and it now 
appears that there is variation in the glycaemic response to 
various food stuffs containing equivalent amounts of carbohydrate 
(417). This is particularly apparent with fibre-rich 
carbohydrate where absorption is delayed and the glycaemic 
response (the 'Glycaemic Index') is suppressed (418). In 
addition the timing of the carbohydrate intake affects the 
glycaemic response. This is most apparent in the morning where 
the insulin dose is greater than that required to dispose of a 
meal of similar carbohydrate content eaten at lunch-time (419, 
420). Diurnal variation in insulin requirements or an extended 
'dawn phenomenon' may account for such observations (421).
Although dietary advice to avoid the use of rapidly absorbed 
sugars is often ignored, alternative sweeteners without calorific 
value, such as saccharin, have been introduced into diabetic 
diets. Recent concern over a possible carcinogenic effect of 
saccharin (422) has led to examination of alternative nutritive 
sweeteners such as fructose, or the sugar alcohols sorbitol and 
xylitol. Whilst they may help to improve dietary compliance, 
xylitol causes caries, and sorbitol can cause a dose dependent
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diarrohea (416, 423). Furthermore the use of sorbitol in
diabetes must now be regarded as of dubious value and 
potentially hazardous, with the realization that increased aldose 
reductase activity in tissues leads to a build up of sorbitol, 
which has been implicated in the pathogenesis of the renal, 
neurological and opthalmological canplications of IDDM (424). 
All the aforementioned sweeteners of course have a calorific 
value which needs to be taken into account. On the other hand, 
non-carbohydrate sweeteners like aspartame are non-nutritive, 
non-calorific, and therefore will not affect glycaemic control, 
but long term safety data is not yet available (416).
The use of alcohol as an integral part of the diet in IDEM 
has not attracted much attention previously despite the high 
sugar and calorie content of many alcoholic beverages and the 
capacity to potentiate and promote hypoglycaemia by suppressing 
hepatic gluconeogenesis (425). This is particularly relevant to 
the development of nocturnal hypoglycaemia when misleadingly high 
blood glucose levels may be present before retiring to bed due to 
the caloric load frcm the alcohol, which could inhibit the 
patient frcm taking his/her usual bed time snack.
Further considerations to the diet may be relevant in 
specific cases. There is increasing recognition that a diet high 
in saturated fat can impair glycaemic control as well as 
encourage hyperlipidaemia (312), and likewise a diet rich in 
refined carbohydrate can encourage hypertriglyceridaemia (315- 
317). However it is the fibre content that has been suggested to 
be the major dietary factor determining glycaemic control and 
lipid levels in IDEM (426). Supplements of non-absorbable fibre
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rich substances such as pectins or guar gum have been used to 
reduce post-prandial hyperglycaemia and cholesterol in diabetics 
with variable results (427-430), and the high incidence . of 
gastrointestinal side effects would be likely to lead to poor 
compliance in the long term (430). An alternative approach to 
reducing alimetary lipaemia and glycaemia in IDEM has been the 
use of alpha-glucosidase inhibitors, which delay digestion of 
starch and inhibit intestinal disaccharidase activity, but as 
with the fibre supplements, iatrogenic malabsorption leads to 
unpleasant flatulence and non-compliance with treatment (431, 
432).
The role of dietary protein and salt has received relatively 
little attention till recently. Although a liberal protein 
intake was previously recommended, there is increasing evidence, 
at least in diabetics with incipient nephropathy and glomerular 
hyperfiltration, that a reduced protein intake may benefit renal 
dysfunction (354-356) and there are certainly proponents 
advocating low protein diets in established renal failure in IDEM 
(433). I have previously reported a marked reduction in urinary 
protein excretion and blood pressure accompanied by a fall in 
glomerular hyperfiltration as a consequence of reduced protein 
intake (lOOg) in a young hypertensive diabetic body-builder who 
was consuming over 250g protein/day and performing regular weight 
training prior to this (434). High protein diets might also 
encourage post prandial hyperglycaemia by acting as a substrate 
for hepatic gluconeogenesis (435).
There is now sufficient evidence to justify sodium 
restriction in the management of hypertension associated with
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diabetes (436), and in addition support for the hypothesis that 
low sodium diets may improve glucose tolerance (437), although 
more recently this view has been challenged (438).
Paramount in all aspects of dietary management is the 
recognition that the diet should be sufficiently flexible and 
easily understood to ensure compliance, which has been found in 
the past to be poor (439, 440). A high fibre intake appears to
be of undoubted benefit but centres who enthusiastically 
recommend such diets have reported variation in the willingness 
of diabetics to maintain them for long periods of time (441, 
442).
Physical activity has been encouraged for many years to help 
achieve good metabolic control. However recent acute and longer 
term metabolic, hormonal and circulatory studies of the response 
to exercise suggest that not all the consequences are beneficial 
for everyone with IDEM, and that as with diet, a programme of 
exercise should be defined on an individual basis to be relevant, 
realistic and safe.
The normal acute metabolic response to exercise is an 
increased muscle consumption of fuel and hepatic glucose 
production. Glucose levels in serum are normally maintained by 
appropriate glucose utilisation although they may increase by up 
to 20% in response to strenuous exercise (416). In IDEM the 
ambient glycaemic control determines the response. If IDDM is 
poorly controlled (random blood glucose greater than 15mmol/L), 
patients should be cautioned against severe exercise as worsening 
of the hyperglycaemia and ketonaemia is well documented in these 
cases due to exaggerated hepatic glucose output despite
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inadequate glucose utilisation (443, 444), and an associated 
exaggerated increment in counter-regulatory hormones (445). The 
idea that chronic hyperglycaemia is best treated by strenous 
exertion is a common misconception amongst diabetics which should 
be clarified.
Exercise induced hypoglycaemia in stable IDEM is much 
more common and was first recognised by R.D. Lawrence 60 years 
ago (446). It is due to a combination of the failure to inhibit 
endogenous insulin release (if still present) in response to 
exercise (416), suppressed hepatic glucose production (447), and 
an increase of up to 135% in the absorption rate of subcutaneous 
insulin from the leg (448). This problem should be eminently 
preventable by anticipation of exercise and modification of 
either carbohydrate intake or the preprandial insulin dosage.
With regular training however, beneficial alterations in 
metabolism ensue. Reduced insulin secretion in obesity (449), an 
attenuated counter-regulatory hormone response to exercise (445), 
impaired insulin sensitivity (450) and increased insulin receptor 
binding (451) are all described. Intravenous (452) and post­
prandial glucose tolerance (453) may improve in NIDDM and IDEM 
respectively with a possible reduction in insulin requirements 
(454). However, there is controversy as to whether glycaemic 
control actually improves. Whilst it has perhaps unsurprisingly 
been demonstrated in one study (454), this was not apparent in 
others (450, 455) and was attributed to a compensatory increase 
in the caloric intake over the period of training (455). Other 
encouraging alterations reported in IDDM as a result of training 
are reductions in body weight, blood pressure, serum
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triglycerides (450, 455) and basement membrane thickness (456), 
although the latter improvement could not be independently 
attributed to exercise. An increase in serum HDL cholesterol 
levels has also been reported in IDDM with exercise (450). These 
observations could make regular exercise in IDEM an attractive 
pursuit in the prevention of atherosclerosis. There are however 
cogent reasons to be cautious in adopting this policy on a 
widespread basis in IDEM, particularly in cases where 
microvascular disease is established. It is known that diabetics 
perform less well during exercise than age, sex matched non­
diabetics of similar body mass. The maximum heart rate and 
cardiac output is less whilst a higher blood pressure response is 
observed leading to a reduction of maximum oxygen consumption 
(456, 457). Asymptomatic coronary heart disease, diabetic
cardiomyopathy and autoncmic dysfunction may be in part 
responsible, but metabolic inefficiency characterised by 
excessive fat utilisation and production of lactate and pyruvate, 
and deficient glucose utilisation may also have a contributory 
role. Glycosylation of haemoglobin could also theoretically 
reduce oxygen delivery to the tissues (458). I have previously 
demonstrated that exercise tolerance in hypertensive IDEM with 
underlying coronary heart disease and autoncmic dysfunction is 
associated with an attenuation of the normal blood pressure 
response although calcium antagonist not only improved the 
systolic blood pressure gradient but also improved exercise 
tolerance and ischaemic E.C.G. features in response to exercise 
on a treadmill (459). Other reports have confirmed that 
diabetics with microangiopathy may display a greater blood
pressure response in addition to lower maximal exercise ability, 
although the increment may be attenuated (456, 457). Exercise is 
also recognised to increase transcapillary albumin escape (458) 
and transglcmerular albumin loss leading to increased urinary 
protein excretion (360) and there are anecdotal reports of 
worsening renal function and retinopathy after exercise (458). 
In the case of the hypertensive body builder with diabetic 
nephropathy I previously reported (434), weight training led to 
obvious acute increases in systemic hypertension, urinary 
protein loss and renal blood flow. Exercise such as jogging may 
also not be advisable in diabetic peripheral neuropathy, where 
altered sensation and disturbed foot pressure may promote the 
development of neuropathic arthropathy.
It has even been proposed on the basis of seme of these 
observations that exercise may be used to provoke renal and 
haemodynamic functional abnormalities as a sensitive marker of 
early diabetic microvascular disease (458).
On balance therefore, the triad of exercise, diet and 
insulin need to be modified in the light of established 
complications, and a case could be made for dynamic evaluation of 
the response to exercise in ostensibly healthy IDEM of long 
duration before recommending regular physical activity.
2:3 SELF-MONITORING OF METABOLIC CONTROL
It could be argued that blood glucose self-monitoring is 
primarily a tool for assessing metabolic control and not a factor 
determining it. However since its advent in 1979, a plethora of
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publications has also testified to the pivotal role of 'heme 
blood glucose monitoring' in producing inproved glycaemic control 
perhaps by acting as an aid to education and behaviour
modification. Its overwhelming acceptance may have neglected to 
separate out the parallel and powerful role of increased
attention frcm medical personnel in achieving metabolic control, 
and psychological aspects and the quality control evaluation of 
patient-generated results of heme monitoring require serious 
attention. In the following section I will review the
literature on 'home blood glucose monitoring' and try to put its
role in routine clinical management of IDEM into perspective.
It is perhaps surprising to younger medical practitioners 
that a concept as logical as home blood glucose monitoring took 
so long to be introduced into clinical practice. The publication 
of two papers back-to-back in the Lancet in 1978 (460, 461) are 
often acknowledged to be the first clinical reports of the 
effectiveness of heme blood glucose monitoring in patients' 
hands, although reflectance meters capable of measuring blood 
glucose and sufficiently compact to be used in patients' hemes 
were available in the early 1970's. Patient generated samples 
for heme blood glucose analysis had in fact first been described 
for use in unstable diabetics or in those with abnormal renal 
glucose thresholds as early as 1962 (462). This early
innovation of filter paper impregnation with blood is a patient- 
independent determination of blood glucose, and as such denies 
the opportunity of immediate feedback to the individual. However 
this early concept has recently undergone a renaissance with the 
realisation that by laboratory based validation, quality control
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of patient generated glycaemic data is possible.
All methods of self-monitoring of blood glucose involve 
collection of a drop of capillary blood obtained by fingerprick 
using single prong lancets onto a reagent strip impregnated with 
glucose oxidase, peroxidase and a chrcmogen reagent. It is 
important to stress to patients and health care professionals to 
avoid application of skin cleansing agents prior to blood letting 
(463). Glucose oxidase promotes the production of gluconic acid 
and hydrogen peroxide from the interraction of glucose, oxygen 
and water. The peroxidase catalyses the reaction between 
hydrogen peroxide and the chrcmogen to give a colour change in 
proportion to the concentration of blood glucose. After a set 
time of exposure (usually 60 seconds), the blood is removed frcm 
the strip by either wiping dry with cotton wool, or by washing 
with a stream of water, depending on the reagent strip used. The 
blood glucose level is estimated, after at least a further 60 
seconds, by visual comparison of the strip with a colour chart, 
or by insertion into a reflectance meter. This straightforward 
method works best if the tips of warm digits are used, preferably 
the thumb and index fingers which have the best blood supply. 
Pain may be reduced by using pressure on the target digit using 
an opposing digit to produce counter-irritation. With repeated 
use finger tips coarsen and pain diminishes. The use of elastic 
bands to encourage vascular congestion of the finger tip may also 
promote free flow of blood for sampling. The use of automated 
spring- operated devices (e.g. Autolet and Autoclix) has been of 
particular help in removing the need for visually apparent 
self-assault.
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There are several test strips and meter systems currently 
available and all initial reports validating these methods were 
performed by trained personnel in a hospital setting.
(i) Reagent Strips
Five different systems have been or are presently in use and 
can be read visually or by a meter. The 'Dextrostix' and 
'Visidex' strips (Ames, (UK) Ltd) require application of whole 
blood to the reagent pad for exactly 60 seconds prior to removal 
with a jet of water. After blotting dry, the strip is then read 
immediately. Visual Interpretation of 'Dextrostix' is only 
semiquantitative and is frequently inaccurate in most peoples' 
hands (464), although it provides excellent results when used 
with a reflectance meter (v.i).
On the other hand 'Visidex' is specifically designed for 
visual interpretation, and uses a two colour block system (one 
for values less than 9. 9mmol/L and one for values above 
ll.Ommol/L) to ease interpretation. 'Visidex' readings over a 
wide range of blood glucose values have been reported to 
correlate fairly closely with laboratory reference readings (r= 
0.81-0.97) (465) and in one study with 'EM Stix' (Boehringer, UK) 
(466) (v.i.). However at low ranges of blood glucose (4-
8mmol/L), a poor correlation (r=0.49) with laboratory 
measurements was reported (467), and most studies have reported a 
correlation with laboratory estimates inferior to simultaneous 
'EM Stix' readings (467-469). The overestimation of glucose 
values in the normoglycaemic-hyperglycaemic range reflects 
instability with storage (467-470), and the need for rigid
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adherence to timing of the reaction, in addition to possible
between-batch variability (465).
1
'Visidex' has therefore been superceded by the 'Visidex II' 
which has an additional advantage in not requiring a wash step, 
although instability with storage has been described (471, 472).
The alternative sticks ('Stat Tek Glucose', 'Stat Tek
Glucose Low Level' and 'EM Test 1-44') are all produced by 
Boehringer, Mannheim (West Germany) and can be used with whole 
blood, serum or plasma. After application of the sample to the 
strip, 60 seconds is allowed to elapse before removal with cotton 
wool. An additional minute should expire before the strip is 
read, although glucose levels factor greater than 13.3mmol/L 
require the whole procedure to last at least 3 minutes, to allow 
completion of the colour reaction and accurate measurement. 
'Stat Tek Glucose' sticks cover the range 2.8-19.8mmol/L, and 
'Stat Tek Glucose Low Level' stick measures glucose levels of
0.6-8.3mmol/L, but both methods are semi- quantitative and best 
read with glucose meters, although they are no longer routinely 
used in the United Kingdom. 'EM Test 1-44' sticks cover the 
range l-44mmol/L. They are divided into two colour blocks with 
different colour spectra thereby easing identification. In seme 
individuals, the strips can be cut in half to lower costs. When 
used by patients and health professionals in controlled settings, 
close correlations were reported with the laboratory glucose 
determinations (r=0.85-0.96), irrespective of the level of 
glycaemia (466) . The presence of impaired colour vision and 
retinopathy may (473) or may not (474) impair interpretation of 
results although a poorer performance in older patients has been
described (474).
One further method, 'Glucoscan Test Strips 1 (Lifescan, USA)
i
uses a system of blotting the blood twice, 40 seconds after 
application, and reading the level after a further 20 seconds. 
This semi-quantitative method also requires a meter for reliable 
interpretation and is not used at present in the United Kingdom.
The suggestion that visual assessment of reagent strips is 
not as accurate as meter recorded blood glucose (466) is 
therefore not universally accepted and remains an open question.
(ii) Reflectance Meters
'Eyetone' (Ames Ltd) was the first reflectance meter to be 
introduced in 1973, and was designed for use with 'Dextrostix'. 
It requires an electrical outlet and a warm-up time of 30 
minutes. Although its performance characteristics are acceptable 
for patient use it is bulkier than more recent machines which 
have superseded it.
'Statek' (also known as the 'Reflcmat') (Boehringer 
Mannheim) was introduced in 1977 and is used with ' Stat Tek 
Glucose' or 'Glucose Low Level' reagent strips. As with the 
'Eyetone', it has been validated for patient use, but it also 
requires to be connected to a mains and is rather cumbersome.
The 'R.A.H.C. Glucose Tester' (Australian Biotransducer), 
although lighter and modified for either 'Dextrostix' or 'Stat 
Tek' strips, requires either main line current or batteries for 
operation, and is only available in Australia.
More recent models include the 'Dextrcmeter' (Ames), which 
requires recalibration before each use and has no built in timer,
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and 'Glucocheck' (Lifescan) which although it has a built-in
timer and is mains-operated, cannot be recalibrated with repeated
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use by patients. Both these systems use 'Dextrostix'. The 
'Glucoscan' has recently been replaced by 'Glucoscan II' 
(Lifescan) which uses its own 'Glucoscan' test strips but which 
also has no capacity for recalibration.
'Hypocount I and II' (Betascan) (Orange Medical) are small 
portable battery charged meters with automatic calibration and 
the ability to use either 'Dextrostix', 'Stat Tek' or 'EM 1-44' 
sticks. They have an advantage over meters with liquid crystal 
display such as the 'Gluccmeter' and 'Reflolux' systems (v.i), in 
that they use a light emitting device to produce a bright red 
digital readout, which may be more helpful for patients with 
poor vision, although they are more expensive.
The most widely used machines in the United Kingdom are the 
'Gluccmeter' (Ames) and 'Reflolux' (Boehringer) systems which 
have recently undergone modification to provide additional 
facilities, although at an extra cost.
The 'Gluccmeter' uses 'Dextrostix' and reads glucose values 
between 0.6-22mmol/L. A liquid crystal display (dull black) 
digital readout is provided after 60 seconds, and either 
calibration with plastic chips or solutions (0.6 and 16.5mmol/L) 
ensure reproducability. The calibration is maintained when the 
equipment is not in use. Laboratory glucose values have been 
found to correlate closely with 'Gluccmeter' readings (r=0.97) in 
the hands of technicians over the range 2.0-22.2mmol/l (466), and 
it has been suggested that the precision at lower levels (less 
than lQmmol/L) (r=0.92) may be superior to the 'Reflolux' system
133
(r=0.84), although they are comparable at higher glucose levels 
(466). The major problem with the system relates to batch to 
batch variations in the reagent strips. Using Error Grid
analysis, it has been clearly shown that the 'Gluccmeter' may 
fail to detect hypoglycaemia in patients' hands (475).
This latter problem may have been overcome by the 
introduction of batch-orientated calibration for the 'EM 1-44' 
sticks to be used with the 'Reflolux' machine, with the use of 
the bar code strips for external automatic calibration, produced 
' en masse' with large batches of strips to ensure 
reproducability. The batch bar code strip is inserted into a 
slot on the hinged flap of the 'Reflolux', prior to use. After 
ensuring that the battery system is functioning by the display of 
'888' on the liquid crystal display digital readout, a blank 
reagent strip is then inserted to confirm calibration by display 
of ' 000'. After this, application of a drop of blood onto the 
test slip is followed by pressing the timer button. The display 
window then counts up till 60 seconds have elapsed at which time 
a bell rings and the strip should be wiped with cotton-wool. A 
further 60 seconds should pass before a further bell is heard, at 
which time the hinged flap holding the strip should be closed to 
allow immediate digital display of the result. The 'Reflolux' 
measures blood glucose values between 2.2-22.2mmol/L. Values 
less than 2.2mmol/L are record as 'LEiL', whilst values greater 
than 22.2 are displayed as 'HHH'. Although a high correlation 
is described in several laboratory based evaluations over the 
range 2.2-22.2mmol/l (466, 476, 477), a consistant over-reading 
of up to lmmol/L in relation to the laboratory standard method is
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reported in 2 studies (476, 477), with the opposite finding in 
another (466). All 3 studies seemed to indicate inaccuracy at 
lower levels of blood glucose, but unfortunately the range chosen 
(2.2-10.0mmol/L) by including normoglycaemic and hypoglycaemic 
values, may have flattered the ability of the Reflolux to 
reliably report hypoglyaemic levels (less than 3mmol/L), with a 
tendency to overvaluation. The suggestion that this is 'not of 
therapeutic significance' (476) is I think unfair, particularly 
when put into the context of individuals with hypoglycaemic 
unawareness where a 'Reflolux' reading of 3.2mmol/L may lull the 
subject into a false sense of security despite the fact that the 
laboratory could have estimated the gluose level at 2.3mmol/L. 
It has been suggested that the 'Gluccmeter' may be more reliable 
than the 'Reflolux' in this critical range (466), although this 
remains unconfirmed, as does the suggestion that visual 
assessment of 'EM 1-44' strips is less reliable than the 
'Reflolux' based recordings (466). One major benefit of the 
system is that EM 1-44 strips have been shown to be robust enough 
to be stored and rechecked by meters in clinics to validate 
patient generated data (471, 478). To my knowledge, no one as 
yet has reported long term experience with the 'Reflolux' in 
patients' hands.
Other systems with similar performance characteristics 
include 'Diatron Easytest' (Eastlands Electronics), 'Glucocheck 
II' (Medistron Limited), and Hypocount MX (Hypoguard Ltd.) which 
allows 'EM 1-44' sticks to be cut in half thereby reducing the 
cost of the item with major recurrent expenditure (477). The 
major Improvements in the 'Hypocount MX', 'Diatron Easytest' and
135
the new 'Gluccmeter M' systems, are their size and their ability 
to store and automatically to update glucose values. This 
provides the basis for patient-generated data recorded by a 
patient-independent method to assess the reliability of heme 
blood glucose estimations (478). However the 'Reflolux' system 
costs fifty nine pounds, which is less than other systems (range 
sixty five to eighty five pounds), and was found in a laboratory 
based assessment to be the most precise and accurate (478). 
Premature battery failure seems to be unfortunately frequent with 
most meters in current use. The main refinement in the 'Reflolux 
II' and 'Gluccmeter II' instruments over their predecessors 
relates to their size. They perform to a similar degree of 
precision and accuracy (479-481), although the 'Reflolux II' 
reads over a wider range (0.5-27.7mmol/L) of blood glucose 
values. 'Gluccmeter II' uses specifically designed reagent 
strips - 'Glucostix', which are self calibrated in a similar way 
to 'EM 1-44' strips.
A multitude of alternative instruments have recently ccme 
onto the market: 'Glucoscot GT 4310' (Kyoto-Daiichi), 'Glucocheck 
SC' (Medistron), both of which have memories to store readings, 
and 'Glucoscan 2000' (Lifescan), 'Trendsmeter' (Orange Medical 
Instruments), 'Diascan' (Heme Diagnostics) and 'Glucokey' (Ulster 
Scientific) which do not have this facility; of these the 
'Glucoscan 2000' came up top for precision and accuracy in a 
recent report, and 'Diascan' and 'Glucokey' were found to be the 
most unreliable (481).
On balance it would appear that the 'Reflolux' systems are 
closest to the requirements for an ideal heme blood glucose meter
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for general use at the present time. They are compact, light, 
mains independent, contain the minimum of buttons and mobile 
parts and glucose results compare favourably (r=0.96) with 
reference methods. However problems with short battery life and 
variable performance in the hypoglycaemic range raised the 
important question of how the system operates in patients' hands. 
Such an investigation forms a part of the thesis to be presented.
Sonksen et al in 1978 (460) reported an uncontrolled study 
conducted over four years on 53 insulin-treated diabetics, who 
used the 'Eyetone/Dextrostix' (Ames) system at heme for periods 
of up to 18 months. Patients were lent machines for variable 
periods, and the following scheme for blood glucose readings 
suggested: fasting, pre meals and bedtime recordings as routine, 
with spot checks at other times, particularly when hypoglycaemia 
was suspected. They reported a high degree of acceptability of 
meters by patients, accompanied by an improvement in metabolic 
control assessed by blood glucose results, which was maintained 
for up to 18 months. Patients reported less frequent 
hypoglycaemic episodes and increased ease with adjustment of 
insulin dosage, without significant complications developing. 
70% preferred blood testing to urine testing and 92% wanted to 
purchase a meter although the cost of the system at the time (two 
hundred pounds) precluded this option for most patients. Most 
individuals in this report came frcm social classes I and II, and 
in addition to the use of the meters, 55% of patients changed 
insulin species or the number of daily injections, which clearly 
also had an impact on metabolic control. Finally, no validation 
of patient generated data was reported.
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In another uncontrolled study, Walford et al (461) reported 
on 67 insulin-dependent diabetics who used the 'Reflcmat' meter 
(Boehringer) for varying periods in a study that lasted one year. 
Using a group with a wide scatter of intelligence and social 
class, a 10 point profile was collected whilst working, and 
during a rest day. Samples were taken before, one and two hours 
after each main meal, and before bed. Measurements were repeated 
as necessary after changes in treatment. A close correlation 
(r=0.96) was reported between 'Reflanat' recordings of 20 
individuals and 20 simultaneous auto-analyser recordings. 
Random blood glucose values from the clinic correlated poorly 
with patient generated fasting (r=0.37) and mean morning 
(r=0.41) glycaemic values. A high degree of acceptability was 
reported and over 50% of individuals had produced daily profiles 
in which not more than one blood glucose value exceeded lGmmol/L 
although no attempt was made to validate patient data generated 
at heme.
Outside the United Kingdom, 4 other uncontrolled reports 
without laboratory validation of data were published, using a 
smaller selected sample of individuals. Danowski and Sunder 
(482) reported on 5 individuals on multiple daily insulin 
injections who used the 'Eyetone' (Ames) system for over a year. 
They measured their blood glucose 23 times a week (11 point 
profile once a week ccqprising pre and post prandial and 
nocturnal measurements, and fasting and random glucose 
evaluations on the 6 remaining days). These manoeuvres were 
accompanied by almost all reported glucose values ranging between 
3 and 8mmol/L over the year.
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Peterson et al (483) used the same meter system on 10 
subjects who measured their blood glucose 6 times daily over a 6 
month period, leading to a fall in Hh^ frcm 10.3 to 5.4%. Ikeda 
et al (484) studied 8 subjects with IDEM, reported similar 
results, and confirmed a close correlation between patient­
generated and simultaneous laboratory determinations at the start 
of the study.
Skyler et al (485) studied 32 subjects of unspecified age 
range and reported similar improvements in glycaemic control 
without an alteration in insulin dose. As well as concluding 
that self blood monitoring acted as an educational tool, this 
report demonstrated an effective role for self blood glucose 
monitoring in the confirmation of suspected hypoglycaemia.
These reports were received with great enthusiasm although 
an editorial in Lancet at the time (486) correctly pointed out 
the data was derived frcm small selected groups of motivated 
individuals in whcm other innovations such as more efficient 
insulin delivery and increased attention frcm medical personnel 
would quite reasonably also be expected to have a bearing on the 
outccme. Indeed in one presumably highly motivated group of 
individuals - pregnant diabetics - whilst blood glucose 
monitoring was quite acceptable to them, glycaemic control in the 
last trimeter of gestation was not necessarily better, in 
comparison to wcmen who used urinanalysis to monitor their 
metabolic state (487). One report has suggested that glucose 
self monitoring itself produced little inpact on control in 
unstable diabetic patients following renal transplant if there 
was inadequate contact with medical personnel, irrespective of
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whether individuals were compliant or not (488), and reservations 
have been voiced about widespread use of meters in IDDM, with 
studies yielding comparable results between visual measurement 
and meter measurement of reagent strips (466, 489, 490).
The effect of heme blood glucose monitoring on glycaemic 
control clearly needed to be separated frcm other variables. In 
perhaps the only study of it's kind to date, Worth et al (77) 
studied 38 insulin-treated diabetics and reported no improvement 
in glycaemic control when blood glucose monitoring was used as an 
alternative to urinary glucose monitoring. In view of the 
suprising conclusion, this study requires careful scrutiny.
In objectively evaluating the role of heme blood glucose 
monitoring on a large scale, Worth et al started by inviting 154 
insulin-treated diabetics to participate. The response rate of 
35% (54 subjects) suggests a degree of self-selection, and
pregnancy or established renal disease (plasma creatinine greater 
than 200pmol/L) were deliberately chosen as exclusion critera. 
This study therefore appears to have studied a selected 
population with insulin-treated diabetes. The run-in period of 6 
months, during which time all individuals were reviewed 
fortnightly whilst performing regular urine glucose analysis, was 
designed to separate out the effect of increased attention and 
patient motivation frcm the role of blood glucose monitoring. 
Thereafter patients were randcmised to 3 sequential 3 month 
cycles of continued urine testing or alternatively blood testing 
using either 'Glucocheck' meters (Medistron Ltd) or visual 
assessment with 'EM 1-44R1 reagent strips (Boehringer Ltd). 
During the run-in period, patients were educated about dietary
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and insulin dosage modification as well as receiving instruction 
in heme blood glucose monitoring. It is not clear whether self- 
generated glycaemic data during this period was 'fed-back' to 
patients to allow for alterations in their diabetic care regime. 
They also provided urinanalysis data frcm pre-prandial and pre­
bed samples (4 times daily) using 'Diastix', and were asked to 
provide a 7 point capillary blood glucose profile in fluoride- 
oxalate containers and a 24 hour urine collection, one to two 
days before each fortnightly visit.
Fortnightly measurements of HhAx were made, and cholesterol 
measured after 6 months run-in and at the end of each of the 
optimisation periods. Endogenous insulin reserve was assessed 
by measurement of post-prandial C-peptide. During the cross-over 
period, patients were asked to carry out blood testing on 7 
occasions 2 days each week, and intermittent recordings on 
intervening days when the patient suspected hypoglycaemia or was 
concerned about glycaemic instability. Adjustment of insulin 
dosage was recommended according to a standard algorithm for all 
individuals. It should be observed that only 46 of the
original 54 individuals who commenced the study completed the 6 
month inn-in period, and of these 38 completed the cross over 
period. It could be argued that the final drop-out rate of 33% 
would subject the data to such bias as to invalidate statistical 
analysis.
Whilst the authors suggested that glycaemic control improved 
over the 6 month run-in period, this conclusion was based 
primarily on the graded reduction in urinary glucose excretion 
based on 24 hour samples and analysis of 'Diastix'. However mean
141
blood glucose values determined by laboratory measurement of the 
7 point daily profiles did not alter over this period, although 
it should be stressed that patient compliance in producing these 
profiles was as low as 50% for the fasting sample. It is
debatable whether a maximum fall of 1% in Hh^ is relevant 
despite reaching statistical significance, particularly when one 
considers the persistent elevation of HbA.! throughout this period 
and return to baseline values by the end of the 6 month run-in 
period. Other workers have suggested that a fall in of at
least 1.4% is required if the original value was 10%, to take 
account of the limitations of the assay, before one can claim an 
improvement in overall glycaemic control (115). The fall in 
cholesterol over the initial 6 months may be more attributable to 
alterations in diet, particularly as a fall in dietary 
carbohydrate intake was recorded. Numbers were inadequate to 
state whether residual C- peptide secretion had any bearing on 
the degree of glycaemic control throughout the whole study. 
There were no significant changes in the frequency of 
hypoglycaemic episodes, daily insulin dosage, or body weight.
During the cross-over period of the study, glycaemic control 
remained suboptimal as assessed by various criteria, 
irrespective of the method of monitoring, and cholesterol 
concentration, dietary carbohydrate intake, frequency of 
hypoglycaemia and insulin dosage did not alter. A suprising 
increase in mean serum creatinine concentration was observed in 
all 3 monitoring groups during the cross-over phase of the study 
which may reflect failure to revise the level of significance 
inthe light of multiple ccmparisons. Despite these disappointing
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results, the vast majority of individuals who completed the 
cross-over phase felt more confident with blood glucose 
monitoring, although 40% preferred a combination of blood and 
urine glucose measurements to monitor their own control. There 
was a suggestion when data was analysed chronologically 
irrespective of the method of monitoring, that glycaemic control 
measured by Hh^ improved over 6 months in the cross-over period 
in association with a reduction in dietary carbohydrate, but 
thereafter returned to baseline values.
The major conclusion of the study was that patient education 
and motivation were paramount in improving metabolic control, and 
that whilst self blood glucose monitoring was an attractive 
option, it did not lead to further improvements in control. The 
subsequent deterioration in glycaemic control was attributed to a 
'waning of initial enthusiasm1.
My own interpretation of this study is that the authors may 
have inadvertently introduced a touch of nihilism in addition to 
realism. One of the most striking observations was the 
Inability to lower mean levels of Hh^ much below 10% throughout 
the study. Although this could be interpreted as failure of any 
approach to significantly improve control, this data should have 
been compared with the performance of the much larger group of 
insulin-treated diabetics under ordinary clinic supervision, as 
it is possible, and indeed likely in view of the self-selection 
for the study, that glycaemic control would have been even poorer 
in the residual clinic population.
Furthermore the approach taken to blood glucose monitoring 
may have prejudiced against a more obvious improvement. The
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failure to monitor blood glucose daily is an important factor, as 
glycaemic control is likely to respond better to more frequent 
blood testing (483, 485). The use of algorithms to modify the 
insulin regime was used by Worth et al (77), and would appear a 
sensible approach, but it is not clear whether this system was 
modified for each individual. It is not apparent how often 
patients adjusted their insulin dosage during the periods of 
blood glucose monitoring but the lack of change in insulin dosage 
might infer that very little changed.
At present the question of any independent role for heme 
blood glucose monitoring in improving glycaemic control in IDEM 
remains unanswered. The study to produce that information should 
have the following design and fulfil the following criteria
1. A large unselected sample representative of the clinic 
population with IDEM should be studied, and comparison 
made with data collected in parallel frcm the clinic 
patients who do not participate.
2. The independent effects of education and motivation should 
be separated out by a run-in period of appropriate length 
during which time glycaemic control should improve by a 
combined approach of blood and urine glucose monitoring, 
with advice on adjustment of the insulin dosage appropriate 
for each individual.
3. The opportunity for continued hospital access should be 
encouraged during the phase of the study when blood 
monitoring is compared with urine monitoring, and this 
should be of sufficient duration to see whether loss of
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interest by patients has a major bearing on outcome.
4. In addition to assessing metabolic control, an attempt 
should be made to assess how well individuals retain 
knowledge about aspects of diabetic self-care and perhaps 
more importantly to evaluate how often this information is 
put into practice.
5. Quality control assessment to validate patient generated 
glycaemic data is absolutely essential if patient generated 
data is to be used in statistical analysis.
Following on frcm the final statement, it is clear that 
provision of glycaemic data, collected at heme but resistant to 
falsification or technical error, is often not undertaken, 
although it is necessary in longer term studies. At present 
there are several techniques available which allow comparison of 
patient generated data with a laboratory method, but filter paper 
blood glucose analysis is probably the most realistic approach.
(iii) Filter Paper Blood Glucose Collection
The principle of collecting capillary blood on filter paper 
for storage and subsequent laboratory analysis was first 
suggested by Keen and Knight in 1962 as a method for assessment 
of glycaemic control at heme (462), and later reports have used 
the technique in the same way. More recently Petranyi et al
(491) have reported a high incidence of disparity between 
patient and laboratory determined glucose levels simultaneously 
collected on filter paper, and have suggested a role for filter 
paper blood glucose measurement in quality control.
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Therefore filter paper blood glucose measurement by 
diabetics at heme provides the potential not only for 
documentation and consequent modification of glycaemic control, 
but also in verification of results recorded by patients. Before 
discussing clinical experience with these methods it is necessary 
to discuss certain methological considerations. Several 
approaches to the measurement of blood glucose spotted on filter 
paper have been described (462, 492-499). The type of filter 
paper and blood used, method of glucose determination, storage 
conditions and use of preservatives have led to different 
conclusions regarding precision and reproducability of the method 
and have raised the important practical point of stability of 
blood glucose after application to the filter paper.
The original description of filter paper sampling for blood 
glucose used Whatman GF1B paper and an insensitive manual 
colorimetric method which calculated glucose concentration in 
relation to the prevailing haemoglobin concentration (462). It 
was suggested that glucose recovery frcm filter paper was 
satisfactory for up to one week when stored at rocm temperature, 
but that the use of preservatives would be necessary for 
stabilisation of glucose for longer periods. Seiter et al (492) 
introduced an automated fluorcmetric method and used S+S filter 
paper No. 903. Wakelin et al (493), used plain Whatman No. 4619 
filter paper and a manual method for glucose measurement, which 
was later modified by West et al (494) in the same laboratory for 
use with an auto-analyser. Abyholm (496) used S and S No. 2992 
filter paper and a manual method, whilst Taylor et al (498) used 
Whatman No. 4619 paper and automation, and Burrin et al (495,
146
499) in their work, used automated methods with Whatman No. 3 
filter paper impregnated with boric acid.
Despite the heterogeneity in methods, there is relative 
uniformity in the performance characteristics of the assay 
between those different laboratories, although blood glucose 
recovery and stability could be subject to variation with 
different types of filter paper.
Assessment of filter paper glucose measurements has usually 
been based on either venous or capillary blood spots. However 
although capillary blood glucose and blood volume may be higher 
than venous samples (81), the one report to measure duplicate 
capillary and venous samples taken simultaneously found no 
significant difference in blood glucose measurements frcm the two 
sources (493). The disc of blood-impregnated paper which is 
subsequently eluted is obtained by the use of a hole puncher. 
The sample size used in practice has been either 6mm (493, 494, 
496, 498, 499) or 10 mm (492, 495) in diameter. It is uncertain 
whether this difference could affect comparison of these studies, 
although sample sizes of 15-2Qmm have been found to yield 
significantly greater glucose concentrations than smaller blood 
spots (7-9mm) (496). It is agreed however that blood spots of at 
least 1cm diameter containing approximately lOpl of blood should 
be applied to saturate the paper completely with blood. The 
blood glucose is subsequently eluted frcm the paper using 
different protein precipitants and elution times. Seiter et al
(492) used 1ml of saturated aqueous benzoic acid for 30 minutes, 
but 0.3% perchloric acid (PCA) (495, 496), 2.5% sulphosalicylic 
acid (SSA) (493, 494, 498), or 2% trichloroacetic acid (TCA)
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(498, 499) for 60 minutes are more ccmmonly used. Burrin and 
Price (499) have suggested that TCA has the advantage over SSA 
and PCA since elution is complete after only 20 minutes, but 
there is a suggestion that mechanical agitation may accelerate 
the process regardless of the protein precipitant. Abyholm 
(496) has suggested the use of a correction factor to take 
account of the different distribution of glucose in the standard 
and control serum in comparison to that of filter paper blood, 
but this has not been confirmed by other reports (498, 499).
Recovery of glucose frcm the filter papers has been reported 
to be as low as 79.6% (492), but usually ranges from 80-104% 
using manual methods of glucose determination (493, 496, 498), 
whilst continuous flow automated analysers usually yield 97-110% 
of added glucose (494, 495, 498, 499), in comparison to 94.7% 
with a Beckman glucose analyser (498).
The accuracy of the procedure is usually calculated at 
different glucose levels, in comparison to a standard laboratory 
measurement of glucose in blood without application to filter 
paper. Surprisingly only one report has examined this important 
aspect, and a close correlation (r=0.90) was found when the 
laboratory glucose oxidase method values were compared with 
filter paper glucose levels eluted by TCA and measured by glucose 
dehydrogenase (GDH) (499).
The sensitivity of the assay is defined as the lowest 
reproducable detection limit for that method. It would appear 
that the GDH method is more sensitive for filter paper blood 
glucose measurement (0.26mmol/L) than either hexokinase (HK) or 
glucose oxidase (GOD) methods, and that TCA and PCA appear to be
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more efficient eluants than SSA in contributing to this 
sensitivity (499). These data however, remain unconfirmed.
Within batch precision with glucose levels ranging frcm 3.2- 
32.4mmol/L has ranged frcm 1.8-5.0% in most studies (493-498), 
with higher precision at higher glucose levels. It has been 
suggested that at normal blood glucose concentrations (4- 
5mmol/L), within run reproducability is poorest with the 
hexokinase method, and that GDH and GOD derived values are 
comparable, although the combination of GOD with TCA as an eluant 
led to more variation. At hyperglycaemic levels (15-2Gmmol/L) 
the GDH method has the worst coefficient of variation, 
particularly if SSA was used as the eluant (499). Between batch 
precision also takes into account stability of filter paper blood 
glucose, which may be important, particularly if samples are left 
at rocm temperature without preservatives. Despite this Seiter 
et al (492) reported a within batch coefficient of variation (CV) 
of 4.6% for a normoglycaemic sample stored at rocm temperature 
over 3 days, and CVs of 4.2-7.6% have been reported in other 
studies (493, 496, 498), one of which examined samples at rocm 
temperature for up to 6 weeks (498). Between batch coefficient 
of variation did not vary according to whether manual or 
automated methods were employed (498) and ranged frcm 3.2-6.3% 
for glucose values in the range 8.0-43. 9mmol/L (496-498). The 
observation of between batch coefficients of variation ranging 
frcm 2.3-3.7% over a 3 month period when glucose values ranged 
frcm 6.4-18.8mmol/L, using the GDH method with TCA as an eluant, 
is more encouraging, but this information is difficult to 
interpret since filter cards were stored at -20° C and were
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impregnated with boric acid (499).
Of evident relevance is the effect of storage conditions and 
preservatives to the stability of blood glucose in filter paper. 
This remains an area of controversy and is addressed in the 
series of experiments on filter paper blood glucose measurement 
later in the thesis.
In 1962 Keen and Knight suggested that filter paper glucose 
levels were stable at rocm temperature for up to one week (462), 
and negligible falls were reported by Seiter et al (492) after 72 
hours storage at rocm temperature with or without a dessicator, 
although a reduction of 10% in glucose values was seen by 13 
days. Samples frozen at -20°C under dessication did not lose 
appreciable amounts of glucose (492). Wakelin et al (493) 
reported no significant change after 4 days storage at rocm 
temperature, although by 8 days the glucose concentrations were 
significantly reduced (p<0.05), irrespective of whether or not 
preservatives were applied to the paper.
Abyholm (496) demonstrated stability of glucose without 
preservatives for up to 8 days at rocm temperature, and suggested 
no change in initially low glucose values for at least 3 weeks, 
but an 18% reduction in samples with the highest glucose content 
by 5 weeks. In addition extremes of humidity (10% or 100%) led 
to instability and variability in filter paper glucose values, 
although haematocrits ranging frcm 0.20-0.80 had little effect on 
the measured glucose concentration.
Burrin et al (495) suggested that glucose levels on 
untreated filter paper fell by 20-30% at 5 days, irrespective of 
the storage temperature (rocm temperature 4°C or -20°C), but that
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prior impregnation of the filter paper with 0.8mmol/L boric acid 
prevented any degradation for up to 10 days regardless of the 
temperature. Hochella and Hill (497) have also claimed that 
borate impregnation prevents glycolysis, although this was not 
confirmed by Seiter et al (492) or Wakelin et al (493), who 
likewise found that impregnation with sodium fluoride or benzoic 
acid did not have a glucose protective effect.
Despite these discrepancies, all the studies to date have 
suggested that filter paper blood glucose spots for patient self 
monitoring is a sufficiently robust procedure to allow assessment 
of glycaemic control at hone, and the technique has been applied 
to the management of adult and paediatric IDEM (495, 500), as 
well as NIDDM (501). Self blood glucose monitoring using reagent 
strips or reflectance meters may have an advantage over filter 
paper glucose recording, in delivering immediate feedback of data 
to the individual, but the complementary role of the two methods 
became quite apparent in the report by Petranyi et al (491) who 
found that in 80% of patients with IDEM who were allegedly 
experienced in hone blood glucose monitoring, visual readings 
correlated poorly with the laboratory determined data fran filter 
card blood spots. Whilst only 3 of 14 subjects using reflectance 
meters produced data which correlated poorly with filter card 
glucose values, this survey highlighted how inaccurate patient 
recorded data may be, and highlighted the need for quality 
control of glucose concentrations recorded at hone. One further 
interesting observation fran this study which was not expanded on 
was the recording of biochemical hypoglycaemia at least once 
over the 48 hours of the study in over 60% of cases. It is not
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apparent whether symptomatic hypoglycaemia was observed, but 
these findings could concur with those who have suggested that 
hypoglycaemic unawareness is frequently observed in IDEM (502).
Quality control of patients recordings is of course possible 
using alternative media such as sodium fluoride tubes or Unistep 
bottles (Owen Mumford, U.K.) for the delivery of samples to 
hospital for validation. However practical problems such as 
clotting of samples (493) has inhibited their introduction into 
general use.
A more sophisticated and inevitably more expensive approach 
to quality control is to use reflectance meters modified to store 
recorded glucose values. Whilst these meters have been found to 
be reliable (503, 504), it was demonstrated that many individuals 
who used them were not (505) and even pregnant diabetics have 
been found to under-report high glucose values (506). Whilst 
this technique suggests that there are psychological barriers to 
recording hyperglycaemic data, perhaps to receive the doctors’ 
favour, there are a variety of alternative reasons why errors in 
recorded data may arise, such as unsatisfactory blood monitoring 
technique, use of poorly calibrated meters or reagent strips 
after their expiry date, and inappropriate handling or chemical 
contamination of the strips. The role of memory 'Gluccmeters1 
in improving the self-monitoring performance of diabetics needs 
to be examined in more detail (507), but the more recent studies 
demonstrate that the introduction of self monitoring equipment 
leads to altered behaviour patterns which may not always be 
desirable.
Over the last decade the use of self-monitoring of blood
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glucose (SMBG) has beccme widespread as an aid to diabetic care. 
Major questions remain as how best to implement recommendations 
in a recent consensus statement on self-monitoring of blood 
glucose (508). Whilst there are now well defined subgroups of 
IDDM where self-monitoring of blood glucose (SMBG) should be of 
particular benefit, it is useless in isolation. Appropriate 
instruction in blood testing must be accompanied by general 
education in aspects of diabetic self care and an insulin regime 
which is corpatable with reasonable glycaemic control. More 
information is required on reliability, accuracy and precision of 
meters and reagent strips in unselected patients' hands, which 
can only be achieved by quality control of user-generated data. 
It is also important to see how SMBG influences day to day 
metabolic control and in particular how patients modify their 
diets, insulin or behaviour in the light of the information they 
receive.
2:4. EDUCATIONAL AND BEHAVIOURIAL ASPECTS
It has been suggested that the Joslin clinic medal awarded 
to diabetics of 50 years standing, depicting a charioteer 
directing the three 'wild horses' of insulin, diet and physical 
activity, is reflecting the major controlling influence of 
education in the management of IDEM.
There is certainly little doubt with the introduction of 
heme blood glucose monitoring, diabetic liaison sisters, and 
improvements in insulin delivery, that patients should also 
receive adequate education to facilitate self-care.
In addition to education leading to improved self management
153
and the potential for lessening complications, the diabetic may 
also be able to enjoy an improved quality of life, to decrease 
the cost of medical care by decreasing hospitalisation costs, and 
to improve the general economy by minimising absenteeism from 
work.
At present national and international diabetic associations 
have expanded to take account of this innovation with the 
introduction of education sections. These organisations have in 
turn highlighted certain deficiencies in the educational process.
Perhaps the most important question is to decide exactly who 
should be taught and who should teach. It is logical and 
practical to inform diabetics and relatives, and there is 
increasing recognition of important roles for diabetic liaison 
sisters, dieticians, chiropodists and pharmacists. The role of 
the physician should be pivotal, although there are concerns as 
to how well they educate patients, and suggestions that whilst 
knowledge and the commitment to provision of adequate diabetic 
care may be sufficient in full time diabetologists,it may not be 
in medical practitioners who manage diabetics in a more sporadic 
fashion (509). Whilst a programme of education of non-specialist 
doctors would appear logical to ensure that they are not left 
behind patients and other health care professionals in the quest 
for knowledge, implementation of this process may be difficult in 
practice.
There are two main aspects of the educational process which 
I will discuss: the content of the education programme, and how 
best to implement it. In adopting any educational package it 
would appear fundamental to ensure that it is appropriate and
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realistic for the individual. The one, as yet unanswered 
question, is how to increase the motivation for self-care amongst 
less compliant diabetics. Even with these provisos, diabetic 
educators should implement a programme with objectives defined in 
advance. Whether diabetics respond better to group discussion or 
a one-to-one approach is difficult to be dogmatic about, although 
the management of IDEM tends to be idiosyncratic and 
individualising care may be more appropriate. Involvement of 
family, friends and colleagues at work would also be advantageous 
where possible, particularly in the management of hypoglycaemia 
and illness. The education programme should be designed to 
impart basic knowledge, and ensure understanding of the 
principles by encouraging feedback frcm the patient with the 
opportunity to demonstrate techniques in self management. The 
recommended objectives are summarised in Table 3.
It is important to recognise that establishing attitudes and 
adoption of self-care skills in newly diagnosed IDEM is likely to 
require a different approach to that which will modify the 
practice of neglected long-standing diabetics. It is also fair 
to state that these objectives may need to be modified in 
selected cases, e.g. mountaineering is not ccmpatable with 
hypoglycaemic unawareness.
Whilst I do not concur with specific recommendations of those 
who advise altering the insulin dosage according to algorithms 
by no more than 1-2 units at a time, regardless of the total 
daily dosage (510), it is vital to impart information, if 
necessary in algorithm form, about the onset and duration of 
action of insulins being administered, to help the patient decide
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which type of insulin and which dose (i.e. morning or evening) 
should be altered to stablise glycaemic control.
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TABLE 3 OBJECTIVES OF PATIENT EDUCATION
ATTITUDES
The patient should:
(a) appreciate that IDEM is a permanent condition which can be 
controlled but not cured at present.
(b) recognise that self care is (now) essential to diabetes 
management and should be routine, although professional 
support is available when necessary.
(c) understand that whilst diabetes will impose a few 
restrictions in lifestyle, he or she can do almost anything 
a non -diabetic person can do.
KNOWLEDGE
The patient should be able to:
(a) discuss the normal relationship between blood glucose and 
circulating insulin, and the absence of circulating insulin 
response in IDEM.
(b) describe the relationship between the primary factors 
controlling blood glucose (i.e. food intake, energy 
expenditure and insulin).
(c) discuss the rationale - reducing symptoms and lessening the 
risk of complications - for careful control of blood 
glucose.
(d) state the goals of therapy (target blood glucose levels) and 
discuss the importance of routine self monitoring of blood 
glucose in attaining and maintaining these goals.
(e) discuss the use of glycosylated haemglobin as an indicator 
of glycaemic control.
(f) discuss several possible multi-ccmponent insulin-regimes,
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including the relative advantages and disadvantages of each.
(g) discuss the indications for alterations in insulin dosage
(h) describe the factors that may predispose a patient to 
hypoglycaemia, how to prevent it, and how to recognise and 
treat it.
(i) describe the factors that may lead to hyperglycaemia and 
impending ketoacidosis, and how to intervene to correct 
these.
(j) describe the effects of physical illness and emotional 
stress on blood glucose levels.
SELF CARE
The patient should be able to demonstrate the following skills
and techniques:
(a) insulin dose measurement and injection technique.
(b) dietary selection and estimation of the calorie, 
carbohydrate, protein and fat content of meals, and 
awareness of the Importance of high fibre intake and high 
polyunsaturated: saturated fat ratios.
(c) blood glucose monitoring.
(d) urine glucose and ketone monitoring.
(e) recognition and treatment of hypoglycaemia, including 
accessability to glucagon.
(f) adjustment of insulin dosage.
(g) use of insulin supplements.
(h) alteration of insulin regime to accarimodate exercise.
(i) foor care including cutting of the nails and using 
appropriate footwear.
(Modified from Krall (509)).
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It should be recognised that the educational programme 
outlined is comprehensive and ideal, and therefore not always 
practical. Over the last 20 years, various attempts have been 
made to evaluate diabetic patients' knowledge, to estimate their 
educational requirements and thereafter to audit the results of 
implementing educational packages.
Diabetic education programmes gained early acceptance in the 
United States following reports by Williams et al in 1967, 
demonstrating widespread ignorance amongst insulin-dependent 
diabetics regarding diet, insulin administration, foot care and 
urine testing (511, 512). The indices of knowledge correlated 
with aspects of self-care although not with the relatively crude 
measures of metabolic control available at that time. These 
early findings encouraged the more widespread acceptance of the 
role of diabetic education in the United Kingdom, although it is 
sad to relate after almost 20 years, that a recent survey of 
knowledge amongst 182 Scottish insulin-dependent diabetics 
revealed a degree of ignorance comparable to those early studies, 
particularly with regard to insulin requirements during illness 
and confusion over food constituents and carbohydrate exchanges 
(513). These disappointing findings have been confirmed by other 
reports (514), including one from my own unit (515). Indeed, 
educational defecits have been identified as the cause of up to 
47% of urgent hospital admissions in diabetics in one report 
(516).
These frightening statistics raise the need for more 
preparative planning of educational programmes as well as 
highlighting certain limitations in the educational process. In
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designing educational material, certain patient characteristics 
should be taken into consideration. Demographic factors such as 
learning disabilities and ethnic background are relevant, as are 
psychosocial factors such as health beliefs, attitudes towards 
health providers, and compliance, as well as the level of the 
individual' s diabetic knowledge. Whilst this might be self - 
apparent, medical, nursing and dietetic educators attach 
different priorities to these variables (517). Educational 
strategies should be designed not only to instill knowledge, but 
by improving patient motivation and compliance, to benefit self- 
care and hopefully metabolic control. Non-ccmpliance remains the 
major obstacle to improved performance. It is suggested that 
normal aspects of human behaviour such as self-concept may be 
disturbed in diabetes leading to the development of 
psychological defence mechanisms such as denial or projection 
(518). Failure by the diabetic educator to recognise this 
response often compounds the problem if the education process 
becomes a 'teacher-centred' as opposed to 'learner-centred' 
process. Rather than the educator unloading a mass of information 
onto the patient, the diabetic subject should be encouraged to 
reveal his own expectations and fears. If these aspects are 
incorporated into further education programmes, the behaviour of 
the individual may be beneficially influenced.
Patients' attitudes to diabetes are the consequence of 
several interacting factors: the premorbid personality and
previous experience of ill health, the individual's views on the 
cause of the diabetes and the perception of it's severity, the 
presence of physical symptoms and the immediate and remote
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impact of the condition on his/her lifestyle, and the attitude of 
family, friends, workmates and medical attendants (519). These 
attitudes will almost certainly have an impact on compliance, 
although attempts to investigate this relationship have reached 
distinctly different conclusions (520-522). The health belief 
and social learning models are usually employed to assess 
diabetics1 attitudes to their illness. The health belief model 
suggests that the four factors which dictate compliance with a 
treatment regimen are beliefs about (i) the benefits of 
treatment, (ii) the barriers to treatment, (iii) the severity of 
the condition and (iv) vulnerability to the condition. The 
social learning model or the concept of 'locus of control' 
attributes perceptions of general health and illness to either 
internal or external influences. External influences in turn may 
arise by chance or be the consequence of medical intervention 
(classified as 'powerful others'). When the health 'locus of 
control' scale was applied to obese non-insulin-dependent 
diabetics, compliance was found to be associated with older 
individuals who saw their condition as significantly more severe 
and who exhibited more of an internal locus of control than their 
non-ccmpliant counterparts (520). However compliance in that 
study was assumed, and based on outcome, determined by weight 
loss and improved glycaemic control.
In a study by Schlenk and Hart of 30 insulin-dependent 
diabetic outpatients (521), compliance was assessed as a 
theoretical concept based upon self-reports detailing the 
frequency of good diabetic practice. This was assessed by the 
Multidimensional Health Locus of Control (MHLC) questionaire, a
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'social support1 scale recording patients beliefs regarding the 
frequency of appropriate diabetic management by their family, and 
a 'health value' scale where the importance of health is put into 
overall perspective. A high degree of compliance was reported 
with the exception of appropriate foot care and exercise. 
Compliance was judged to be closely correlated with social 
support, and the 'internal' (IHLC) and 'powerful others' (FHLC) 
health loci of control. Multiple regression analysis 
demonstrated that social support and PHLC accounted for greater 
than 50% of the variance in compliance scores. In simple terms, 
appropriate diabetic practice by patients is most likely where 
there is a high level of family support, and a recognition of the 
importance of medical personnel in control of their diabetes. 
Whilst the conclusions from this study are likely to be valid, 
the high degree of compliance reported suggests a degree of 
selection in the patients studied, which is confirmed by the 52% 
response rate to invitations to participate in this study.
Bradley et al examined 286 insulin-dependent diabetic 
men and women using scales to assess perceived control and health 
beliefs (523). These were specifically designed for IDDM and 
were internally validated. The perceived control scales used 
descriptions of 6 hypothetical events with either negative or 
positive outcomes (e.g. 'Imagine that you have recently 
experienced a hypo' as a negative outcome) with responses graded 
to assess the relative roles of Intemality, Treatment, 
Externality, Chance, Personal Control, Medical Control and 
Forseeability.
Inevitably self-reporting may bias the assessment of
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compliance although patients1 opinions of practical issues may be 
more relevant than questionaires which unintentionally anticipate 
the appropriate response. The results from the study of Bradley 
et al (523) also suggested that patients made primarily internal 
attributions and saw outcomes as forseeable and under their 
control. In addition situations with positive outcomes were also 
reported to be due to recommended treatment and medical control, 
whilst negative outcomes were foreseen to occur by chance. The 
1 health belief scale' measured patients ' perceptions of the 
benefits of and barriers to treatment, and their impressions of 
vulnerability to and severity of problems associated with diabetes 
treatment or complications of diabetes. The benefits of 
treatment were found to outweigh any potential barrier. The 
diabetics not surprisingly perceived themselves as particularly 
vulnerable to all diabetes-related complications with the 
exception of cardiac disease. They were reassuringly.accurate in 
reporting insulin reactions as more likely but less severe than 
hyperglycaemic coma. Of diabetic-related complications, 
deterioration in eyesight generated most concern.
The consensus of opinion from both these reports (521, 523) 
is that effective control of diabetes is the consequence of 
responsable self-management, with adequate support from the 
medical care team and to a lesser degree, the family. When 
things go wrong this is attributed to chance.
The dominant concept of 'self-efficacy' in determining 
compliance has been suggested by Rosenstock (522), and may be 
achieved by a gradual incremental approach to education with 
'proximal rather than distal goals' agreed by the patient and the
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health provider. Maintenance of compliance remains a major 
problem, as suggested by the outcome of longer term longitudinal 
studies of diabetic education (v.i.). The 'relapse prevention 
model' is suggested as a solution, whereby patients are 
encouraged to pre-empt situations which could lead to loss of 
compliance. If the individual can cope in such situations, 
'self-efficacy' is suggested to increase for the next challenge 
(522).
Such concepts are mainly in the province of educational 
psychologists but clearly need to be extended to diabetic 
education programmes in a form that the educators can comprehend. 
This is apparent when reviewing those studies where deterioration 
in patient educational skills is almost universal with time, 
although the success of educational programmes could also be 
judged by improvements in metabolic control or by a reduction in 
hospital admissions or contacts with medical personnel. Laurence 
and Cheely (523a) reported errors in critical areas of self-care 
developing in one third of cases six months after the initial 
programme, and suggested reassessment of patients' knowledge 
every six months.
Korhonen et al (524) found that diabetic knowledge in 
IDEM could be retained for up to 12 months, regardless of the 
intensity of the education programme. Performance was not 
related to age or duration of diabetes, but the level of 
schooling had a bearing on the outcome. No change in dietary 
adherance was reported although patients increased their 
frequency of self-monitoring for urine glucose, irrespective of 
whether they received standard or intensive education. Perhaps
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most important was the observation that a transient improvement 
in metabolic control after one month in both these groups 
regressed to base line levels after six months. Those factors 
which did relate to poor metabolic control were increased levels 
of anxiety and depression, and poor self-confidence (v.i), 
whereas the length of schooling was positively correlated with 
good control. This could suggest that intellect may have a 
bearing on attaining educational goals in diabetes.
Rettig et al (525) noted that a diabetes hone education 
programme made no impact on the number of preventable diabetes- 
related hospitalisations, nor in the length of hospital stay, 
extent of foot problems, number of days off work, or the number 
of 'emergency rocm visits' (usually with hypoglycaemia), despite 
marked improvements in measures of diabetic knowledge and 
practical skills, when carpared to the control group who only 
received cursory education. This study suggested that the 
environment for education is crucial and is supported by the 
report of Beggan et al (526), who despite providing access to a 
hospital based teaching centre, found a dearth of knowledge 
amongst the majority of 75 young patients with IDEM of less than 
5 years standing. The extent of knowledge was confirmed to 
correlate poorly with glycaemic control, but an association was 
found between the duration of formal school education and the 
level of diabetic knowledge.
A recent report has suggested that the best determinants of 
compliance and a positive attitude to diabetes are the carriage 
by patients of a source of sugar and a diabetic identification 
card (527).
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On balance, diabetic educators appear to be crucial in 
advancing knowledge and practical skills in IDEM, but it is 
unfair to claim that this is solely responsible for any reported 
reductions in health service costs, since education programmes 
are often combined with heme blood glucose monitoring and 
improved methods of insulin delivery, each with their own 
independent effects (528).
An unfavourable educational background or attitude to 
diabetes, or a poor self image may contrive to modify 
compliance, thereby limiting the impact of education on metabolic 
control and hospital admissions. Even in apparently motivated 
patients, regular reinforcement of information appears to be 
fundamental. The introduction of computer-assisted learning 
programmes may prove to be more cost effective than diabetic 
educators (529), but this remains to be proven.
Attention was focussed on the psychological and psychiatric 
aspects of IDEM, even before the biochemical basis for the 
condition was understood. The hypothesis that diabetes was the 
consequence of mental illness was proposed by Thcmas Willis in 
1679, who suggested that ’an ill manner of living ..... sometimes 
sadness, long grief, also convulsive affections, and other 
inordinations and depressions of the animal spirits are want to 
beget and cherish this morbid disposition1 (530). In support of 
this, Willis reported on 'two wemen obnoxious to convulsive and 
hypochondriack affections, to whan accrued frcm thence, a great 
flood of urine and langour, and wasting away of the flesh' (530). 
The concept of a diabetes-prone personality is now discredited, 
although there is still considerable support for a role for
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psychological processes in the development of diabetes mellitus 
(531). There is little doubt however, that the patient psyche 
may have an important bearing on the outcane of all chronic 
diseases.
There are several important considerations in discussing 
psychological aspects of IDEM. Firstly, it is important to 
discuss psychiatric illness in a separate context frcm the 
impact of personality traits on the diabetic. Secondly it is 
important to recognise that the age of the patient and the 
particular stage of the diabetic condition can have a bearing on 
how each individual1 s premorbid personality responds to the 
stresses accarpanying IDEM. Thirdly it is necessary to consider 
the role of the family and additional social factors.
With the recognition that development of personality is at 
its most vunerable during childhood and adolescence, a 
predominance of psychological assessments in this particular age 
group of diabetics is apparent. The development of diabetes in 
early adolescence can be viewed as one additional cruel hurdle to 
overcome in addition to the physical and emotional changes that 
accctipany puberty. Diabetic adolescents have been found to have 
lower levels of ego development than their peers, and this is 
particularly apparent in boys (531). Despite this, levels of 
self-esteem were not found to differ between diabetics and 
healthy controls, although the duration of diabetes was inversely 
related to the level of self-esteem (531). Drexler (532) stated 
that such deficiencies in self-image could lead to disordered 
development.
Baker et al (533) used a 'psychosomatic model of diabetes1
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to demonstrate that emotional arousal led to rises in free fatty- 
acid levels, secondary to increases in catecholamine, cortisol 
and growth hormone secretion in young diabetics with recurrent 
ketoacidosis. Furthermore the metabolic changes were blunted by 
administration of beta blockers, which were claimed to be 
prophylactic against stress-induced ketoacidosis. It was 
suggested that such patients had difficulty in handling stress 
and tended to internalize anger. The biochemical abnormalities 
were most apparent in response to parental conflict. The 
suggestion was made that so called 'psychosomatic diabetics' with 
recurrent ketoacidosis would be best managed in a family setting 
with their parents rather than being referred for implantation of 
an intraperitoneal insulin pump. Such cases form a tiny minority 
of the young diabetic population, although lesser degrees of 
psychopathology are commonly recognised.
The suggestion by Swift et al (534) that 60% of diabetic 
children have psychiatric illness has not been substantiated by 
Simonds (535) in a study designed to eliminate selection bias, 
where psychiatric diagnoses were made with the same frequency in 
healthy controls and diabetics (10-15%), irrespective of 
metabolic control. Inter-personal and non-interpersonal conflicts 
were reported in significantly fewer diabetics with good control 
in comparison to either the poor control diabetic group or the 
healthy controls, which could suggest that by rising to the 
challenge of diabetes, the former group achieved a state of 
higher mental well-being. Simonds (535) also found that those 
diabetics with poor control were perceived by their parents to 
have more anxiety and depression than the other groups. Bearing
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in mind the conclusions of Baker et al (533) and Hauser and 
Pollets (531) that family interaction was a major factor in the 
mental health equation, it might be argued that in effect Simonds
(535) had demonstrated the concern of parents projected on to 
their children.
Recently, eating disorders have been recognised as a more 
subtle manifestation of psychiatric illness in IDDM. Wing et al
(536), used validated questionnaires, and found that young 
diabetics did not differ significantly frcm non-diabetic control 
subjects on measures of control of food intake or bulimia. An 
increased score on the dieting subscale of the questionnaire in 
diabetics was said to reflect appropriate adherance to the 
diabetic dietary regime rather than indicating underlying 
anorexia. It was apparent that features of sub-clinical eating 
disorders were ccmmoner in both diabetic and non-diabetic females 
and that self-reported bulimic behaviour was related to poor 
glycaemic control in IDEM. The consequences of disordered eating 
patterns are of course much more dangerous in IDEM than in non­
diabetics, irrespective of the prevalence. Steel et al (537) 
have suggested that the 7% incidence of young female diabetics 
with clinically apparent anorexia nervosa or bulimia in their 
study was higher than expected frcm surveys of non-diabetics. As 
in the report by Wing et al (536) almost all their patients had 
poor metabolic control, although hyperglycaemia was present prior 
to the eating disorder, suggesting that poorly controlled young 
diabetic wcmen are primarily at risk of developing an eating 
disorder, although it does not exclude a role for dietary 
indiscretion in further aggravating glycaemic control.
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Perhaps the most Important finding by Steel et al (537), was 
the close association between eating disorders and complications, 
and in particular the development of acute painful polyneuropathy 
in subjects with anorexia nervosa coinciding with the peak of 
weight reduction. On balance it would appear prudent to treat 
young female insulin-dependent diabetics as a high risk group for 
the development of psychological disturbances, but what of the 
bulk of adult diabetics outwith this category?
Murawski and colleagues (538) studied the personality 
patterns of 112 diabetics of long duration, of whcm two thirds 
were said to be free of vascular complications. Those with 
vascular complications, and males in particular, had 
significantly higher hypochrondriasis scores, and the highest 
incidence of abnormal depression scores. The authors 
acknowledged the difficulty in attributing cause and effect in 
retrospective studies, particularly in the absence of a non­
diabetic control group.
Sanders et al (539) assessed emotional attitudes in an 
uncontrolled study, by a personality assessment questionnaire and 
direct interview with 60 insulin-dependent diabetics and their 
close relatives. Mean values for personality factors were within 
the normal range, although the patients studied were 
characterised by a high incidence of anxiety about hypoglycaemia 
and vascular complications. Those perceived to have problems in 
day-to-day control of diabetes were found to be significantly 
more emotionally unstable. It was suggested that anxiety 
generated by the consequences of hypoglycaemia was often 
transferred to patients1 relatives although data to support this
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conclusion was rather sparse.
In the study by Cassileth et al (540), the assumption that 
certain psychological traits were specifically exaggerated in 
diabetes was challenged. In a comprehensive evaluation of 758 
patients suffering frcm one of six different chronic illness 
(including 199 diabetics aged 18-84 years), the Mental Health 
Index Questionnaire was used to assess anxiety, depression, 
general positive effect, and emotional ties and control. The 
diabetic group, irrespective of whether they were insulin-treated 
or not, did not differ significantly frcm the general public or 
frcm the other groups of physically ill patients for any of the 
measures of psychosocial status. All groups, including 
diabetics, had higher psychological scores (i.e. less 
psychopathology) than a group under treatment for depression. A 
significant direct relationship between higher mental health 
scores and ageing was noted, and newly diagnosed diabetic 
patients had greater anxiety, depression and loss of control. It 
was concluded that there was effective psychological adaptation 
amongst patients with chronic illness including diabetes, which 
was strengthened with increasing duration of disease. Diabetes 
in particular was not associated with any unique emotional 
traits.
In a study of 84 insulin-dependent diabetics without 
advanced complications, Mazze et al (541) found no significant 
difference in personality, anxiety, depression or quality of life 
in comparison to non-diabetics, although all psychosocial 
variables with the exception of personality correlated 
significantly and positively with glycaemic control, independent
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of the type of insulin regime. It was concluded that whilst 
intensive management had no adverse psychosocial effects, 
improved glycaemic control was accompanied by reduced anxiety and 
depression and an improved quality of life, although this was not 
necessarily a one-way relationship. It would appear, therefore, 
that well-controlled healthy diabetics are no more depressed or 
anxious than the general population, in contrast to those 
diabetics with poor metabolic control. However psychological 
disturbances in the latter group seem to respond to improved 
glycaemic control, a feature noted previously in another study of 
depressed diabetics during a period of hone blood glucose 
monitoring (542). It was unclear however, whether it was the 
inproved glycaemia or other factors which determined mood.
An alternative approach has been to examine the effect of 
stress reduction on glycaemic control, and one uncontrolled 
report suggested that biofeedback reduced the range of glycaemic 
excursions in previously stabilised IDEM as well as alleviating 
stress (543).
Whilst acknowledgeing that the majority of healthy adult 
insulin-dependent diabetics appear to be remarkably well adjusted 
psychologically, it would be unfair to extrapolate this level of 
well being to those diabetics with long term complications. 
Although diabetes is the commonest cause of blindness under the 
age of 65, very little is written about psychological impairment 
following visual loss in diabetics, although the pattern is 
likely to parallel blindness frcm other causes, with denial 
initially giving way to depression, anger, guilt and latterly 
acceptance (544-546).
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Impotence has a multifactional aetiology (v.i), and may 
affect 25-50% of male diabetics. Although psychological overlay 
is recognised in all cases, the effect of established impotence 
on the psyche of diabetics is uncertain (544, 545), although a 
higher depression rating has recently been reported (547).
The response to anputation may vary according to the 
premorbid personality, but has been likened to the grief reaction 
following bereavement (544).
The uraemia associated with renal failure may itself 
produce neuropyschiatric features, and it has been suggested 
that the behaviour of patients with renal disease may regress to 
resemble the dependency apparent when diabetes was first 
diagnosed (544). Although myocardial infarction is ccrnmon in 
diabetics, there is little written on the pyschological impact of 
coronary heart disease in diabetes, despite the fact that up to 
20% of infarct survivors develop a treatable depression within 5 
months of the event (544). Finally, the development of
hypoglycaemic unawareness in longstanding diabetes, by imposing 
certain restrictions on the individual might be expected to lead 
to anxiety, if not in the patient then at least in a relative 
(544).
Therefore it is inappropriate to assign psychological 
stereotypes to all diabetics and the balance of opinion suggests 
that psychological evaluation should not be a priority for the 
vast majority of metabolically stable patients with IDEM. A low 
index of suspicion for psychological disturbance may be helpful 
in the management of unstable diabetics (particularly young 
females) and/or those with debilitating coiplications, in whcm
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the levels of glycaemic control and mood may have a bearing on 
one another.
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2; 5. SPECIFIC CLINICAL AND BIOCHEMICAL FACTORS
It is not stated in standard textbooks with any certainty, 
but there is a strong clinical impression that metabolic control 
is poorer in insulin-dependent diabetics with vascular 
complications when compared to those without. An accumulation of 
different factors may combine to create this situation. For 
example, individuals with retinopathy may be less reliable when 
it comes to monitoring reagent strips visually (473, 474) and 
diabetics with neuropathy may be more prone to infections and 
subsequent hyperglycaemia (sensory neuropathy and foot 
infections, autonomic neuropathy and urinary tract infections). 
The development of nephropathy-associated hypertension or 
coronary heart disease may require treatment with p-blockers 
which could affect metabolic control (548), whilst microvascular 
changes in the skin might affect the bioavailability of injected 
insulin leading to erratic glycaemic control (394). Autonomic 
neuropathy may be accompanied by hypoglycaemic unawareness (549), 
although the two problems may be associated rather than the 
former being causal. Whatever the cause, rebound hyperglycaemia 
(the 1Scmogygi1 effect) may therefore be more frequent leading to 
metabolic instability. In addition cross-sectional surveys have 
testified to the role of metabolic control in the pathogenesis of 
vascular complications (7-9, 15, 17, 57) when in fact they have 
provided only circumstantial evidence of this by demonstrating 
poorer metabolic control in those with established vascular 
complications who were matched for demographic variables with a 
group free of complications.
Another controversial issue is the role of residual
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endogenous insulin secretion in metabolic control. Whilst it 
used to be thought that true type I (insulin-dependent) diabetes 
was characterised by canplete loss of p cell function (550), 
there is now conclusive evidence that this is not so (551). 
Because insulin and C-peptide are secreted in equimolar amounts 
after cleavage fran proinsulin, measurement of C-peptide gives an 
estimate of residual endogenous insulin secretion. C-peptide can 
be measured in serum or urine, following fasting, or in response 
to physiological or pharmacological stimuli (552, 553). Equally 
reliable ways to measure all residual p cell function are to 
measure the C-peptide increment 6 minutes after Img of 
intravenous glucagon, or C-peptide levels 1 hour after a mixed 
meal (553). Detectable levels of C-peptide have been found in 
almost 100% of patients with IDEM 2 years after diagnosis, but 
thereafter there is a gradual fall off in the response so that 
only 15% of patients have measurable C-peptide activity after 15 
years of diabetes, although the incidence is then said to remain 
constant (551). Those factors which have been found to be 
important in predicting the quantitative C-peptide response are 
the duration of diabetes, the insulin antibody titre and the 
degree of hyperglycaemia, all of which are inversely related to 
C-peptide, and the age at diagnosis, which is directly related to 
C-peptide levels (554).
One outstanding question is whether residual p cell
function itself has any impact on long tem metabolic control
and the prevention of complications. There are suggestions 
that a persistent albeit reduced portal insulin supply may
improve glycaemic control (551, 555), but this remains
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controversial (551, 554, 556), although more recently C-peptide 
secretion in middle-aged insulin-treated diabetics was found to 
have a bearing on lipoprotein levels, in particular on the HDL2 
and HDL3 cholesterol subfractions (293). At the time of
writing of this thesis a report has been published suggesting 
that residual insulin production assessed by urinary C- peptide 
excretion, leads to improved metabolic control, and that these 
patients have a lower prevalance of microvascular complications 
(557).
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3 EPIDEMIOLOGICAL AND PATHOPHYSIOLOGICAL ASPECTS OF VASCULAR AND
NON-VASCULAR COMPLICATIONS
I have suggested that the excessive morbidity and mortality 
associated with IDEM is determined by a combination of metabolic, 
haemodynamic, environmental and genetic factors. The evidence to 
support this is based predominantly on large cross-sectional and 
retrospective epidemiological surveys, but also on prospective 
longitudinal studies. Unfortunately many such studies have 
examined non-insulin-dependent diabetics along with small numbers 
of insulin-dependent diabetics.
In addition, the criteria for classification of 
macrovascular disease is often rather crude and excludes patients 
with clinically evident but asymptomatic atherosclerosis.
In broad terms, insulin-dependent diabetics appear more 
susceptable to atherosclerosis than the non-diabetic population, 
and develop a specific angiopathy of the microvasculature which 
most significantly affects the eyes and kidneys. The 
pathogenesis of the somatic and autonomic neuropathy of IDEM 
appears to have both vascular and metabolic components.
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3:1. ATHEROSCLEROSIS (MACROVASCULAR DISEASE)
In assessing the impact of atherosclerotic disease on IDDM , 
it is necessary to acknowledge limitations in published 
literature on the subject. Firstly, although less relevant to 
non-insulin dependent diabetes, temporal factors such as the age 
and duration of diabetes at the time of the study are of 
overwhelming importance in both cross- sectional and longitudinal 
surveys of IDEM. The second point is to take into consideration 
the ethnic background of the population studied, as this has a 
bearing on the development of atherosclerosis. In this regard, 
epidemiological data on non-diabetics frcm the same ethnic 
background makes useful comparison. Thirdly, it is important to 
appreciate that epidemiological surveys may provide different 
information according to the design of the study. For example 
morbidity and mortality data are not always comparable, and 
mortality can be expressed as an acute event, or by using 
cumulative mortality rates, assess the long term prognosis. The 
term prevalence refers to the frequency at a particular point in 
time (i.e. in cross sectional studies) whilst incidence reflects 
the development of the particular trait over a period of time 
(i.e. in longitudinal surveys). It is also important to 
recognise that risk factors are not necessarily causal factors 
but may simply be acting as a marker for more important 
unidentified variables.
Notwithstanding these considerations, there is evidence of a 
changing pattern in the incidence of atheromatous vascular 
disease in diabetes. Albrink et al (244) found that whilst 10% 
of diabetics treated with or without insulin during the decade
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1930-1939 had clinical evidence of large vessel disease, the 
frequency in a group of similar age and duration of diabetes was 
56% over the period 1951-1961, despite no change in the incidence 
of microvascular disease. The observation could not be explained 
by improved diagnostic techniques and was supported by mortality 
data, suggesting a true increase in diabetic atherosclerosis. 
More recent evidence has confirmed that atherosclerosis, 
primarily conorary heart disease, is the leading cause of 
premature death in diabetics under fifty years of age (558). In 
a study by Deckert et al (559), renal failure was said to be a 
more canmon cause of death than coronary heart disease in Danish 
insulin-dependent diabetics diagnosed under the age of 31, 
although the contribution of vascular disease to mortality in 
those with nephropathy was not disclosed, and an intimate 
relationship between diabetic renal disease and coronary heart 
disease has since been described (560).
The prevalence of coronary heart disease in IDEM is 
difficult to ascertain with certainty because of differing 
diagnostic criteria. In a study by Reckless et al (561) of 154 
middle-aged diabetics of greater than 20 years duration, of whcm 
70% were insulin dependent, roughly 38% had features of 
macrovascular disease at varying sites. The WHO Multinational 
Study of vascular disease in diabetes (8) revealed considerable 
variation in the apparent prevalence of vascular disease between 
centres. Over 6,500 diabetics aged 35-54 years were studied, of 
whcm 40% were likely to have been insulin-dependent. The 
prevalence of large vessel disease ranged frcm 29-36%, with 
unequivocal ECG evidence of previous myocardial infarction in 4-
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7%, and general features suggestive of coronary heart disease in 
25-34% of cases. In a report by Knuimann et al on 179 insulin- 
dependent diabetics (7), whose mean age was 33.8 years and mean 
duration of diabetes 12.6 years, the prevalence of macrovascular 
disease (coronary heart disease, peripheral vascular disease or 
cerebrovascular disease) was 14.9% in men and 16.7% in women. 
Deckert et al found objective signs of myocardial infarction in 
21% of patients whose duration of IDDM exceeded 40 years (559).
Post-mortem examinations have demonstrated more extensive 
atheroma and myocardial damage in diabetic coronary arteries, 
particularly in those who were insulin-treated (562-564).
Diabetic atherosclerotic lesions have been reported to have an 
increase in the extent of fatty streaks, and an excess of raised 
lesions complicated by ulceration, thrombosis or haemorrhage
(562). These adverse features explain in part the worse short­
term prognosis following myocardial infarction in diabetics 
(565). In addition the cumulative 18 year incidence of coronary 
events in diabetic patients (myocardial infarction, angina or 
sudden death) in the Framingham study (566) was 1.6 times that of 
non-diabetic men, and 2.1 times that of non-diabetic women. The 
cumulative 16 year cardiovascular mortality rates from the
Framingham study were even more striking when one looks
specifically at insulin-treated patients, where the rate was 
increased 2-fold in males and over 7-fold in women (567). The 
Finnish Social Insurance Institutions' Health Survey (564) has 
also reported a 9-fold excess of coronary heart disease mortality 
in insulin-treated diabetic women in relation to the general 
population, whereas in insulin-treated diabetic males it was
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increased 3 fold over a 9 year period of observation. In the 
prospective Whitehall study, Jarrett and Shipley (568) reported 
that the 10 year coronary heart disease mortality in insulin- 
dependent diabetics was 1.6 times higher than non-diabetics, 
although only 46 insulin- dependent diabetics were recruited at 
the beginning of the study.
Peripheral vascular disease is usually diagnosed if typical 
symptoms of intermittent claudication and/or absent foot pulses 
or amputation are recorded. Although involvement of the lower 
extremities is most common, branches of the thoracic and 
abdominal aorta may also be involved. The pattern of peripheral 
vascular disease in diabetes reflects more widespread deposition 
of atheroma and has a particular propensity for the distal 
popliteal arteries below the knees. The prevalence of peripheral 
vascular disease in IDEM is difficult to determine because it is 
often not categorised separately, and is often recorded as a 
component of macrovascular disease. In the WHO multinational 
study, intermittent claudication was reported in roughly 1.5% of 
cases, whilst amputation was recorded in 1.2% of female and 2.0% 
of all male diabetics (8).
In the Framingham study (567), intermittent claudication was 
found to be roughly 5 times more common in diabetic men and 4 
times more common in diabetic women than non-diabetics in the 16 
year follow up report. The study by Beach et al (569) reported 
on insulin-dependent diabetics aged 33-35 years whose duration of 
diabetes averaged 17 years, and found that 26% of 77 men and 22% 
of 67 women had evidence of peripheral vascular disease. Deckert 
et al reported the prevalence of amputation and gangrene as 12%
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in insulin-dependent diabetics who had survived for more than 40 
years (559).
Relatively little attention has been paid to the association 
between cerebrovascular disease and IDEM, although 7% of 
premature deaths in young diabetics have been attributed to this 
cause (558). Cerebrovascular disease is usually diagnosed by the 
rather crude end point of an established stroke. Cerebral
infarction has been reported with increased frequency in post 
mortem studies of diabetics (570) and in the prospective 
Framingham study where the rate was roughly two and a half times 
greater than in non-diabetics (567), but cerebral haemmorhage may 
not be more canmon in diabetes (570). In a study of non-insulin 
dependent diabetics, the degree of hyperglycaemia correlated 
directly with the severity of the ischaemic stroke (571). In the 
WHO multinational study completed strokes were recorded in
roughly 1-2% of cases (8). Kuebler et al (572) assessed
subclinical carotid artery occlusive disease in 482 diabetics 
whose average age was 58 and duration of diabetes was 8.8 years, 
of whcm 5% were insulin-dependent. They found 20% of all cases 
and 14% of those with IDEM had detectable carotid artery disease. 
Deckert et al found a 10% prevalence of stroke in IDEM of more 
than 40 years duration (559).
There is therefore overwhelming evidence for a more 
widespread aggressive atherosclerosis in all types of diabetes in 
comparison to the rest of the population, regardless of the
ethnic background. What remains uncertain is whether this is due 
to an excess of risk factors which predispose to athercma in 
general or whether additional specific factors operate in
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diabetes.
An abundance of epidemiological studies testify to 
independent roles for cigarette smoking, hypertension and both 
hypercholesterolaemia and hypertriglyceridaemia as risk factors 
for the development of atherosclerosis and premature 
cardiovascular mortality in the general population (573-578). 
Additional factors with less predictive value include obesity 
(577), stress (16) and relative hyperinsulinaemia (579). A role 
for impaired glucose tolerance, short of overt diabetes mellitus, 
has been suggested as a mediator of large vessel disease (580), 
although this relationship has not been found in other studies 
(581, 582).
There is more disagreement as to the relative importance of 
these risk factors in the development of macrovascular disease in 
diabetes, and suggestions that there are marked differences in 
the associations of risk factors and vascular disease at 
different sites. One major reason for the dilemna is the failure 
to separate insulin-dependent frcm non-insulin-dependent 
diabetics in the analysis. A s a  result, differences between 
these two broad categories in age, body mass index, lipid 
metabolism and blood pressure, which may be relevant to the 
pathogenesis of atherosclerosis, have been neglected. In 
addition, the phenomenon of 'clustering1 of risk factors, whereby 
the presence of one cardiovascular risk factor is associated with 
another, is more common in diabetes (583), and this will further 
hinder attempts to demonstrate an independent predictive role for 
risk factors in diabetics by multivariate analysis. Finally, the 
recent awareness of the specific susceptability of proteinuric
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IDEM for developing macrovascular disease (560) was not 
appreciated in the earlier population studies.
The WHO multinational study on over 6000 diabetics found 
that the risk and prevalence of macrovascular disease was the 
same for diabetic wcmen and men in contrast to non-diabetics (8, 
17). Although age and body mass index were often powerful 
predictive variables for all types of cardiovascular disease, 
these might have reflected the preponderance of older non­
insulin-dependent diabetics. This possibility was supported by 
the lack of correlation with coronary heart disease and duration 
of diabetes, which has since been recognised to be important in 
determining coronary heart disease in IDDM (559, 584). Using 
multiple regression analysis, coronary heart disease was most 
strongly related in insulin-treated diabetics to serum 
triglyceride levels, and to a lesser extent cholesterol, whilst 
systolic blood pressure was a weak independent risk factor (17). 
Neither fasting blood glucose levels nor the duration of diabetes 
were related to coronary heart disease, although both were 
important determinants of peripheral vascular or cerebrovascular 
disease, as was systolic blood pressure. Serum triglycerides 
were not found to determine non-cardiac vascular disease, 
although cholesterol levels were weakly predictive of strokes. 
The fact that many individuals were receiving anti-hypertensive 
medication may have minimised the importance of blood pressure as 
an independent risk factor, particularly since one major 
longitudinal study by Christlieb et al (58) has suggested that 
hypertension is the major risk factor for vascular disease in 
insulin-dependent diabetes. Perhaps even more suprising was the
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failure to find an effect of cigarette smoking on vascular 
disease, although this may reflect the weakness of cross- 
sectional prevalence studies.
In contrast, the Framingham study was able to prospectively 
evaluate risk factors for diabetic vascular disease (566, 585). 
293 diabetics were incorporated into the original cohort. The 
major finding frcm multivariate analysis was the overriding 
predictive value of HDL cholesterol for coronary heart disease, 
particularly in insulin-treated diabetic women (585). Lew 
density lipoprotein cholesterol and measures of hypertension were 
also found to be significantly associated with macrovascular 
disease in both males and females, but triglyceride levels were 
not independently correlated with coronary heart disease. Body 
mass was related but reflected the large number of obese non­
insulin-dependent diabetics in the study. The cluster effect may 
again have 'blurred1 any independent role for cigarette 
consumption in diabetic vascular disease .
The Whitehall study comprised 168 diabetics (of whcm only 46 
had IDEM) out of a total of over 18,000 civil servants (568, 
580). Subsequent death frcm macrovascular disease, primarily 
related to systolic blood pressure in the diabetic group, was 
predominantly due to myocardial infarction, but the IDEM group 
was too small for independent analysis. The most striking 
feature was the lack of relationship between macrovascular 
disease and smoking, cholesterol or post-prandial glucose values.
Beach and colleagues examined risk factors for peripheral 
vascular disease in both insulin-dependent and non-insulin- 
dependent diabetics in cross-sectional and retrospective studies
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(569, 586). Neither fasting blood glucose nor glycosylated
haemoglobin values correlated with the prevalence of peripheral 
vascular disease, but smoking was found to be the major 
determinant, and independent associations were also found with 
duration of diabetes, and VLDL triglyceride and LDL cholesterol 
levels.
Zimmerman and colleagues found that high levels of 
triglycerides were the only distinguishing feature of lipid 
metabolism in diabetics with peripheral arterial disease (587)).
The report by Tunbridge (558) on premature death in young 
diabetics canmented that deaths frcm myocardial infarction were 
associated with hypertension, smoking and obesity, but no attempt 
was made to assess their role as independent risk factors.
Knuiman et al (7) pointed out in a cross-sectional survey of 
1084 diabetics (179 with IDDM) that there were few differences in 
the risk factor profiles for large vessel disease in IDDM and 
NIDDM, after correcting for time-related risk variables. The 
major association for macrovascular disease was with age, but 
Interestingly stepwise regression analysis also found direct 
associations with renal dysfunction (reflected by serum 
creatinine), autoncmic dysfunction (implied by the postural blood 
pressure gradient), glycaemic control (assessed by glycosylated 
haemoglobin), plasma cholesterol, and an inverse correlation with 
HDL cholesterol.
In a cross-sectional analysis of risk factors for carotid 
artery occlusive disease (CAOD) in 482 diabetics (of whcm only 5% 
had IDDM), those subjects with CAOD were older and had 
significantly higher levels of cholesterol and systolic blood
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pressure, but no correction for age or regression analysis was 
carried out (572). Likewise, in the cross-sectional study by 
Reckless et al (561), those insulin-dependent diabetics with 
vascular disease had significantly higher levels of total and LDL 
cholesterol and total and VLDL triglyceride, and were older, more 
hypertensive and obese, but the specific contribution of each of 
these risk factors was not stated, although as in the Framingham 
study (585) diabetic watien had low HDL cholesterol levels in the 
presence of vascular disease, regardless of their type of 
treatment.
Whilst blood pressure appears on balance to be an important 
deteminant of macrovascular disease in diabetes (including 
IDDM), the suggestion of an independent role for cigarette 
smoking or cholesterol is not overwhelming, although as stated 
earlier (576), this may reflect limitations in study design. The 
important inverse relationship between HDL and vascular disease 
in wcmen with IDDM needs to be restated although confirmation is 
required in prospective studies. However even if all associated 
risk factors are taken into consideration and one accepts the 
principle that small increments in combined risk factors could 
make a sizeable impact on large vessel disease (588), this would 
fail to account for the excess of cardiovascular mortality 
which is particularly apparent in insulin-dependent diabetic 
wcmen. Therefore currently unrecognised risk factors need to be 
incorporated into the equation. In this respect, it is of 
interest to find in the study by Knuimann et al (7), that serum 
creatinine levels figured prominently in the risk equation for 
macrovascular disease. The development of renal dysfunction in
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IDDM characterised by proteinuria has been found to predict 
mortality not only frcm renal disease but also frcm cardiac 
disease (560). In fact the life expectancy of non-proteinuric 
patients was not much different frcm non-diabetics of similar age 
(560). It may be more than coincidental that the rises in blood 
pressure which predict vascular disease accompany the 
development of nephropathy (357, 358). However the additional 
potential for disturbances of lipoprotein metabolism (331), 
vascular permeability (589), and coagulation (590, 591) in early 
diabetic renal disease to enhance the risk of macrovascular 
disease should not be underestimated.
Platelet dysfunction and disturbed coagulability and 
haemorheology are features of poorly controlled IDEM which may 
also accompany diabetic nephropathy (592-594). Fibrinogen in 
particular may accelerate diabetic macrovascular disease, and 
elevated levels have been reported in association with diabetic 
nephropathy (591, 595). Therefore, whilst previous
epidemiological studies have failed conclusively to demonstrate 
independent roles for all the traditional risk factors in the 
development of cardiovascular disease in IDDM, the recognition 
that it is the proteinuric sub-group of IDEM who are most at risk 
of macrovascular disease should make clear the need for a 
prospective examination of the role of risk factors in IDDM with 
or without nephropathy to define their pathogenic role more 
clearly. In particular, the combination of hypertension, 
disturbed lipoprotein metabolism and altered haemorheology in 
those insulin-dependent diabetics with established nephropathy 
may act synergistically to propagate atherosclerosis. Whilst
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such speculation will remain hypothetical for sane time, it is 
worth considering how these additional factors may influence 
current concepts on the mechanism of atherogenesis.
The prime mover in the process of atherogenesis is thought 
to be endothelial injury, whereby the integrity of the arterial 
intimal endothelia is breached. It is thought that prior to 
this, circulating monocytes adhere to endothelial walls and then 
migrate across intact endothelial barriers, accumulating lipid 
and thereby transforming into foam cells in the sub-endothelial 
space (16, 596, 597). Haemodynamic factors such as arterial 
stiffening and hypertension (598), irrmune complex deposition 
associated with microangiopathy (599), and peripheral 
hyperinsulinaemia (16) and the modified lipoproteins of IDEM 
(597) might all be expected to affect endothelial function. An 
increased transcapillary escape rate of albumin is described in 
diabetics with incipient nephropathy (589), and a similar process 
might operate in larger vessels to facilitate the entry of 
atherogenic blood components into the arterial wall. Further 
evidence for endothelial damage in diabetes is provided by the 
observation of reduced levels of endothelial-derived 
prostacyclin, and elevated circulating levels of factor VIII 
related antigen (597).
The accumulation of foam cells in the arterial intima may be 
enhanced in diabetes by the effects of glycosylation and 
oxidation of lipids (600). There is evidence to support a 
cytotoxic effect of lipid peroxides on the arterial intima, and 
glycosylation of low density lipoprotein (LDL) in particular may 
promote lipid deposition in the intima (597). In addition there
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is evidence for preferential uptake of very low density 
lipoprotein (VLDL) remnants by both foam cells and smooth muscle 
cells, and levels of these remnants (the so called intermediate 
density lipoproteins (IDL)) may be particularly high in diabetes 
(597).
The next stage in the atherogenic process is the migration 
of smooth muscle cells frcm the media to the intima, possibly in 
response to mitogens produced by the foam cells. The smooth 
muscle cells then proliferate with the accumulation of 
connective tissue and the deposited lipid, leading in turn to the 
formation of a fibrous plaque. The adherance of platelets to 
the exposed sub-endothelial connective tissue promotes extension 
of the athercma, by secreting platelet-derived growth factor 
(PDGF), which further stimulates smooth muscle cell proliferation 
and uptake of LDL. Most studies have demonstrated an increased 
capacity of diabetic platelets to adhere and aggregate both in 
vitro and in vivo (592-594), and an excess of FDGF has also 
been recorded in diabetes (601). These latter abnormalities are 
of course also relevant to the final thrcmbo-embolic sequelae of 
athercma.
The effects of diabetes on the metabolism of the connective 
tissue which accumulates in the atherosclerotic plaque may also 
encourage progression of the lesion. Increased amounts of 
glycosylated collagen are apparent in diabetic skin and muscle 
(602), and may also be present in arterial wall collagen. This 
cross-linked glycosylated collagen is less susceptable to 
enzymatic degradation, and appears to act as a stimulus for 
further influx into and platelet adherence to the athercmatous
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plaque (597, 600).
The final expounding variables in promoting both athercma 
and thrombosis in diabetes are disturbed coagulability, 
characterised by increased level of clotting factors and platelet 
dysfunction (591-594), hyperviscosity as a consequence of reduced 
erythrocyte deformability, and elevated levels and enhanced 
aggregability of fibrinogen (590, 591, 595, 598). These
abnormalities are often reported in those diabetics with 
microangiopathy (591, 595), which strengthens the hypothesis that 
the development of microvascular disease (exemplified by diabetic 
nephropathy) is a vital link in explaining the excess of atheroma 
in IDEM.
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3:2 MICROVASCULAR DISEASE-RETINOPATHY AND NEPHROPATHY
Both retinopathy and nephropathy make a substantial 
contribution to morbidity, and nephropathy is also implicated in 
the excess mortality of IDEM. Whilst metabolic and temporal 
factors appear to play a dominant role in epidemiological and 
pathophysiological studies of diabetic microangiopathy, there is 
continued resistance to the idea that these complications are 
specifically caused by metabolic derangements (603). As with 
many aspects of diabetic complications, there are likely to be 
additional undetermined immunological, genetic and vascular 
components to the problem. In discussing clinical studies which 
have attempted to shed light on the natural history of these 
complications, it is important to state that apparent 
contradictions when ccnparing cross-sectional analyses with 
either prospective or retrospective studies may reflect a role 
for both hyperglycaemic and hypoglycaemic fluctuations in the 
pathogenesis of microangiopathy.
Diabetic retinopathy is the ccmmonest cause of blindness in 
the under-sixties in the western world, and is equally common 
amongst males and females (11). Deckert et al (559) found that 
16% of those who had survived over 50 years of IDEM were blind, 
whilst a further 14% had severe impairment of vision. Virtually 
all surveys (7-13, 40, 604, 605) have demonstrated that the risk 
of retinopathy increases with increasing duration of the 
diabetes. Consequently prevalence data is dependent upon the 
mean duration of diabetes in the population studied.
The WHO multinational study (8) had the benefit of
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studying over 6,000 diabetics aged 35-54 years, of whcm over 
1,000 were insulin-treated diabetics of at least 7 years 
duration. Retinopathic blindness was present in 1% and 6% of all 
diabetics with a duration of disease less than 7 years and 
greater than 14 years respectively, whilst new vessel formation 
was a feature of 0.8% and 8% of the two respective groups. 
Minimal microvascular disease of the eye (microaneurysms or no 
discemable retinopathy) was found in roughly 6.5% of diabetics 
of more than 14 years duration.
Using a slightly different classification, Knuimann et al 
(7) found vision-threatening retinopathy (proliferative, 
obstructive, ischaemic or macular retinopathy) in 10.3-10.9% of 
insulin-dependent diabetics whose average age was 34 and whose 
duration of diabetes averaged 12.6 years. Interestingly over 
60% of cases had no opthalmoscopic or fundus photographic 
evidence of retinopathy.
Telmer et al (606) reported a prevalence of proliferative 
retinopathy of 16.7-20.4% in 668 insulin-dependent diabetics 
whose mean age was 36.5 and duration of diabetes 21 years. These 
figures are very much in keeping with those of Borch-Johnsen et 
al (584) who found proliferative retinopathy in 24% of the 187 
insulin-dependent diabetics of more than 40 years duration. 
Background changes were recorded in 38% of cases, but at least 
26% of the patients had no opthalmoscopic evidence of 
retinopathy.
In a prospective evaluation, Young et al (40) recorded that 
7% of the 75 young insulin-dependent diabetics whose duration of 
diabetes ranged frcm 7-17 years had early background retinopathy,
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whilst after a further average follow up of 2.5 years, 33% had 
detectable retinopathy, and 12% had either pre-proliferative or 
proliferative changes.
In general, whilst these studies reaffirm the development 
of a high incidence of significant retinopathy with time, it 
appears that as many as one quarter of long-standing insulin- 
dependent diabetics will never develop clinically detectable 
retinopathy, although angiographic evidence is said to be present 
in up to 90% of diabetics of over 20 years duration (607).
Several cross-sectional evaluations of risk factors for 
retinopathy have demonstrated that the duration of diabetes is 
the strongest predictor (7-9, 604, 605), but thereafter all 
markers of glycaemic control are independently associated with 
retinopathy. Blood pressure and systolic levels in particular 
have also been reported to be independent risk factors for 
retinopathy (7-9, 604), above all for proliferative changes (584, 
605).
Various markers of renal dysfunction have been evaluated as 
predictors of retinopathy. Borch-Johnsen et al (584) and 
Knuimann et al (7) found that increased urinary albitnin 
excretion was independently associated with retinopathy whilst 
levels of serum urea (608) and the inverse of the creatinine 
clearance (604) have also been recorded as associated factors.
There is less certainty as to whether or not lipid levels 
are independently associated with retinopathy. Cholesterol 
levels correlated with severe retinopathy in the WHO study in 
wcmen in particular, using univariate analysis (8), but this 
probably reflected the stronger relationship with body mass index
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in obese non-insulin-dependent female diabetics. Testa et al 
(604) also found a relationship between cholesterol and 
retinopathy, but this was not apparent once duration of diabetes 
had been taken into account, and Knuimann et al (7) also failed 
to find a relationship. There are however several smaller cross- 
sectional studies where a relationship between retinopathy and 
lipids was apparent. Groop et al (605) studied 44 insulin- 
dependent diabetics with proliferative retinopathy, who were 
matched with a similar number without retinopathy. Cholesterol 
and triglyceride levels were increased and HDL cholesterol levels 
reduced in the retinopathy group, but only if proteinuria was 
also present. In addition, glycaemic control was appreciably 
poorer in the group with retinopathy, which could account in part 
for the altered lipid levels. In a similar study, Doman et al 
(609) also found higher total and LDL cholesterol levels and 
lower HDL/LDL ratios in insulin-dependent diabetics with 
proliferative retinopathy after correction to a standard 
creatinine clearance. However glycaemic control again remained 
poorer and was not corrected for in the group with proliferative 
retinopathy. Kissebah et al ' (608) found higher levels of 
triglycerides and cholesterol in a rather atypical group of non­
insulin-dependent diabetic retinopaths with insulin deficiency 
but apparently similar glycaemic control to a group without 
retinopathy. However the renal factor may yet again have 
explained the lipid abnormalities, since serum urea levels were 
also higher in the group with retinopathy, and Wardle et al (595) 
reached similar conclusions.
Eckel et al (329) looked at relationships between lipids,
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apoproteins and microangiopathy in insulin-dependent diabetics 
using multiple linear regression analysis. They found that the 
number of microaneurysms correlated with the ratio of 
apolipoprotein AI/AII in HDL, and the HDL/LDL cholesterol ratio, 
but only in wcmen. Retinopathy was also found to be associated 
independently with triglyceride, glucose and total and LDL 
cholesterol levels, but again the relationship was predominantly 
in women. The high degree of concordance between retinopathy and 
nephropathy, and the small numbers of patients limit the 
conclusions that can be drawn from this study.
The association between smoking and retinopathy remains 
contentious. Several cross-sectional studies have not defined a 
role for smoking (8, 9, 605), and Telmer et al (606) and 
Christiansen et al (610) failed to demonstrate a difference in 
the prevalence of proliferative retinopathy in smoking and non­
smoking diabetics. Mulhauser et al (611) used a rather different 
approach comparing insulin-dependent diabetic smokers and non - 
smokers matched for sex, age and duration of diabetes. Roughly 
59% of the subjects in each group had no retinopathy after a mean 
duration of diabetes of 14 years, but a higher prevalence of 
proliferative retinopathy> was recorded in the smoking group. The 
authors suggested that smoking represented a risk factor for the 
progression of retinopathy to the proliferative stage.
Such associations do not of course necessarily confirm that 
each risk factor has a pathogenetic role in retinopathy, but they 
do provide the rationale for those prospective studies where 
improved glycaemic control was associated with an improvement in 
the degree of established retinopathy (21, 22).
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Testa et al (604) and Young et al (40) have attempted to 
evaluate prospectively whether changes in risk factors relate to 
changing patterns of retinopathy. Testa et al (604) used CSII 
and conventional insulin therapy, and reported that the 
progression of retinopathy correlated inversely with the mean 
treatment levels of plasma glucose, M values, Hh^ and serum 
cholesterol, and with the changes during treatment in plasma 
levels of glucose and triglycerides. In fact the single most 
important predictor for the progression or retinopathy was lower 
plasma glucose levels. Decreased creatinine clearance was also 
able to discriminate between mild and moderate progress of the 
retinopathy.
In contrast, Young et al (40) studied conventionally 
treated insulin-dependent diabetics and found that the 
deterioration in retinopathy was most strongly associated with 
increased blood glucose levels and the duration of the diabetes. 
There were also parallel changes in diastolic blood pressure, 
urinary albumin excretion and neurophysiological abnormalities. 
Smoking did not appear to influence the outccme. It was 
concluded that hyperglycaemia had an essential permissive role 
for the progression of microangiopathy but that other influences 
were also important.
Whilst these two reports might appear contradictory, what is 
apparent and has been confirmed in clinical practice is that both 
hyperglycaemic and marked hypoglycaemic fluctuations can 
aggravate established diabetic retinopathy (23-25).
In trying to elaborate the pathogenesis of retinopathy, 
other potential risk factors have been identified. Abnormalities
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of platelet function (612-614), increased whole blood and plasma 
viscosity (615), elevated levels of fibrinogen (595, 615) and 
alpha2 macroglobulin (59, 595), reductions in IgG and complement 
(605, 616), and abnormal glycoprotein metabolism (59) have all 
been reported in diabetic retinopathy, although their relative 
importance remains open to speculation. There are discrepant 
data as to whether or not there is a real excess of insulin- 
binding antibodies and immune complexes in diabetic retinopathy 
(599, 605, 617).
The pathogenic role of lipids in retinopathy remains a 
matter for dispute. Hard exudates, which are lipid rich 
particles, have clearly been shown to regress in response to 
diets rich in com oil or other polyunsaturated fats, clofibrate 
or p-amino-salicylate, all of which lead to improvements in 
hyperlipidaemia (618-620), but it remains uncertain whether the 
long term prognosis for vision is affected by such manoeuvres.
Diabetic retinopathy is characterised pathologically by 
early structural abnormalities with the loss of pericytes and 
development of retinal capillary microaneurysms in association 
with endothelial cell proliferation and ' deposition of 
glycoprotein in the vasculature leading to thickened excessively 
permeable membranes. The subsequent development of haemorrhages 
and exudates may be a response to lipid thrombi (621), 
hyperviscosity, or haemodynamic alterations. The proliferation 
of retinal blood vessels and inappropriate vasodilation that 
follows may be a response to hypoxia and consequent ischaemia 
(622). At this point, vitreous haemorrhage, retinal detachment, 
and rarely rubeosis iridis, lead to serious visual impairment.
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At the present time a prudent policy for the prevention and 
management of retinopathy would appear to be a graded reduction 
in hyperglycaemia without excessive hypoglyaemia, effective 
treatment of hyperlipidaemia and hypertension, and encouragement 
to stop smoking.
A variety of abnormalities of renal function, structure and 
biochemistry are recognised at different stages of insulin- 
dependent diabetes (Table 4), which have been incorporated into 
the hyperfiltration hypothesis for the pathogenesis of diabetic 
nephropathy (623), but this attractive unified concept remains to 
be proven in human diabetes. Furthermore, a clear disparity 
between structural abnormalities and the extent of functional 
disturbances has been found (624). Features of diabetic 
glomerulosclerosis are universal in renal biopsies from long­
standing insulin-dependent diabetics, many of whom have no 
apparent functional disturbances (625, 626).
There are however, unequivocal findings regarding the extent 
of the problem based upon studies of diabetic nephropathy in 
which there is established proteinuria or chronic renal failure. 
Uraemia, secondary to diabetic nephropathy, has been reported to 
be either the leading (559) or the second commonest (558) cause 
of death in insulin-dependent diabetes. The mortality risk in 
IDEM is characteristically increased once persistent proteinuria 
has developed (560).
A clear relationship between the prevalence of overt 
nephropathy and increasing duration of diabetes is recorded. In 
the WHO study (8), 'severe' proteinuria was found in 5% of those 
whose duration of diabetes was less than 7 years, and in 16%
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after 14 years. Lesser degrees of proteinuria were apparent in 
13% of diabetics of less than 7 years duration, and in 16% after 
14 years. Oakley et al reported proteinuria in 9% of individuals 
with long-standing IDEM (627). Knuimann et al (7) found that 
serum creatinine levels were elevated (greater than 120pmol/L) in 
6.4-6.9% of insulin-dependent diabetics whose mean age was 33.8 
and average duration of diabetes 12.6 years.
In perhaps the most comprehensive study, Andersen et al 
found that the cumulative incidence of proteinuria in insulin- 
dependent diabetics was 45% after 40 years or more of diabetes, 
although persistant proteinuria did not develop in over 50% of 
cases (326). The prevalence of nephropathy was 21% in diabetics 
of 20-25 years standing which thereafter was followed by a 
decline to 10% (secondary to mortality) after 40 years.
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A male preponderance of diabetic nephropathy (1.79:1) was 
demonstrated in this study, although since then Borch-Johnsen et 
al have revealed equivalent absolute mortality rates for male and 
female insulin-dependent diabetics with proteinuria (560). In 
addition they found that the relative mortality (i.e. in relation
to the non-diabetic population) was higher in proteinuric
diabetic wcmen than men. Cardiovascular disease was recorded 
in both these studies as a cannon cause of death, particularly 
in cases where the duration of diabetes exceeded 20 years at the 
time of death.
Most cross-sectional studies have reported systolic, 
diastolic, or longitudinal increments in systolic blood pressure 
as being independently associated with proteinuria in IDEM (8,
9, 584, 628), although Knuimann et al (7) did not find an
association between blood pressure and increased serum 
creatinine levels, but this could reflect the absence of abnormal 
creatinine levels in the study group.
Serum lipid levels (cholesterol and the inverse of HDL 
cholesterol) were independently associated with proteinuria in 
the WHO study (8) and with serum creatinine levels in the study 
of Knuimann et al (7), although no such correlations were 
reported in other studies (9, 560). There is however a well 
recognised link between hyperlipidaemia and the nephrotic 
syndrane, and it is therefore likely that the association between 
lipids and proteinuria may depend on the degree of proteinuria. 
Vannini et al (331) found increased levels of triglycerides, 
total and LDL cholesterol, and apolipoprotein B, with reduced HDL 
cholesterol levels, in proteinuric insulin-dependent diabetics
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ccropared to a group with normal albumin excretion rates who were 
similar with regard to age, duration of diabetes, and glycaemic 
control. Eckel et al (329) reported significant associations 
between proteinuria and increased levels of triglycerides and 
total LDL cholesterol, and with reductions in the HDL/LDL 
cholesterol ratio, particularly in wcmen.
Whilst the role of smoking in retinopathy is uncertain, 
smoking in most circumstances is independently associated with 
proteinuria (8, 584, 606, 611), but interestingly predominantly 
in men, who of course have more proteinuria and smoke more often 
than wcmen.
Additional independent associations have been reported with 
proteinuria, namely a low age at diagnosis, daily insulin 
requirements and the age and insulin-antibody titre at the time 
of assessment (584). Rather suprisingly, glycaemic control has 
not been found to be an important independent correlate with 
proteinuria in several studies (8, 9, 584, 606). This may 
reflect the relative unimportance of glycaemic control in 
established diabetic nephropathy. Notwithstanding this, 
established proteinuria has been reported to be associated with 
fewer previous ketoacidotic episodes (629), and higher levels of 
HhAi (15, 326) and plasma glucose (9) at the time of assessment.
The pathophysiological relevance of these epidemiological 
observations can be determined fran those clinical studies which 
have investigated the impact of risk factors on the natural 
history of established diabetic nephropathy.
It has been suggested that death supervenes on average 6 
years after the establishment of proteinuria in IDEM, but a
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highly variable course (2-32 years) has been observed between 
individuals (630). Likewise, although Jones et al (631) 
reported that once serum creatinine levels exceeded 200pmol/l, a 
predictable linear progression in renal failure was observed with 
time, there appeared to be remarkable intra-individual variation 
in the rate of decline. Mogensen et al (632) reported a 
decline in glanerular filtration rate (GFR) ranging from 0.2- 
2. Iml/min per month in insulin-dependent diabetics with 
established nephropathy, which correlated positively with 
diastolic blood pressure measured after a mean observation period 
of 34 months. Parving et al (633) studied insulin-dependent 
proteinuric diabetics with normal serum creatinine levels in all 
but two cases. Over a mean observation period of 26 months, 
they recorded a mean fall in GFR from 107 to 87ml/min/1.73m2, in 
effect a fall of 0.75ml/min/1.73m2 per month, although again the 
variation (0.1-1.5ml/min/1.73m2) was considerable. Rises in 
blood pressure and proteinuria excretion over this period were 
more uniform, but the decrease in GFR did not correlate with 
either, nor with the duration of diabetes, age of onset, insulin 
requirements, blood glucose, or initial GFR.
In contrast, Hasslacher et al (15) found that hypertensive 
proteinuric diabetics developed elevated serum creatinine 
concentrations more often, and the delay till serum creatinine 
levels rose was negatively correlated with blood glucose levels. 
Thereafter the decay in renal function occurred faster in 
patients with persistent as opposed to intermittent
hypertension.
Takazakura and colleagues (634) performed serial renal
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biopsies in a prospective study and demonstrated that progressive 
glomerulosclerosis accompanied poor glycaemic control. However, 
Thcmsen et al (626) found that the severity of 
glomerulosclerosis and arteriolar hyalinosis bore no relation to 
the presence of clinically overt diabetic nephropathy, although 
increases in interstitial connective tissue and glomerular 
mesangial tissue, and a reduction in the number of open 
glomerular capillaries were specific histological findings in 
those diabetics with proteinuria.
The recognition of the importance of hypertension in the 
progression of diabetic renal disease was reinforced by Parving 
et al (626), who demonstrated that diastolic hypertension in 
particular was common in insulin-dependent diabetics with 
nephropathy but normal serum creatinine levels. Since then the 
consensus from long-term interventional studies is that 
aggressive anti-hypertensive therapy can at least delay 
progression, and may possibly reverse the decline of renal 
function, in addition to reducing the transcapillary escape rate 
of albumin (635-638). The selection of specific anti­
hypertensive agents such as ACE inhibitors may have an additional 
role in reducing proteinuria in diabetics, independent of the 
blood pressure lowering action (639).
The impact of improved metabolic control on the progression 
of established nephropathy is likely to be of less importance and 
remains controversial. Viberti et al (28) suggested that 
greatly improved metabolic control made no impact on the decline 
in renal function in the six insulin-dependent diabetic 
nephropaths studied, although in one case it led to a dramatic
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reduction in the rate of decline of GKR, and overall a non­
significant reduction in the rate of decline of GFR fran 1.35 to 
0.69ml/min/month was observed. Nyberg et al (640) suggested 
that the decline in GFR was directly related to the degree of 
glycaemic control, and that poor glycaemic control independently 
contributed to one third of the progressive reduction in GFR.
In addition to these factors, more marked proteinuria and 
renal histological changes may act as poor prognostic markers 
(641), whilst a reduction in dietary protein intake may reduce 
proteinuria excretion and keep renal failure at bay (642). 
Residual endogenous insulin secretion has also been associated 
with less nephropathy, possibly due to improved glycaemic control
(643).
The recognition that sub-clinical increases in urinary 
albumin excretion ('microalbuminuria') during the stage of 
incipient nephropathy can predict later clinical nephropathy 
(364-366, 644), has led to intense interest in factors
controlling albumin excretion. However, a note of caution should 
be introduced. Firstly, what occurred in the intervening period 
frcm the stage of microalbuminuria to proteinuria in these 
retrospective studies remains obscure. Secondly it could be 
argued that the detection of albumin excretion rates (AER) of 
30pg/min or more merely identifies individuals in whcm the 
development of proteinuria is inevitable, particularly if one 
regards an AER of 70pg/min as the predictive cut off point (644). 
In addition there is still no agreement about the level of 
microalbuminuria and the collection conditions with which to 
categorise individuals at risk of nephropathy.
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Several studies have attempted to define those factors that 
could promote the transition frcm incipient nephropathy to 
clinical nephropathy. Unlike established clinical nephropathy, 
increases in AER do not appear to be more apparent with
increasing duration of diabetes (584, 645), and intra-individual
day to day variations in AER of up to 50% have been reported
(646, 647). Consequently the prevalence of microalbuminuria 
could vary according to the duration of diabetes and the 
frequency of urine collections in the various studies.
Borch-Johnsen et al (584) reported that elevated AERs
(greater than 3Qmg/24hours) were present in 45% of 184 insulin- 
dependent diabetics who had survived at least 40 years. Hdnmel 
et al (647) reported the prevalence of microalbuminuria (20- 
200pg/min) in 1254 insulin-dependent diabetics as 14%. 5% of
265 diabetics (type not defined) had microalbuminuria (greater 
than 30pg/min) in the study of Gatling et al (648). Mogensen et 
al (645) reported a 12% prevalence of microalbuminuria in a 
clinic survey of 1082 insulin-dependent and non-insulin-dependent 
diabetics with a wide range of ages and duration of diabetes.
Cross-sectional studies designed to examine correlates of 
microalbuminuria have reached different conclusions. Borch- 
Johnsen et al (584) found the most important in long term 
survivors was the age at diagnosis, but the systolic blood 
pressure increment, insulin-binding antibody capacity, and 
regular smoking were also significantly correlated, although 
glycaemic control (assessed by HhAi), was not.
Wiseman et al (357) matched noimoalbuminuric with 
microalbuminuric insulin-dependent diabetics for age, sex, and
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duration of diabetes, and found significant independent 
associations between albumin excretion, HbAx and arterial 
pressure. Mathiesen et al (644) found frcm their longitudinal 
data that AER was only predictive of nephropathy at levels
greater or equal to 70pg/min, and that cross-sectional analysis 
demonstrated that such patients had significantly higher systolic 
and diastolic blood pressures, without significant differences in 
levels of serum creatinine, HhAx, or GFR, when compared to 
normoalbuminuric patients.
Christensen and Mogensen reported a significant correlation 
in incipient nephropathy (AER greater than 15pg/min) between AER 
and systolic but not diastolic blood pressure (649).
Correlations between renal haemodynamics and AER were not 
reported separately for patients with incipient nephropathy, but 
when data frcm diabetics with normal AER and those with incipient 
and clinical nephropathy were combined, significant negative 
correlations were reported between AER and both GFR and renal 
plasma flow. A later study frcm the same authors reported that 
GFR as well as diastolic blood pressure was higher in insulin- 
dependent diabetics with incipient nephropathy compared to the 
group with normal AER (650).
Together these papers suggest that the true relationship 
between AER and GFR is probably more like a bell shaped curve
than a negative linear regression line. Therefore whilst renal
haemodynamics and glycaemic control may be relevant, cross- 
sectional studies would suggest that blood pressure is the most 
irrportant pathogenic determinant of the elevated AER of incipient 
nephropathy.
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In attempting to clarify how all these variables influence
the progression frcm incipient to overt nephropathy,
retrospective and prospective observational studies and 
prospective interventional studies have been carried out.
Hasslacher et al (15), in a retrospective analysis of 52 insulin- 
dependent diabetics, found that systolic blood pressure and the 
median post-prandial glucose levels were significant indicators 
of future nephropathy. This confirmed the earlier observation 
of Pirart (14) in a prospective study based on clinic blood 
glucose recordings over 40 years, where poor glycaemic control 
was clearly associated with the later development of nephropathy. 
In prospective studies using CSII to improve glycaemic control, 
Viberti et al (651) reported an accompanying fall in AER in an 
uncontrolled study of 7 patients with microalbuminuria, although 
a more recent report frcm the same group found no beneficial 
effect of CSII on AER once intermittent clinical proteinuria was 
established (29). The Kroc group found that CSII significantly 
reduced elevated AER (greater than 12pg/min) during an eight 
month controlled study (24). Longer term controlled studies have 
reported that at best, persistent near-normoglycaemia stabilises 
AER rather than leading to continued reductions (20, 25, 26, 29, 
30, 33-35).
In prospective non-interventional studies, Mathiesen et al
(644) reported that nephropathy developed in seven cases where 
the AER was initially greater than 70pg/min, whilst only three 
of the remaining 64 patients with less marked elevations of AER 
developed clinical nephropathy. In the studies of Christensen 
and Mbgensen (649, 650), the mean AER increased frcm 58.8 to
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118. lpg/min over an average period of 4.9 years in 10 
individuals. There appeared to be great intra- individual 
variation in the rate of yearly increase in AER, ranging frcm - 
7.3 to +58.5%, but a significant correlation was observed between 
yearly increases in AER and parallel changes in diastolic blood 
pressure and renal vascular resistance. The lack of change in 
glycaemia in the study suggested that haemodynamic factors might 
operate independently of metabolic factors in the pathogenesis of 
diabetic nephropathy.
Young et al (40) suggested that rises in both EhA* and 
diastolic blood pressure significantly paralleled rises in AER 
over a two and a half year period, but multiple regression 
analysis showed that blood pressure was the more important 
determinant of progression.
It would therefore appear that as in established 
nephropathy, haemodynamic factors exert a dominant influence over 
metabolic factors in the early stages of renal dysfunction. This 
is not to say that improved glycaemic control has no role to 
play. If one acknowledges that the higher GER in incipient 
nephropathy may be relevant to progression, then the observation 
of reductions in glcmerular hyperfiltration with CSII is 
encouraging (652, 653). More recent work has suggested that CSII 
may achieve this by reducing not only hyperglycaemia but also 
intermediary metabolites, since ketone bodies have been reported 
independently to increase glcmerular filtration, and perhaps more 
significantly, tubular protein excretion (367). Reduced dietary 
protein intake has also been found to normalise glcmerular 
hyperfiltration and reduce fractional albumin clearance (355,
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356). Glcmerular hyperfiltration probably only improves after 
insulin administration by virtue of its effects on lowering 
blood glucose and ketone body levels, rather than by a direct 
effect of insulin on the renal vasculature (654, 655).
Whilst metabolic and dietary factors appear to exert an 
influence on renal haemodynamics, hormonal disturbances such as 
elevated levels of growth hormone and glucagon do not 
characterise diabetic patients with high glcmerular filtration 
rates (656).
Alternatively the intrarenal prostaglandin system could 
prcmote renal vasodilatation. Administration of non-steroidal 
anti-inflammatory drugs did not affect glcmerular hyperfiltration 
in insulin-dependent diabetics of less than 5 years duration 
(657), although reductions in GFR and AER in established 
nephropathy have been reported with indcmethacin (658), and one 
report has suggested that specific thromboxane synthetase 
inhibitors can reduce microalbuminuria (659).
Autoncmic neuropathy is ccmmon in insulin-dependent diabetes 
(v.i.) and has been found to modulate renal haemodynamics (660), 
but its role in albumin excretion and nephropathy remains to be 
elucidated.
Non-enzymatic glycosylation of serum albumin and of the 
glcmerular basement membrane may lead to changes in ionic change 
which might lead to increases in AER (188, 189).
The use of antihypertensive agents in incipient 
nephropathy holds much premise and there are seme early reports 
of reductions in AER following administration of ACE inhibitors 
to insulin-dependent diabetics with microalbuminuria (661). It
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remains to be demonstrated whether such therapy can also improve 
morphological abnormalities.
Nephrcmegaly associated with hyperfiltration is an early 
feature of IDEM (662) which persists in early nephropathy and is 
closely related to glcmerular filtration function, but which does 
not appear to relate to either urinary albumin excretion or the 
extent of mesangial expansion (663). Histological features of 
diabetic nephropathy developed in donor kidneys following 
transplantation into insulin-dependent diabetics (664, 665), but 
the most dramatic representation of the relative importance of a 
diabetic environment for the development of nephropathy is the 
report demonstrating improvements in glomerulosclerosis following 
transplantation of diseased diabetic kidneys into healthy 
recipents (666).
As yet there are no controlled studies of the effects of 
inproved glycaemic control on renal morphology, but the data frcm 
renal biopsies following transplants supports the concept that 
the risk for nephropathy is acquired with the diabetic state for 
whatever reason, rather than inherited.
In addition to haemodynamic and metabolic factors, there is 
continued support for immunological and haemostatic mechanisms of 
nephropathy. High levels of immune complexes (559) and insulin 
antibody titres have previously been associated with nephropathy 
(584). A role for platelet dysfunction (667) in the 
establishment and progression is also suggested, and antiplatelet 
agents such as dipyridamole (668) and thrariboxane synthetase 
inhibitors (659) have been successfully used at different stages 
of diabetic nephropathy.
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Early intervention with aggressive antihypertensive 
therapy, effective glycaemic control, and advice to stop smoking, 
are likely to become cornerstones in the management of incipient 
diabetic nephropathy but properly designed controlled studies 
have yet to be carried out. Roles for antiplatelet, lipid 
lowering agents, and aldose reductase inhibitors (v.i.) in the 
treatment and prevention of diabetic nephropathy also remain to 
be defined.
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3:3. HMNEUROKmff
Whilst peripheral sensori-motor and autoncmic neuropathy 
are recognised complications of diabetes, it has only recently 
been appreciated that both subclinical and symptomatic 
disturbances of both nerve conduction and cardiovascular 
autoncmic tone are commonly found, and are often present 
together (669, 670). Although the somatic and autoncmic
neuropathies may have a ccmmon pathogenesis, the clinical 
manifestations and implications of the two conditions are quite 
different, and will be discussed separately.
(a) SENSORY AND M3T0R NEUROPATHY
The diabetic peripheral nerve appears to be acutely 
sensitive to metabolic peturbations but is also subject to 
progressive long-term damage. Diagnostic criteria for peripheral 
neuropathy abound, and sensory symptoms frcm concomitant 
peripheral vascular disease may be difficult to distinguish from 
a neuropathic source. Consequently the prevalence of diabetic 
peripheral neuropathy has been reported to vary between 0 and 93% 
(671). The lowest prevalence rates were obtained frcm history 
taking, which emphasises the observation that despite abnormal 
clinical and neurophysiological findings, diabetic neuropaths are 
often symptcm-free.
In a study by Boulton et al (672), which was carefully 
designed to exclude ' false positives1, symptomatic diabetic 
neuropathy was present in 10.7% of 382 insulin-treated diabetics 
aged 15 to 59 years, whose duration of diabetes ranged frcm 12.3 
to 21.5 years. Diabetics whose symptoms could have been related
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to associated peripheral vascular disease or alcohol abuse were 
excluded, and the prevalence would have been nearer 20% had they 
also been included in the survey.
Knuimann et al (7) examined lower limb sensation and 
reflexes in 179 insulin-dependent diabetics, mean age 33.8 and 
average duration of diabetes 12.6 years, and found objective 
clinical evidence of sensory neuropathy in 8-9% of cases. In the 
huge prospective study by Pirart of 4,400 diabetics (14), 
neuropathy was clinically detectable in 8% of cases at the time 
of diagnosis, and in 50% after 25 years of diabetes.
It is acknowledged that abnormal electrophysiological 
findings are often a feature of asymptomatic diabetic patients. 
One such study confirming this is that by Young et al (673), who 
found abnormalities of peripheral somatic neurophysiology in 
almost three-quarters of 79 cases of IDEM without symptoms of 
neuropathy.
Temporal and biological factors which could contribute to the 
development of neuropathy have been examined. Both age and 
duration of diabetes are positively associated with clinical 
sensory neuropathy and abnormal electrophysiblogy (7, 14, 36, 40, 
672).
There is strong circumstantial evidence for a pathogenic 
role for hyperglycaemia in symptomatic neuropathy, operating 
either directly or indirectly. Boulton et al (672) and Young et 
al (673) found that HhAx correlated with either clinical or 
subclinical peripheral neuropathy in cross-sectional studies, and 
in a prospective evaluation of the same group of patients, Young 
et al (40) confirmed that deterioriation in nerve condition
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velocities paralled rises in HhA.x. Knuimann et al (7) could not 
confirm an association between Hh^ and neuropathy but found that 
plasma creatinine, insulin dose and diastolic blood pressure all 
correlated independently with sensory neuropathy. Young et al 
(40) suggested that subclinical neuropathy was also independently 
associated with diastolic blood pressure, renal dysfunction 
(assessed by AER), and the presence of retinopathy.
Prospective intervention studies have produced conflicting 
results as to the role of improved glycaemic control on 
neuropathy. The well recognised associations between neuropathic 
symptoms and acute hyperglycaemia (671) were supported by the 
report frcm Pirart (14) who demonstrated less severe neuropathy 
in diabetics whose control had been ’good’. Pietri et al (37) 
found an improvement in symptoms and seme, but not all, measures 
of nerve conduction velocity in response to improved metabolic 
control, using CSII in a short term uncontrolled study. Holman 
et al (38), and Service et al (39) found in longer term studies 
that improved metabolic control by either intensified 
conventional therapy or CSII led to sustained improvements in 
vibration sensation and nerve conduction velocities, but 
vibration sensation was not appreciably different from baseline 
after 2 years of improved metabolic control in the study by 
Lauritzen et al (22). In addition, increased residual insulin 
production and the associated relative improvement in glycaemic 
control was not associated with less abnormalities of sensory and 
motor nerve conduction velocity in one study (557). Young et al 
(40) suggested that although a certain level of hyperglycaemia 
was essential to initiate neuropathy, there was inherent or
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acquired variation in the susceptability to its development. In 
addition it was suggested that the strong association between 
renal and microvascular complications independent of 
hyperglycaemia meant additional factors were implicated in their 
pathogenesis.
Diabetic neuropathy is characterised by distal axonal 
degeneration associated with segmental demyelination (671). The 
clinical course is quite variable, and the onset of symptoms may 
be abrupt or insidious, whilst progression of symptoms can be 
rapid or slow, and spontaneous remission is well described. The 
suggested role of hyperglycaemia in the pathogenesis of 
neuropathy is likely to be indirect since nerves are relatively 
insensitive to insulin. However the accumulation of sorbitol in 
nerves secondary to hyperglycaemia and saturation of the capacity 
of sorbitol dehydrogenase to convert sorbitol to fructose despite 
the continued ability of aldose reductase to convert glucose to 
sorbitol, as a low affinity system, may be important. Both 
sorbitol accumulation and myo-inositol deficiency are thought to 
reflect abnormalities of the polyol pathyway operating in human 
diabetic neuropathy as well as in animal experimental models. 
Clinical studies of aldose reductase inhibitors have produced 
inconclusive findings (674, 675). A high incidence of drug 
toxicity was observed in earlier studies, and the conclusions of 
one early open study demonstrating both subjective and objective 
improvements in neuropathy (676) has been the subject of 
criticism (677). Whilst neurophysiological measures do seem to 
improve in asymptanatic patients (678), aldose reductase 
inhibitors may (676) or may not (679) provide symptomatic
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benefit, with variable changes in nerve condition over an 8 week 
period, although it should be appreciated that short term 
treatment may be an unrealistic approach to a condition that 
usually develops over several years. An alternative suggestion 
is that longstanding neuropaths have extensive nerve damage which 
is not amenable to correction and therefore aldose reductase 
inhibitors might be more logically used as prophylactic agents 
for subclinical neuropathy.
The use of dietary myo-inositol supplements has likewise led 
to inconclusive results (671).
Alternative proposed mechanisms for neuropathy are 'in 
vogue1 at present. A microvascular aetiology was first suggested 
by observations of small vessel occlusion in human diabetic 
nerves (680, 681), and more recently abnormal platelet function 
has been reported in insulin-dependent diabetics with neuropathy 
but without evidence of microvascular renal or opthalmological 
disease (682). Haemodynamic alterations could induce 
microvascular damage to nerves and the close association between 
neuropathy and diastolic blood pressure (7, 40) may support such 
a hypothesis. As with retinal and renal complications, the 
pathogenesis is likely to be multifactorial and metabolic and 
haemodynamic abnormalities are likely to act in concert with one 
another in those who are genetically predisposed, and effective 
treatment might therefore require a combination of different 
modalities.
(b) AUTONCMIC NEUROPATHY
The diverse clinical features of advanced diabetic autoncmic
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neuropathy were first comprehensively described in 1945 (683). 
Since then, awareness of the poor prognosis associated with 
symptomatic autoncmic neuropathy (684) has led to widespread 
interest in the pathophysiology of the earlier subclinical stage 
of autonomic dysfunction (685).
There are several problems inherent in studying diabetic 
autoncmic neuropathy, quite apart frcm the tendency to mix groups 
of patients with IDEM and NIDDM (686). The first is that 
subclinical autoncmic dysfunction often affects many organ 
systems without a predictable sequence of denervation (685), and 
secondly there is still no clear agreement as to what are the 
most appropriate sensitive tests of autoncmic tone (685). 
Thirdly, the demonstration of functional changes in autoncmic 
tone may not always represent structural damage, as suggested by 
the observation of disturbed cardiovascular autoncmic function 
tests in newly-diagnosed insulin-dependent patients (687), in 
whom established nerve damage would be unlikely. Finally, in 
applying tests of autoncmic tone to diabetic patients, the 
importance of age-related normal ranges has recently been 
emphasised (688-693). Failure to recognise that apparent 
functional changes in autoncmic tone are a normal feature of the 
ageing process can lead to detection of 'false positives' amongst 
elderly diabetic patients, and exclusion of 'false negatives' 
amongst younger diabetic patients. In addition, whilst
autoncmic tests were previously categorised as measuring either 
parasympathetic or sympathetic tone, it is apparent that this 
classification is physiologically imprecise and that both systems 
act in combination to produce the standard cardiovascular
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reflexes (685).
A suggested sequence of autoncmic nerve damage (685) remains 
to be confirmed in prospective studies. Impaired sweating of 
the feet, impotence (v.i), and bladder dysfunction have been 
suggested to be the earliest features, followed by abnormal 
thermoregulation of the hand, cardiovascular reflex 
abnormalities, and finally the late severe symptomatic 
manifestations of excessive body sweating, hypoglycaemic 
unawareness, postural hypotension and gastroparesis. It is still 
uncertain whether there is inevitable progression through these 
various stages.
Most studies of the prevalence of autoncmic neuropathy 
employ measures of cardiovascular autoncmic tone. It has been 
suggested that such disturbances correlate closely with abnormal 
autoncmic function in the gastro-intestinal, optic and 
neuroendocrine systems (685). Although there are many tests the 
canmonest in use assess heart rate or blood pressure changes 
at rest, or during deep breathing, the Valsalva manoeuvre, 
adopting a lying from standing position or vice-versa, or the 
response to sustained handgrip. Ewing and Clarke have pioneered 
the use of a battery of tests, suggesting that one single test is 
misleading, as autoncmic dysfunction is often not an all or none 
phenomenon (694). This is supported by reports of poor 
correlations between different measures of cardiovascular 
autoncmic tone in healthy individuals (689). Whilst Ewing has 
suggested that the maximal beat-to-beat variation in heart rate 
detected during the course of 6 deep breaths in and out over one 
minute is the most reproducable test (685, 694), others have
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suggested that a single deep breath is a more potent stimulus 
(693, 695). It has been suggested that even with the use of four 
standardised tests with age corrected ranges, up to 2% of the 
normal population will have more than one abnormal test result 
recorded (693).
The heart rate response to lying down may prove to be the 
most sensitive discriminator of autoncmic dysfunction (696), 
although this requires confirmation. Despite methodological 
limitations, it is clear that asymptomatic autoncmic dysfunction 
is detectable in a sizeable minority of insulin-dependent 
diabetic patients.
Hilsted and Jansen (697) measured beat-to-beat variation 
during maximal respiration in 119 asymptomatic insulin-treated 
diabetic patients whose average age was 36 years and duration of 
diabetes ranged frcm 3 months to 41 years. They recorded that 
37.8% had abnormal values, although no age related normal range 
was reported.
Dyrberg et al (688) reported on 75 insulin-dependent 
diabetic patients whose mean age was 40 years and whose duration 
of diabetes ranged between zero and 40 years . In comparison to 
a group of healthy age matched controls, 27% of the diabetic 
patients had reduced beat-to-beat variation during forced 
respiration, whilst 17% had an abnormal heart rate response to 
the Valsalva manoeuvre, but none had an altered heart rate 
response to standing. When three sub-groups with increasing 
duration of diabetes but equivalent glycaemic control and age 
were compared, the prevalence of autoncmic dysfunction 
significantly increased with the longer duration of diabetes. In
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addition an association between autoncmic neuropathy and 
nephropathy and proliferative retinopathy was recorded.
Young et al (673) used a series of five cardiovascular 
autoncmic reflex tests and found that 31% of 79 asymptcmatic 
teenage insulin-dependent patients had at least one abnormal 
heart rate response (Valsalva ratio, maximum-minimum heart rate, 
or the 30:15 lying to standing ratio), although the blood 
pressure response to handgrip dynamcmetry was normal in all 
cases. Those individuals with autoncmic dysfunction tended to 
have poorer glycaemic control and an increased duration of 
diabetes.
Masaoka et al (691) confirmed that both the age and the 
duration of diabetes independently affected autoncmic tone in 
diabetic patients compared to age related healthy controls. They 
reported that 36% of 102 asymptcmatic patients with IDDM had 
reduced heart rate variability during deep breathing. Pronounced 
inter-individual variability was observed, which could explain 
why three of the patients with asymptcmatic autoncmic neuropathy 
(18%) had normal heart rate variability during deep breathing. 
This last finding again confirms the ability of autoncmic 
neuropathy to damage selectively seme reflexes whilst sparing 
others.
There are no adequate studies of the prevalence of 
symptcmatic diabetic autoncmic neuropathy, but it is uncommon and 
related to the age of the patient and increasing duration of the 
diabetes (685).
The pathophysiology of diabetic autoncmic neuropathy is 
still far frcm clear. As with scmatic neuropathy, axonal loss
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and segmental demyelination take place (671), although whether 
this is patchy or progressive and generalised is unknown (685). 
As sympathetic fibres are larger, it is often suggested that 
parasympathetic nerve fibre damage takes place before changes in 
sympathetic nerves (685), although it is now clear fran 
microneurographic findings that sympathetic nerve activity is 
disturbed relatively early in diabetic neuropathy compared to 
other types of polyneuropathy (698). Once established, 
progression seems to be the rule (684, 685). As with peripheral 
neuropathy, metabolic and vascular aetiological mechanisms are 
proposed for diabetic autoncmic neuropathy (671). The close 
association between both symptomatic and subclinical autoncmic 
and peripheral neuropathy in IDEM and NIDDM suggests a ccmmon 
pathogenesis (669, 670, 687).
The observation of lymphocytic infiltration of autoncmic 
ganglia (699) has led to suggestions of an immunological basis 
for autoncmic neuropathy, and the recent demonstration of 
increased levels of immune complexes and reduced complement (C3) 
levels in diabetic autoncmic neuropathy strengthens this 
hypothesis (700).
Relatively few studies have examined the impact of potential 
risk factors on established autoncmic dysfunction. Young et al 
(40) found an increased prevalence of abnormal heart rate 
variation during deep breathing in insulin-dependent diabetics 
after a two and half year period of poor metabolic control, 
although the mean value was not different. The change in heart 
rate independently paralleled changes in albumin excretion rate 
and HbAi, suggesting a role for glycaemic control. A weaker
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assocation was reported with the development of retinopathy 
although the heart rate variability during the Valsalva 
manoeuvre and the blood pressure response to sustained handgrip 
did not alter during this period.
The effect of improved glycaemic control on established 
autoncmic dysfunction has also been examined in prospective 
studies with variable results. The Steno study group (22) found 
that beat-to-beat variation during maximum respiration did not 
decline and could improve when CSII was used to improve 
glycaemic control in diabetics without symptomatic autoncmic 
dysfunction.
The St. Thomas ’ s Diabetic Study Group also found that the 
beat-to-beat variation in heart rate declined least where 
glycaemic control improved most with intensified conventional 
therapy over a 2 year period (701). However the Valsalva ratio, 
postural blood presure response, and tests of pupillary autoncmic 
tone all worsened over this period. Other groups have reported 
that autoncmic cardiovascular tone improved with improved 
glycaemic control (702, 703).
The possible role of sorbitol as the pathogenic agent for 
both autoncmic and peripheral neuropathy (671) led to a report 
of a beneficial effect of Sorbinil, an aldose reductase 
inhibitor, on autoncmic function in one uncontrolled study (676). 
However two later double-blind cross-over studies in insulin- 
dependent diabetic patients with symptomatic neuropathy failed to 
demonstrate any change in autoncmic tone after 8 weeks (675, 
679), although it could be argued that longer periods of 
treatment would be required to demonstrate a beneficial effect.
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Gangliosides and dietary myo-inositol supplements have been 
used without effect in diabetic autoncmic neuropathy (685).
The effects of autoncmic denervation on haemodynamics has 
been reported to be implicated in diabetic foot ulceration (670, 
704), although this suggestion has been contested (705), but 
altered renal and cardiac haemodynamics have been reported to 
acccmpany diabetic autoncmic neuropathy (660), and might be 
expected to modify the natural history of diabetic cardiac and 
renal disease.
The diagnosis of early autoncmic neuropathy has implications 
beyond the potential for associated morbidity. In a five year 
prospective study, Ewing et al (684), reported a 50% mortality in 
patients with advanced diabetic autoncmic neuropathy, usually due 
to renal failure. Cardio-respiratory arrest has been documented 
in severe diabetic autoncmic neuropathy (706), and could account 
for the association with sudden death (684, 685), whilst Zitcmer 
et al (707) reported in a retrospective study that 35% of 
diabetics with gastro-intestinal autoncmic neuropathy had died 
within three years.
At present the recognition of more sensitive markers of 
autoncmic dysfunction should allow the opportunity for further 
understanding of the natural history of diabetic autoncmic 
neuropathy in its early stages, but those factors which lead to 
the advanced stage remain to be ascertained.
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3:4 IMPOTENCE
Impotence (the ability to achieve and maintain an erection 
when desired) has been recognised as a diabetic complication for 
almost 90 years (708). Whilst therapeutic nihilism was 
previously the rule, this could change with recent innovations 
such as penile inplants and vacuum-assisted erection devices 
(709, 710).
The prevalence of diabetic inpotence is often quoted as 
between 18 and 71% (711). This wide range reflects the
difficulty in diagnosis and the multifactorial aetiology. Whilst 
autoncmic dysfunction is often associated with inpotence (685), 
most impotent diabetic men appear to have normal cardiovascular 
autoncmic tone (684). Psychological and vascular factors are 
also likely to be important in seme instances, but hormonal
causes of diabetic inpotence are rare (712).
In recognising the increased prevalence of inpotence amongst 
diabetic men, the crucial inpact of ageing was first recognised 
in a study by Rubin and Babbott of 198 cases (713). The
prevalence of inpotence was reported as 25% in the 30-34 age 
group and 54% in the 50-54 year old age group.
Kolodny et al (714) reported that 49% of 175 diabetic men 
whose average age was 49 were inpotent. These patients were 
older and had more frequent evidence of neuropathy than the rest, 
but interestingly had no excess of cases of hypertension,
retinopathy, or nephropathy. The onset of inpotence was gradual
and libido appeared to be intact in all cases.
A more recent comprehensive report by McCulloch et al (711) 
on 541 diabetic men aged 20 to 59 years revealed that 35% had
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erectile inpotence. In this study libido was reduced in 28% of 
those who were inpotent. Linear regression analysis showed that 
inpotence was most strongly independently associated with age, 
retinopathy, and synptonatic peripheral and autoncmic neuropathy. 
Inpotence was less clearly associated with poor glycaemic 
control, coronary heart disease, and nephropathy. In a 5 year 
prospective study of the same cohort, McCulloch et al (715) found 
that 28% of patients who were initially potent subsequently lost 
their ability to achieve erections. The independent predictors 
of inpotence were age, alcohol consumption, poor glycaemic 
control, and intermittent claudication and retinopathy at the 
outset of the study. It was also found that established 
inpotence was only reversible in younger patients with a short 
duration of the disease, when inpotence was of acute onset and 
likely to have been psychogenic in origin.
In assessing the inpotent diabetic it is clearly inportant 
to screen for autoncmic neuropathy, which frcm present knowledge 
would suggest that the position is irreversable (684, 685). 
Peripheral vascular disease, alcohol abuse, androgen deficiency 
and poor glycaemic control should be detected and corrected. 
There may be a small residue of cases where psychological factors 
predominate who may benefit frcm behavioural modification. 
Whilst psychogenic factors have a bearing on impotence whatever 
its cause, the effect of inpotence on the psyche may be more 
marked, although this aspect has not previously received much 
attention (547).
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3:5 HYPOGLYCAEMIA
Sporadic episodes of hypoglycaemia have complicated the 
management of IDDM frcm the outset (1). The ability to achieve 
near-normoglycaemia with intensified conventional insulin regimes 
has caused understandable concern as to whether meticulous 
metabolic control would be accompanied by an unaccetpable 
increase in the frequency of hypoglycaemia (4). Besides the 
obvious acute symptoms and signs of hypoglycaemia, there may be 
additional psychological and biological sequelae which in 
themselves may be to the detriment of the patient (2).
Assessment of the magnitude of the problem is hampered by 
inevitable difficulties in the diagnosis of lesser degrees of 
hypoglycaemia and this may account for the paucity of information 
on the subject. Severe hypoglycaemia may be defined as loss of 
consciousness or an insulin reaction that required assistance 
frcm a relative, friend, or hospital practitioner, who would have 
administered parenteral glucose or glucagon. Milder
hypoglycaemic episodes, which although clinically significant, 
are self-managed, may also provoke clinical, biological and 
psychosocial disturbances. Inevitably their reliable
documentation proves difficult in practice, and of course 
asymptomatic hypoglycaemia goes undisclosed.
The assessment of biochemical hypoglycaemia would in theory 
detect all three categories of clinical hypoglycaemia although 
the pick up rate would obviously reflect the frequency of blood 
glucose testing. Detection of biochemical hypoglycaemia might 
however allow estimation of duration which may itself have 
inportant pathophysiological and pathopsychological consequences .
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In one of the few studies of its kind, Gale and Tattersall 
documented previously unrecognised prolonged nocturnal
biochemical hypoglycaemia in up to 50% of a selected group of 
unstable insulin-dependent diabetic patients, in whan symptoms 
were often mild or absent (502).
Reports of an increased number of severe hypoglycaemic 
episodes during intensified therapy (716) led to an investigation 
of the incidence of biochemical hypoglycaemia during a 24h period 
of continuous blood glucose monitoring following either 
intensified conventional therapy or CSII (717). Biochemical
hypoglycaemia was defined as less than 2.8mmol/L and was recorded 
on 31 occasions in the 19 patients studied. Post-prandial 
hyperinsulinaemia was frequently recorded in association with 
hypoglycaemia and the incidence of problems was similar with 
either method of insulin delivery. Although only 25% of cases 
studied had evidence of angiopathy, biochemical hypoglycaemia was 
only accompanied by synptcms in 40% of the episodes.
In a large survey based on almost 10,000 capillary blood 
glucose sartples collected at heme by 99 insulin-dependent 
diabetic patients over an unspecified period, the frequency of 
biochemical hypoglycaemia (less than 3mmol/L) was found to relate 
inversely to median blood glucose concentrations (718). The 
prevalence was not reported, but was apparently more frequent 
preprandially than postprandially, particularly before lunch 
during treatment with conventional insulin therapy.
An alternative approach to assessing the extent of 
hypoglycaemia has been to record the incidence of severe 
hypoglycaemia in large groups of insulin-treated diabetic
230
patients. Basdevant et al (719) reported that 30% of insulin-
dependent diabetic patients experienced a severe reaction at
least once a year, and the same workers later reported an 
incidence of 26% per year for severe hypoglycaemia, whilst mild 
hypoglycaemia was recorded at least once a month in 58% of the 
172 insulin-dependent diabetic patients interviewed (720).
Other groups have reported much lower figures. Potter et al 
(721) found that 9% of known insulin-treated diabetic patients 
attended Casualty with 'severe hypoglycaemia* at least once a 
year, which was readily acknowledged to underestimate the true 
figure by excluding those incidents which were not managed in 
hospital. Goldstein et al (722) reported a 4% incidence of
hypoglycaemia per year in 147 insulin-dependent diabetic 
children. Casparie and Elving reported an 8% patient/year
incidence of severe hypoglycaemia in 400 insulin-treated 
diabetics (723), which is comparable to the 9-10% reported by 
Mulhauser et al (724) during a one year assessment of 434 adults 
with IDDM. Mulhauser et al (725) reported in a later study that 
intensified conventional therapy did not lead to an increased 
frequency of hypoglycaemia when compared to traditional insulin 
regimes.
The causes of hypoglycaemia are multifactorial but Unger has 
suggested that unrealistic therapeutic goals, and inappropriate 
patient selection (advanced age + diabetic complications) for 
meticulous glycaemic control are the main contributory factors 
(4). The latter problem is implicated in the report by Barbosa 
and Johnson of grave hypoglycaemia complicating the management 
of diabetic patients treated with CSII following renal
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transplantation (716).
Defective counter-regulatory responses (726), hypoglycaemic 
unawareness associated with autoncmic neuropathy (685), or a 
central (727), hypothalamic or metabolic defect (4) (e.g. absence 
of ketone bodies as an alternative cerebral fuel) may also 
predispose certain patients to 'severe hypoglycaemia'. In 
addition the response to hypoglycaemia may be attenuated 
following a period of optimised glycaemic control (728, 729).
Patients themselves often attribute hypoglycaemia to 
imbalance of their insulin dosage, calorie intake and energy 
output, but emotional disturbances are often reported as a 
precipitant of hypoglycaemia (720). In a survey of hypoglycaemia 
during a teaching and treatment programme, individuals with an 
extraordinarily high incidence were identified as those with 
excessively high insulin doses, inappropriate alcohol 
consumption, pregnancy, or hepatic/renal disease (725, 730).
However evaluation by patients and their medical practitioners 
still failed to reveal an obvious cause for hypoglycaemia in up 
to 11% of cases in one study (720).
The consequences of acute hypoglycaemia may go beyond the 
initial neuroglycopaenic and adrenergic response. Whilst 
hypoglycaemic encephalopathy is an unacceptable and hopefully 
rare complication, accelerated diabetic retinopathy is now 
recognised to be a consequence of too-rapid tightening of 
glycaemic control (4, 5). Angina has also been reported 
anecdotally to complicate hypoglycaemia (2), and the myriad of 
haemodynamic and haemostatic changes that accompany hypoglycaemia 
may also aggravate pre-existing complications (2).
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Finally, whilst many surveys have testified to the
overwhelming fear of hypoglycaemia amongst insulin-treated 
diabetic patients, there is little data on the psychological 
correlates of recurrent hypoglycaemia and the impact on metabolic 
control thereafter.
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CHAPTER 2
THE SALFORD HOME BLOOD GLUCOSE MONITORING PROJECT
PATIENTS, MATERIALS AND METHODS
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l.THE SALFORD HOME BLOOD GLUCOSE MONITORING PROJECT 
1:1 SELECTION OF PATIENTS AND STUDY PROTOCOL
During the period frcm September 1983 to December 1984, 
insulin-treated diabetics were identified for changeover to U100 
insulin by a combined approach of writing to all general 
practitioners in the Salford Area, and by identifying all 
insulin-treated diabetic patients at the two diabetic clinics 
within Salford. At the time the study began no diabetic register 
existed and there was no computerisation of patient details.
It was originally planned to recruit 200 insulin-treated 
diabetics for the study during the period of U100 changeover. In 
the event over 500 insulin-treated diabetic individuals were 
identified, of whom 153 individuals participated, whilst another 
50 individuals were followed up in parallel at the diabetic 
clinic to serve as a control group.
Eligibility for the study was based on the following 
criteria:
i) Aged 16 - 70 years, 
ii) Receiving insulin treatment continuously since diagnosis or 
for a minimum period of 1 year following therapeutic failure with 
oral hypoglycaemic agents.
iii) Absence of advanced diabetic nephropathy (serum 
creatinine greater than 200pmol/L), severe proliferative 
retinopathy, blindness or foot complications, mental retardation, 
psychiatric illness, previous lower limb amputation or pregnancy.
Women who became pregnant during the study continued to 
participate to allow data collection although they received more 
regular follow-up than the rest of the study population.
235
iv) Duration of diabetes of at least 3 months.
v) Written consent to participate. All were informed about the 
nature of the study which involved intensive efforts to improve 
glycaemic control and regular visits over a 2 year period.
vi) Suboptimal glycaemic control (randcm blood glucose greater 
than 10 mmol/L at the clinic) or inappropriate insulin regime 
(eg once daily insulin in young patients with IDEM).
vii) Not currently performing hone blood glucose monitoring.
viii) Absence of advanced cardiovascular or hepatic disease 
or cancer of any type.
Suitable patients were identified fran the sources outlined 
above and invited to participate. The vast majority who were 
approached consented to take part; the numbers of insulin-treated 
diabetics suitable and those participating at different phases of 
the study are shown in Table 19. Although the study was designed 
to last 2 years, I only present data in this thesis frcm the 
first year of the study.
PROTOCOL (Tables 5-7)
-------------------- r\
Following verbal agreement to take part all participants 
came to the Medical Investigation Unit at Hope Hospital after an 
overnight fast of 10 - 12 hours. Blood (roughly 50ml) was taken 
for measurement of the following parameters:
fasting blood glucose, glycosylated haemoglobin (HbAi), glycosylated 
albumin (GSA), fructosamine, serum urea, creatinine, albumin, 
electrolytes, cholesterol,triglycerides, the cholesterol content 
of low density lipoprotein (LDL), high density lipoprotein (HDL), 
and its subfractions HDL2 and HDL3, and apolipoprotein B and
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insulin antibodies (V.I.).
The usual morning insulin dose was administered, followed 
after 30 minutes by a breakfast composed of their prescribed 
carbohydrate content. Blood and double voided urine glucose 
measures were thereafter made before meals, 1 and 2 hours post 
prandially and prior to retiring to bed at night (V.I.)- Serum 
C-peptide was measured following a standard lunch (V.I.).
Collection of 24 hour urine was started frcm admission as 
timed daytime (erect) and nocturnal (supine) samples. Estimates 
of creatinine clearance, albumin excretion and glycosuria were 
made from the samples (V.I.).
During the day patients rotated between myself, the diabetic 
liaison sister, the dietician, and when necessary the 
chiropodist.
Structured interviews and clinical assessment were carried 
out and recorded in an initial trial entry document (Appendix 1).
Following breakfast the patient was interviewed by either 
the diabetic liaison sister or the dietician. The dietician 
assessed the calorie and carbohydrate intake (Section A of 
Appendix 1) and the dietary history of each patient (Section 
B question 6 in Appendix 1). Reccmnendations were made about 
fibre and fat intake according to the British Diabetic 
Association dietary guidelines and patients were encouraged to 
ask questions regarding their diet. No specific instructions 
were given to modify the diet other than to have a prescribed 
number of carbohydrate exchanges for each individual which could 
be modified in line with altered activity or Insulin dosage.
Most of that day was spent with the diabetic liaison sister
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and myself. The former completed an assessment of the patients' 
attitudes to diabetes and aspects of self management (Sections B 
and E of Appendix 1). The educational assessment of diabetic 
knowledge and practical skills was scored after interview frcm 1 
(excellent) to 5 (terrible) (v.i.). Thereafter a programme of 
education and self management was instituted by myself and the 
diabetic sister which continued over the next 6 to 10 weeks 
according to individual capability. The ccmponents of the 
teaching and treatment programme were as follows: -
i) INSULIN TREATMENT Proper subcutaneous insulin delivery was 
demonstrated and the Importance of weekly rotation of injection 
sites emphasised. The background intermediate or long acting 
insulins were continued, with soluble insulin prescribed in all 
cases, and circumstances for its use were stressed. Patients were 
instructed on how to mix the different insulin preparations and 
were told to take their insulin 20 - 30 minutes before meals. 
All patients but two received Plastipak syringes (Becton and 
Dickinson, U.K.) which they were encouraged to use for up to 3 
days each during the study. ....  '
ii) HOME BLOOD GLUCOSE MONITORING All patients received a 
Reflolux blood glucose meter (BCL, UK) which was loaned to them 
during the 6- 1 0 week run-in period of the study and which used 
EM Glycaemie 20-800R reagent strips (Boehringer, Mannheim, ERG). 
Autolets (Owen Mumford, UK) were prescribed to ease blood 
letting.
Patients were given instructions on how to perform both 
visual and meter-assisted evaluations of blood glucose, and were
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asked to make at least three routine recordings daily with a full 
10 point profile (pre-meals ,1 and 2 hours post-prandial and pre­
bed) once every fortnight. Additional measurements were 
requested if the patient felt unwell, suspected hypoglycaemia, or 
produced unexpected glycaemic results, or following manipulation 
of the insulin dosage or diet. Blood glucose results along with 
urinanalysis, documentation of hypoglycaemia and other comments 
were to be recorded in a diabetic log book. In addition the use 
of filter paper blood glucose cards was demonstrated for later in 
the study.
iii) URINANALYSIS Patients were instructed in the use of either 
Ketodiastix (Ames, UK) or Ketodiabur (Boehringer, Mannheim, FRG) 
and asked to carry out double voided urine tests at heme 
following each blood glucose recording. The importance of 
monitoring for ketones during illness or hypoglycaemia was 
stressed.
iv) GLUCAGON All participants received glucagon sets (Glucagon, 
Novo, Copenhagen, Denmark) for subcutaneous or intramuscular 
administration in cases of severe hypoglycaemia, and whenever 
possible the diabetic liaison sister personally instructed 
relatives or friends of the patients in its use; otherwise 
patients were asked to instruct relatives.
v) SELF MANAGEMENT All patients received practical verbal and 
written advice about the causes, symptoms and treatment of 
hypoglycaemia, hyperglycaemia and ketoacidosis, and information 
on the implications of illness, exercise, alcohol intake, foot
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care and altered dietary practice.The emphasis was to liberalise 
management allowing adjustment of their insulin and diet 
requirements according to their blood and urine glucose results, 
whilst at the same time encouraging them to attain glycaemic and 
glycosuric target levels.
The acceptable blood glucose target range was set at 3-10 
mmol/L although on occasion this was 'shifted to the right' if 
patients conplained of hypoglycaemic symptans with blood sugar 
values recorded at less then 5 mmol/L. Preprandial target values 
were usually 4-6 mmol/L and post-prandial values 6-8 mmol/L.
All recanmendations were reinforced during the 6 - 1 0  week 
run in period whilst efforts to achieve target glycaemic levels 
were in practice. The diabetic liaison sister visited patients 
at least once a fortnight at hone during this period and 
additional hospital contact either direct or by 'phone was 
encouraged with free access to either myself or the diabetic 
liaison sister for advice.
Following lunch and C-peptide estimation on the initial 
assessment day, the patient had an ECG and chest x-ray carried 
out, and underwent a series of 5 tests of cardiovascular 
autoncmic tone as previously described by Ewing and Clarke (694). 
Resting heart rate was assessed frcm the ECG. Thereafter with 
the assistance of the staff of the MRC Trauma Unit and the ECG 
Department at Hope Hospital, I carried out measurements of heart 
rate variation during the Valsalva manoeuvre, during deep 
respiration and after adopting an erect frcm supine posture. I 
later personally manually analysed all data. In addition I 
assessed the blood pressure response to standing and the
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diastolic response to sustained handgrip using the dynamometer 
normally used to assess handgrip strength (maximum grip strength 
300 mmHg). Using the standard criteria (694), each of the 5 
tests was scored as 0 (normal), 1 (borderline) or 2 (abnormal) to 
give a total score ranging frcm 0 to 10. The prevalence of 
impotence was assessed by direct enquiry.
After collecting basic demographic data and assessing 
social circumstances (Section D, Appendix 1), I then made an 
assessment of patients' glycaemic control over the preceding year 
based upon the number of hospital admissions and blood glucose 
recordings at previous clinic visits, and undertook a full 
history and examination with particular reference to the 
cardiovascular, respiratory and peripheral nervous systems. The 
presence of lower limb pulses was assessed clinically and graded 
(0 = absent, 1 = reduced, 2 = palpable), and the femoral pulses 
were auscultated for bruits. Definite peripheral vascular 
disease was diagnosed by a history of intermittent claudication 
associated with one or more absent foot pulses. Pulse and heart 
rate were assessed with the patient supine at 45 degrees after 
resting on a couch for 15 minutes. Blood pressure was measured 3 
times following resting for 15 minutes with the patient lying 
flat and at an angle of 45 or 90 degrees to horizontal and the 
mean figure taken for analysis. Korotkoff phase V was taken as 
the diastolic pressure. Hypertension was classified as systolic 
blood pressure greater then 150 mmHg and/or diastolic blood 
pressure greater or equal to 95 mmHg, and/or current treatment 
for hypertension. Visual acuity was assessed using a Snellen's 
eye chart and retinopathy assessed by direct opthalmoscopy after
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pupillary dilation with tropicamide 0.5%. Acuity was graded frcm 
0(6/6) to 6(6/60). The presence of cataracts, microaneurysms, 
haemmorhages, exudates, new vessels, retinitis proliferans,or 
laser scars was recorded and graded as 0 to 4 according to 
severity. Referral to the opthalmologist was made if necessary 
and recorded. Feet were examined for ulceration and their
state of hygiene. Where necessary the chiropodist was involved. 
The presence or absence of ankle jerks, vibration sense, fine 
touch and pinprick sensation was examined for by routine 
clinical methods. Absence of parameters was scored at 0, 
normality as 2 and equivocal results as 1. A maximum total score 
of 16 was therefore possible.
Ischaemic heart disease was classified as a history of 
myocardial infarction (relevant clinical history with positive 
electrocardiographic and cardiac enzyme evidence), typical angina 
pectoris (exertional chest pain relieved by glyceryl trinitrate), 
pronounced ECG Q wave abnormalities, or T wave inversion and ST 
segment depression, or both (Minnesota codes 1-1,1-2,8-1,8-3).
Renal glucose threshold was calculated as either high, low, 
or normal or the basis or paired blood and urine glucose readings 
carried out during the initial hospital evaluation and frcm 
subsequent recordings at heme. Persistant glycosuria with blood 
glucose values less than 8 mmol/L was categorised as a low renal 
threshold, whilst the absence of glycosuria despite simultaneous 
blood glucose levels greater than 11 irmol/L constituted a high 
renal threshold. Glycosuria in response to glycaemic values of 8 
- 11 mmol/L was taken as a normal renal threshold. Clinical 
nephropathy was categorised as urinary protein concentration
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(assessed by Albustix) >0.3 g/L and subsequently confirmed as 
greater than 500 mg/24 hours.
The following day their insulin regime was switched to twice 
daily bovine or biosynthetic human insulin if glycaemic control 
was unsatisfactory on the 10 point blood glucose profile (mean 
blood glucose greater then 10 mmol/L). The type of insulin was 
determined frcm a randomised schedule with equal numbers 
receiving bovine or biosynthetic human insulin according to a 10 
x 20 randomised schedule matrix. Patients with acceptable 
control remained on their pre-existing type of insulin.
Finally, questionaires were administered which gave ratings 
for intelligence, anxiety, depression, obsessionality and 
assessed patients' attitude to illness (V.I.). Intelligence 
quotient was assessed by the Mill Hill scale, and standard 
progressive matrices and vocabulary sections were scored 
separately to assess integrative and communicative aspects of 
intelligence. An assessment of anxiety was made using the 
Epstein-Fenz questionnaire whereby 3 facets of anxiety were 
assessed: autoncmic symptoms, muscle tension and insecurity.
The Zung Depression Scale Was used both as originally 
devised and as modified by Dr. Chris Main of the Dept, of 
Psychology at Hope Hospital to give a depression rating. The 
Leyton Observation Inventory was used to assess symptoms and 
traits of obsessionality.
The Multi Health Locus of Control (MHLC) questionnaire 
assessed the attitude to illness and patients' perception of who 
controlled their health when applied to diabetes. As well as the 
total score, subscales for the role of chance, self-help,
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powerful others and internal-external factors were assessed.
Patients were then discharged heme and were formally 
reviewed thereafter fortnightly and data collected regarding 
glycaemic control, the Incidence of hypoglycaemia, general health 
and hospital contacts (Appendix 1). Insulin regimes were 
adjusted at these visits and if necessary at hone to achieve 
blood glucose levels of 3 - 10 mmol/L on the blood glucose meter. 
Blood sticks frcm the ten point glucose profile were saved and 
made available to validate their accuracy. Simultaneous urine 
glucose estimates were encouraged to assist in the classification 
of each individual's renal threshold.
After a minimum period of 6 weeks, patients were considered 
for randomisation to the second phase of the study if their 
glycaemic control had reached the target levels, and they were 
judged to be adept in all aspects of self management. If 
patients had not achieved target levels by 10 weeks or were not 
adept at self-management they were withdrawn frcm the study.
At the point of randomisation all patients were performing 
both blood and urine testing and had received instruction on 
insulin dose adjustment using either glycaemic or urinary glucose 
data. Measurements of lipid and carbohydrate metabolism were made 
at this time. They were then randomised to spend the ensuing 
year continuing with blood testing using the Reflolux meter or 
alternatively to relinquish it and continue to perform urine 
analysis as a means of monitoring their control. The 
randomisation schedule was organised in blocks of 20, 
anticipating that 200 would ultimately be randomised. Both 
groups of patients were reviewed 3 monthly when estimates of
244
metabolic control were made and after 1 year all were readmitted 
to the Investigation unit for clinical, biochemical, educational, 
and psychanetric assessment. In the second year of study all 
those who had been performing urine analysis in the first year 
received a blood glucose meter. Those who had been carrying out 
blood testing for the first year were asked about their 
satisfaction with the method, and spent either the first or 
second 6 months of the ensuing year carrying out direct visual 
assessment of blood glucose sticks, retaining the meter for the 
other 6 month period.
As with the first year of the study, all patients were 
reviewed by myself and the diabetic liaison nurse at 3 monthly 
intervals (Appendix 1) and a comprehensive assessment was made at 
the end of the second year.
Following randomisation to either blood or urine glucose 
monitoring after the 6 - 1 0  week run in period, all participants 
received 10 point filter paper cards to perform glucose profiles 
once a month at heme (V.I.). Those who had a blood glucose 
machine were asked to carry out simultaneous recordings to allow 
validation of their self-generated data. The urine testing group 
also carried out 10 point monthly filter paper blood glucose 
profiles. At the 3, 9, 15 and 21 month follow-up visits blood 
was taken for measurement of HbAx, GSA, albumin and fructosamine, 
and at 6, 12, 18 and 24 months additional measurements of fasting 
glucose, lipids and lipoproteins were also taken. A 24 hour urine 
collection and assessment of renal function was made at the 1 and 
2 year visits. (Table 7). Insulin antibody titres were measured 
initially and at 3, 6 and 12 month time points.
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Throughout the 2 year period any changes in health, hospital 
contacts, hypoglycaemic episodes and days off work (where 
relevant) were recorded.
Psychometric tests were re-evaluated after one year in the 
study in a subgroup of patients.
To serve as a control group 52 other insulin dependent 
diabetic patients were subsequently studied. They attended the 
clinics on a regular basis without individualised attention or 
access to a blood glucose meter. None were carrying out regular 
blood glucose monitoring. Blood was taken for assessment of 
glycaemic control and lipid and lipoproteins on 2 occasions 6 
months apart.
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Table 5 STUDY DESIGN
ii OPTIMISATION PERIOD 6-10 WEEKS
. BLOOD GLUCOSE MONITORING WITH REELOLUX METER 
. URINANALYSIS WITH EITHER KETODIASTIX 
(AMES) OR KETODIABUR (BOEHRINGER)
. INTENSIVE CONVENTIONAL THERAPY AS 
NECESSARY TO IMPROVE GLYCAEMIC CONTROL 
. INTENSIVE EDUCATION - HOME VISITING 
BY DIABETIC LIAISON SISTER 
. FORTNIGHTLY BIOCHEMICAL ASSESSMENT
2^  RANDOMISATION TO EITHER URINANALYSIS OR
BLOOD GLUCOSE TESTING WITH REELOLUX METER FOR 1 YEAR
BLOOD GLUCOSE TESTING URINE GLUCOSE TESTING
KETODIABUR OR KETODIASTIX
BOTH GROUPS : . MONTHLY 10 POINT FILTER PAPER BLOOD 
GLUCOSE PROFILE 
. 3 MONTHLY FOLLOW UP FOR BIOCHEMICAL 
ASSESSMENT AND ENQUIRY ABOUT CONTROL AND 
COMPLICATIONS; AND DAYS OFF WORK WHERE 
RELEVANT 
. ANNUAL CLINICAL REVIEW 
. PSYCHOLOGICAL SCREENING
3. .URINANALYSIS YEAR 1 — BLOOD GLUCOSE TESTING WITH
REELOLUX YEAR 2
. BLOOD GLUCOSE TESTING YEAR 1--> 1ST OR 2ND 6 MONTHS OF
YEAR 2 CONTINUING WITH MEIER OR VISUAL BLOOD GLUCOSE TESTING 
WITH BM STICKS
BOTH GROUPS: .MONTHLY 10 POINT FILTER PAPER BLOOD GLUCOSE PROFILE
.3 MONTHLY FOLLOW UP FOR BIOCHEMICAL ASSESSMENT AND 
ENQUIRY ABOUT CONTROL, COMPLICATIONS AND 
ABSENTEEISM FRCM WORK 
.ANNUAL CLINICAL REVIEW AT 2 YEARS
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TABLE 6 MEASUREMENTS AT VARIOUS VISITS ACCORDING TO STUDY
PROTOCOL
RUN IN PERIOD YEAR 1 YEAR 2
(METER vs (METER vs 
URINE) VISUAL)
WEEK
VISIT
0
1
2
2
4
3
6
4
(8
5
10)
6 1 2 3 4 1 2 3 4
MONTH 3 6 9 12 15 18 21 24
DIETARY ASSESSMENT + — — — — — — — — — — - - -
EDUCATIONAL ASSESSMENT 4* - - + (+ +) - - - 4- - - - 4-
CLINICAL EXAMINATION 4* - - - - - - - - 4- - - - 4-
CHEST X-RAY 4-
ECG 4* - - - - - - - - 4- - - - 4-
I.Q. TEST 4-
PSYCHOLOGICAL SCORES 4- - - - - - - - - ‘ 4- - - - -
FASTING BLOOD GLUCOSE 4- + + + (+ +) + + + 4- 4- 4- 4- 4-
MEAN BLOOD GLUCOSE + 4- + + (+ +) + + + 4- 4* 4- 4- 4-
M VALUE + 4- 4- + (+ +) + + + 4- 4- 4* 4- 4-
FILTER CARD PROFILE + + + 4* 4- 4- 4- 4-
(X3)
INSULIN ANTIBODIES 4- , „. + (+ +) + — 4* __ 4- _ 4-
HBAX 4- - - 4- (+ +) + + + 4- 4- 4- 4- 4-
GSA + 4- 4- 4- (+ +) + + + 4- 4- 4- 4- 4*
FRUCTOSAMINE + 4- 4- + (+ +) + + + 4- 4- 4- 4- 4-
SERUM ALBUMIN 4- 4- 4- 4- (+ +) + + + 4- 4- 4- 4- 4-
CHOLESTEROL 4- - - 4- (+ +) - + - 4- - 4- - 4*
TRIGLYCERIDES + - - 4* (+ +) - + - 4* - 4- - 4-
LDL CHOLESTEROL + - - 4- (+ +) - + - 4- - 4* - 4-
HDL CHOLESTEROL + - - 4- (+ +) - + - 4- - 4- - 4-
HDL2 CHOLESTEROL + - - 4- (+ +) - + - 4- - 4- - 4-
hdl3 CHOLESTEROL + - - + (+ +) - + - 4- - 4- - 4-
APOLIPOPROTEIN B 4- - - + (+ +) - + - 4- - 4* - 4-
APOE PHENOTYPING - - - - - - - - - - - - - 4-
POST PRANDIAL CPEPTIDE + - - - - - - - - 4- - - - 4-
SERUM UREA 4- - .. - . _ - 4- - 4-
SERUM CREATININE + - - - - - - - - 4- - - - 4-
24 HOUR URINE GLUCOSE 4- - - - - - - - - 4- - - - 4-
24 HOUR URINE PROTEIN 4- - - - - - - - - 4* - - - 4-
DAY AER 4* - - - - - - - - 4- - - - 4-
NIGHT AER + - - - - - - - - 4- - - - 4-
TOTAL AER + - - - - - - - - 4* - - - 4-
CREATININE CLEARANCE + - - - - - - - - . 4- - - - 4-
URINE ALBUSTIX + - - - - - - - - 4* - - - 4-
HYPOGLYCAEMIA ENQUIRY 4* 4- 4- 4- (+ +) + + + 4- 4* 4- 4- 4-
DAYS OFF WORK 4* 4- + + (+ +) + + 4* 4- 4* 4- 4- 4-
HOSPITAL CONTACTS 4- + 4- 4- (+ + ) + + 4- 4* + 4- 4- 4-
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TABLE 7
Time table for day 1 of heme blood glucose monitoring study
A.M.
P.M.
FASTING VENUPUNCHJRE.
COMMENCEMENT OF URINE AND BLOOD 
GLUCOSE PROFILE.
START OF A 24 HOUR URINE COLLECTION. 
INSULIN ADMINISTRATION AND BREAKFAST. 
10am - 12 noon EDUCATION SESSION WITH DIABETIC
SISTER AND DIETICIAN.
12noon LUNCH.
1.15 - 1.30 POST PRANDIAL C-FEPTIDE ESTIMATION.
1.30 AUTONCMIC NERVE TESTS.
2.30 CLINICAL EVALUATION.
4.00 PSYCHOLOGICAL QUESTIONNAIRES.
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MATERIALS AND METHODS
Table 6 reveals the many measurements that were carried out 
throughout the study. I am very happy to acknowledge the 
assistance of colleagues in the Chemical Pathology Department at 
Hope Hospital who supervised the measurements of HhAi, and 
measures of renal function other than albumin excretion rate and 
urinary glucose excretion. In particular I would like to thank 
Dr. Ian Holbrook for assistance in ensuring reproducability and 
accuracy of the HhAx assay.
I would especially like to thank Miss Monica Ishola of the 
Department of Medicine at the Manchester Royal Infirmary for 
providing me with extensive lipid and lipoprotein data; Dr. Chris 
Gordon of the Department of Medicine of the Manchester Royal 
Infirmary for the C-peptide measurements; Dr. Terry Wilkin of the 
Department of Medicine at the University of Southampton for 
providing the insulin antibody results; and Dr. Lesley Tetlow of 
the Department of Chemical Pathology at the Christie Hospital, 
Manchester for performing apolipoprotein E phenotyping.
I was personally directly involved in the development and 
use of the following assays during the study: - lipids and 
lipoproteins, filter card blood glucose and the urine glucose 
measurements, albumin excretion rate (AER), glycosylated albumin 
and fructosamine. I will discuss these assays in detail and 
those experiments leading to their effective use. During the 3 
years of the study I spent an average of 2 days per week in the 
laboratory performing these assays.
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MATERIALS AND METHODS
1:2 URINARY ALBUMIN EXCRETION RATE (AER)
The method used in the study was effectively the enzyme- 
1 inked-immuno-sorbent-assay (ELISA) for urine albumin described 
by Barbara Fielding and colleagues in the Department of Child 
Health at the Royal Manchester Children's Hospital (731). I 
would like to extend my appreciation to Dr. Fielding and also to 
Dr. Denise Bu'lock of the Department of Chemical Pathology at 
Hope Hospital who together enabled me to establish the ELISA 
assay for AER for use in the heme blood glucose monitoring study. 
I was personally involved in the initial development and the 
early runs but thereafter Dr. P. Kalsi and Mrs H. Dhar, who 
worked with me as research technicians, performed the majority of 
assays.
THE ELISA ASSAY: ELISA is a technique where an enzyme
labelled antibody or antigen is used to amplify an antibody- 
antigen reaction. In the assay the concentration of urinary 
albumin is below that which would form visible iitmunoprecipitates 
using gel techniques, therefore one of the reactants is adsorbed 
to a solid support. After adsorption of antigen or antibody to a 
solid support (in this case rabbit anti-human albumin antibody to 
the polystyrene wall of the microtitre plate), the complimentary 
antibody or antigen (urinary albumin) is bound. An enzyme 
labelled antibody (or further antibody and later enzyme-linked 
antibody in the AER assay - the modified double antibody 
sandwich ELISA) is subsequently attached to the bound molecules, 
and a chrcmogenic substrate for the enzyme is added. The 
intensity of the coloured reaction products generated is
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proportional to the amount of conjugated enzyme bound, and thus 
indirectly reflects the amount of sample molecules. The major 
components of the system are therefore the solid phase support, 
the first, second and third antibodies, the substrate, buffers 
and standards, and a photometer to read the absorbance of the 
reaction.
Reagents: Tween 20 and bovine serum albumin were obtained 
from Sigma Chemical Co., London, UK. The following antisera and 
peroxidase conjugate were obtained from Miles Laboratories 
Limited, Slough, UK.: Rabbit anti-human albumin (lyophilised) 
cat. no. 65-051, goat anti-human albumin (liquid) cat. no. 61-015 
and horseradish peroxidase conjugated to anti-goat Ig G (heavy 
and light chain) cat. no. 61-201. Inactivated rabbit serum was 
obtained frcm the Wellccme Foundation, London, UK.
Buffers: A solution of phosphate buffered saline and Tween 
20 (FBS-TWeen) was made up by dissolving 7.88g Na2 HP04, 2.04g of 
NaH2P04-2H20, 9g of NaCl, and 0.5ml of Tween 20 in 1 litre of 
distilled water to a pH of 7.3.
Diluent was prepared by dissolving 2. 5g of bovine serum 
albumin (BSA) in 1 litre of FBS-Tween. This concentration of BSA 
did not cross react with antisera in the assay system but was 
sufficient to inhibit non-specific binding.
The coating buffer which acted as the first antibody diluent 
was made by dissolving 1.59g of Na2 C03, 2.93g of NaH003 and 
0.20g and NaN3 in 1 litre of distilled water at a pH of 9.6.
The substrate solution comprised 20mg of 0-phenylene-diamine 
(Sigma Labs.) in 100ml of 0.2 mmol/L phosphate solution at pH 
6.0, to which 160 pi of 300g/L hydrogen peroxide solution was
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added. The substrate solution was stored at 4°C in a dark 
bottle, and was found to be stable for 1 week.
Standards: Human serum albumin (Sigma cat. no. A-8763) was 
dissolved in the diluent solution (PBS-Tween), to give a stock 
standard concentration of 20Qmg/L, which was stored at -20° C. 
Frcm a working standard of 400pg/L, doubling dilutions were made 
to give concentrations of 3.13, 6.25, 12.5, 25, 50, 100 and 200 
pg/L.
Antisera: The first antibody (Rabbit anti-human albumin) was 
diluted 10,000 fold in the coating buffer whilst the second 
antibody (goat anti-human albumin) was diluted 10000 fold in the 
PBS-Tween buffer to which normal rabbit sera diluted 1/400 had 
been added. The peroxidase conjugate (Rabbit anti-goat Ig - 
Horseradish Peroxidase) was likewise diluted 1/10000 in 
PBS/Tween.
Equipment: Nunc-Immuno plates (Gibco Europe Ltd., Middlesex, 
UK, cat. no. 439 454) were used as microtitre plates and the 
reaction was read using the Microelisa minireader (Dynatech 
Laboratories Ltd., West Sussex, UK) which was lent to us by the 
Immunology Department at Hope Hospital.
Samples: Timed day time (erect), night time (supine) and 24
hour (pooled day and night) urine samples were taken frcm all 
participants in the study and frcm 52 healthy control volunteers. 
2ml aliquots of the samples were stored at -20° C with 20pl of 
inactivated rabbit serum which was added to minimise adsorption 
of albumin to the storage tubes.
Assay Procedure: The assay was carried out at rocm
temperature:-
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(1) Initially 200pl of the rabbit anti-human albumin is added to 
each well on the plate, and incubated for one and a half hours. 
The wells are then decanted and washed three times with the PBS 
Tween buffer.
(2) 200 pi of the standard or diluted (1/250) samples were then 
added in duplicate to the coated wells and incubated for 1 hour. 
The wells were again decanted and washed three times with the PBS 
Tween solution.
(3) 200 pi of the goat anti-human albumin was then added to each 
well and incubated for 1 hour, and thereafter decanted with the 
same washing procedure as previously.
(4) 200 pi of the peroxidase-conjugate solution was added,
incubated for one further hour and washed with PBS/Tween buffer 
as before.
(5) 200 pi of the substrate solution was then added to each well 
at timed intervals.
(6) the plate was then incubated in the dark for 30 minutes, and 
then 50 pi of 1M HCl solution was added to each well at timed 
intervals.
(7) The absorbance of the contents of the wells was then read at 
490 nM using the microtitre plate reader.
Results: STANDARD CURVES A typical standard curve is shown in 
figure 1.
SENSITIVITY The concentration of the lower standard 
(3.13 pg/L) was reliably detected, which constituted 625 pg of 
albumin per well or 0.78 mg of albumin/litre of urine after 1/250 
dilution.
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FIG. 1 Standard curve for Elisa Assay of Urinary Albumin.
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The range of the assay was initially set at 3-1000 pg/litre, 
although further dilutions allowed albumin concentrations of up 
to 3500 pg/litre to be recorded but with less precision (greater 
than 10% variation) at concentrations greater than 1000 pg/L.
PRECISION 'Within batch' precision was estimated by assaying 
3 urine sanples with differing albumin concentration 20 times in 
one assay. The coefficients of variation (CV) for the 3 
concentrations was as follows: 12 pg/L CV 5.9%, 40 pg/L CV 3.8%; 
and 210 pg/L CV 4.9%.
'Between-batch' precision was estimated by assaying 3 
samples with differing albumin concentrations on 6 separate 
occasions with the following results: 12 pg/L CV 10.4%; 82 pg/L 
CV 8.5%; and 96 pg/L CV 15.1%.
ANALYTICAL RECOVERY The recovery of albumin frcm diluted 
urine sanples was between 92 - 108%.
PARALLELISM Adequate parallelism was demonstrated when 
samples were analysed neat, or in dilutions of up to 1/16.
NORMAL RANGES Based on timed 24 hour collections (split 
into day and night intervals) frcm 52 healthy volunteers (27 men 
and 25 wcmen) aged 36.8+11.3 (mean +SD) years, normal ranges were 
established. Repeated (2-4) collections were made on 10 healthy 
volunteers and the mean between collection variability of the 24 
hour, daytime and nightime sanples was estimated at 45%, 60% and 
30% respectively. The observed range of AER for the daytime 
(erect) sanples was 0.1 to 15 pg/minute, for daytime (supine) 
sanples 0.1 to 7.9 pg/minute, and for pooled 24 hour collections 
0.1 to 9.1 pg/minute. Therefore the upper limit of normal for 
daytime and 24 hour collections was set at 15 pg/minute and for
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nightime sanples at 10 pg/minute.
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1:3 FILTER PAPER BLOOD GLUCOSE MEASUREMENT
The establishment and assessment of an automated method for 
glucose determinations in filter paper blood spots was carried 
out between August and September 1983. I am most grateful to Dr. 
Graham MacKinnon of the Department of Chemical Pathology who was 
principal in establishing the method and with whom I collaborated 
in assessing its potential for use in the heme blood glucose 
monitoring study. The majority of measurements of filter card 
glucose during the study were carried out by Dr. P. Kalsi and 
Mrs. H. Dhar, Research Technicians in the Department of Medicine 
at Hope Hospital, although I continued to assist with these 
measurements on a regular basis.
The technique for measurement of filter paper blood glucose 
involves an enzymatic reaction and the use of a continuous flow 
auto-analyser to increase throughput.
Reagents: Glucose concentrations were determined
enzymatically using the GOD-PAP reagent (BCL glucose kit)
obtained frcm Boehringer Corp., England (kit no. 166391). Bottle 
1 containing glucose oxidase is made up to 200 ml with deionised 
water and stored at 4°C, whilst the phenol in bottle 2 is added 
to 1 litre of 0.9% NaCl in distilled water. 1ml of 30% Brij is 
latterly added to this NaCl/Phenol reagent and stored at rocm
temperature. In addition we made up 5 litres of 1.5%
sulphosalicylic acid solution and 500 ml of 1% boric acid, which 
were both stored at rocm temperature.
Standards: (1) Aqueous Standards - a stock standard of
5Qmmol/L glucose solution in saturated benzoic acid was obtained
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frcm BDH Chemicals Ltd., UK. Working standards equivalent to 
1.0-25.0 mmol/L concentrations are prepared by dilution of the 
stock solution with saturated benzoic acid, and stored at 4°C. 
Before use standards are diluted 1 in 50 (lOOpL + 5ml) in 1.5% 
sulphosalicylic acid.
(2) Blood spot secondary standards - specimens 
which had been analysed on a Yellow Springs Glucose Analyser 
(Clandon Scientific Ltd,. England) were obtained with values 
which corresponded roughly to the aqueous standards. Sanples 
were spotted onto filter paper, allowed to dry, and frozen to 
allow 4 spots on each glucose value to be measured in each assay 
run.
Filter papers: We used pre-printed cards designed by
Professor DC Anderson, with a superimposed strip of Whatman 31 
PKU filter paper (see Appendix III). A quantity of the filter 
papers were saturated with 5% boric acid for 1 hour and allowed 
to dry overnight at rocm temperature. Blood spots were cut out 
using a hand held 6mm diameter paper punch (Velos Ltd, England).
Apparatus: A single channel continuous-flow autoanalyser 
system was set up comprising a Newton Sampler and Turntable, 
Technicon AAII proportioning pump, Technicon AAI heating bath and 
coil, Fisons Vitatron UPS Colorimeter with a 510 mm filter, and a 
Fison's Vitatron flat bed 1 in-log UR 400 recorder with a curve 
regenerator fitted and a chart speed of 2cm/minute (Figure 2).
Assay Procedure: Blood is initially spotted onto the filter 
paper to produce a spot at least 10mm diameter, and allowed to 
dry. A 6mm diameter blood impregnated disc or the standard is 
added to a LP3 test tube, to which 500 pL of 1.5% sulphosalicylic
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acid is added. The sample is then put in a mechanical shaker for 
30 minutes - 1 hour, and precipitated protein is removed by 
centrifugation of the tubes for 10 minutes at 3000 revs/minute. 
The supernatant is then put into autoanalyser cups, and dialysis 
was not required after such treatment. Water is pumped out of 
the sampler wash of the flow system and 1.5% sulphosalicylic acid 
is run through to ensure that no water is sampled during the run 
which would give a negative baseline. Diluted aqueous standards 
are put through first, followed by the blood spot standards and 
blood, spot samples in pairs. A diluted aqueous control is also 
placed at every tenth sample position to act as a control. 
Sanples with values greater than the top standard are diluted in 
1.5% sulphosalicylic acid and repeated. The linearity of the 
assay is checked using the aqueous standards, and samples are 
reported to the nearest 0.5 mmol/1. Glucose is estimated 
spectrophotcmetrically by the colour development following the 
reaction:
GOD
Glucose + 02 + H20 >Gluconate + H202
2H202 + 4 aminophenazone >phenol POD 4H20 +
4 (p.benzoquinone-mono-amino) phenazone.
Results: a) Initial experience with the system - We found 
that complete extraction of glucose was obtained within 30 
minutes of the initial elution with 1.5% sulphosalicylic acid and 
the subsequent mixing, which halved the time suggested by 
previous workers (493, 496, 498). Continuous sanpling of the 30 
mmol/1 glucose standard produced a pink-red colour. The 
extinction of this was set at 100 chart units by the use of the 
’Span1 control. Single sanpling of this standard on a 25/25
261
second wash/sample cycle gave a peak readout of 93 units on the 
chart. The method therefore achieved in the order of 93% of the 
steady state, adequate for the analysis. Because baseline drift 
was apparent in the early stages of development, the sensitivity 
of the recorder was reduced by backing off the 'Span' control so 
that a 30 mmol/L glucose sample would read about 75 chart units. 
In addition two double mixing coils were added to the line 
between the heating bath and the flow cell. This allowed for 
colour development to maximise before readout and reduced 
baseline drift. It was also found that using a smaller pump tube 
reduced reagent consumption and flow rate without impairing the 
sensitivity of the method. Using a total sample volume of 100 
pi, a sanpling rate of 102 per hour was achieved.
b) Collection of filter paper blood spot samples - The dry 
weight of 100 pL of blood was calculated by weighing 6 filter 
papers dry and again after spotting them with 100 pi sanples in 
the form of 5 spots on each card. A disc was punched frcm each 
spot and weighed individually. The mean volume per disc for the 
six sanples was 10.7 pL (SD 1.5 pL; coefficient of variation 
14%). The coefficient of variation for reproducibility of the 
punching procedure was 2.1%.
c) Glucose Measurement - The analytical precision of the 
method was calculated frcm 50 direct measurements of three levels 
of diluted aqueous controls (mean glucose levels 3.8, 8.3 and
17.2 mmol/L), performed over a period of 12 weeks. The between 
batch precision was 4.2%, 3.8% and 3.3% respectively.
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FIG. 3 Correlation between Yellow Springs analyser and filter paper blood 
glucose levels in 50 diabetic samples.
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The within-batch precision of the filter paper derived 
venous blood glucose measurements were also assessed. Twenty 
four specimens were each assayed ten times, with 8 specimens fran 
one of three possible ranges for glycaemia:
Range 1 3.0 - 7.0 nmol/1. Mean blood glucose 4.7 mmol/1,
mean within batch coefficient of variation 4.6%
Range 2 7.0 -13.0 mmol/1. Mean blood glucose 10.5 mmol/1,
mean within batch coefficient of variation 3.6%
Range 3 13.0 - 22.0 mmol/1. Mean blood glucose 17.8
mmol/1, mean within batch coefficient of variation 3.7%.
Between batch precision was evaluated frcm eight successive 
duplicate measurements of seven diabetic patients' venous blood 
sanples collected on filter paper, and stored at -20°C over a 4 
week period of analysis. The mean and range of glucose 
concentrations was 11.4 and 3.7 - 26.4 mmol/L, respectively. The 
mean between batch coefficient of variation was 3.6% (SD 0.4%). 
The accuracy of the assay was investigated using venous sanples 
frcm 50 diabetic patients measured on filter paper and compared 
with results using the Yellow Springs Glucose Analyser (Clandon 
Scientific Ltd., England). An excellent correlation was found (r 
= 0.98) (Figure 3). Glucose levels in quality control serum 
measured by both methods also showed a close correlation (r = 
0.99).
d) Stability Studies - i) Untreated filter paper - The 
effect of storage of filter paper at varying temperature was 
investigated. Sixty blood spots were collected frcm each of 
eleven diabetic patients, of which 20 were kept at rocm 
temperature, and a further 20 were stored at 4°C and -20°C in
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sealed plastic envelopes. Duplicate analyses of each specimen 
were made on the day of collection (day 0) and on days 
1, 3, 7, 14, 21, and 28. The range of initial glucose
concentrations was 4.2 - 26.1 mmol/L. The mean of duplicate 
results was calculated as a percentage of the initial value. 
(Figure 4). After an initial fall in blood glucose concentration 
over 24 hours irrespective of the storage temperature, sanples 
stored at rocm temperature fell on average to 81% of the baseline 
value at one week (p <0.001). Sanples stored at 4°C showed less 
degradation, although this was still significant after 7 days. 
At -20° C, no significant change in glucose concentration was 
found over 28 days (p >0.5). To examine the change in glucose 
concentrations during the first 48 hours after collection, 
sanples frcm a further 4 diabetic patients were analysed at rocm 
temperature after 1,3,5,10, 24 and 48 hours (Figure 5). No change 
was apparent by 10 hrs, although a significant difference was 
seen by 24 hours (p <0.05), when a mean fall of 4% was noted, and 
this had risen to 7% by 48 hours.
ii) The effect of Boric Acid Impregnation of filter paper 
Boric Acid has been suggested to prevent glucose degradation in 
stored filter paper (495). Sanples of 6 diabetic patients were 
collected onto untreated filter paper and filter paper 
impregnated with 5% boric acid, stored at rocm temperature and 
analysed on the day of collection (day 0) and subsequently on 
days 1,2,4,7,21 and 28. Results for the first seven days are seen 
in figure 6. Initial levels of filter paper blood glucose for 
all sanples showed that borate impregnation resulted in an
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FIG. 4 Long term stability study of filter card blood glucose levels.
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apparent rise of 1 mmol/L when ccnpared with untreated filter 
paper values (mean blood glucose on borate treated paper 11.8 
mmol/L, canpared to 10.8 mmol/L on untreated paper; p<0.02).
Comparison of the borate treated samples with the standard 
laboratory Yellow Springs Analyser method showed a similar 
anomaly (mean Yellow Springs Analyser result 11.1 mmol/L; 
p<0.025), whilst there was no apparent difference between the 
initial untreated filter paper glucose and Yellow Springs blood 
glucose levels (p>0.4). Paired borate-treated and untreated 
sanples were subsequently different on all days of analysis 
(p<0.05). In terms of degradation, glucose levels in borate
treated specimens had fallen by 5% by day 2 (p<0.05) (in
carparison to initial value), which was comparable to the 6% fall 
(p<0.01) seen in the untreated specimens. Frcm day 4 onwards both 
sets of sanples showed significant degradation, but borate 
impregnation was shown to have a conserving effect by day 7 which 
was still apparent after 28 days.
e) Carparison with patient derived Reflolux blood glucose 
recordings - Prior to commencing the heme blood glucose 
monitoring study, I compared filter paper blood glucose results 
with glucose concentrations determined simultaneously by 14 
diabetic patients who were experienced at blood glucose 
monitoring. 140 (10 x 14) filter paper spots and Reflolux 
recordings were available for carparison, of which 131 where 
suitable for analysis. A close correlation (r = 0.89) was found, 
(Figure 7), which reassured us of the feasibility of such a 
carparison during the heme blood glucose monitoring study as well
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between Reflolux meter and filter paper blood glucose
as confirming reliability of data collection, at least in these 
patients.
Comment: Filter paper blood glucose measurement was
investigated and validated for use in the heme blood glucose 
monitoring study. The method developed was relatively 
inexpensive, and up to 20 profiles (200 estimations) could be 
estimated in a single working day. Both refrigeration and borate 
impregnation of the filter cards retarded degradation of blood 
glucose although the former was more efficient in this respect. 
The reason for the artefactual rise in glucose following 
impregnation with borate was unclear, but a small significant 
loss of glucose thereafter still occurred if filter papers were 
kept at rocm tenperature. For practical purposes we did not 
routinely impregnate filter paper with borate but instead used 
sealed envelopes and instructed patients to store filter cards in 
the refrigerator prior to bringing them up to hospital the day 
after completion; thereafter they were kept at -20°C till 
analysis.
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1:4 GLYCOSYLATED (GLYCATED) SERUM ALBUMIN (GSA)
This assay was established in two stages. Initially I 
performed a series of experiments to validate the performance of 
a canmercial assay. I was assisted in this work by Mrs. Maureen 
Newman, research technician in the University Department of 
Medicine, to whcm I am most grateful. The realisation of the need 
for an albumin assay with extremely low sensitivity led to 
collaboration with the University of Manchester Department of 
Chemical Pathology in developing an immunoturbidimetric assay. I 
carried out these later experiments in conjunction with Drs. Paul 
Reed and Deepak Bhatnagar frcm Chemical Pathology and Mrs. Hankah 
Dahr, my research technician. After validation of the assay, the 
majority of evaluations for the heme blood glucose monitoring 
study were carried out by Mrs H. Dahr and later Dr. P. Kalsi, 
although I assisted regularly. I also acknowledge the help of 
Mr. G. Warriner of Pierce and Warriner, Chester, UK, who kindly 
supplied me with Glycogel B kits for the duration of the study.
i) EVALUATION OF GLYCOGEL B AS AN AFFINITY CHROMATOGRAPHIC 
METHOD FOR DETERMINATION OF GSA 
The Glycogel system (Pierce and Warriner,Chester, UK) is an 
affinity chrcmatographic support which incorporates an 
immobilised ligand (m - aminophenyl-boronic acid) capable of 
specifically interacting with non-enzymatically glycosylated 
proteins. My own evaluation of this system for the measurement of 
GSA was carried at the same time as John and Jones (163) and was 
later published after modification of the original method (V.I.).
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Material and Methods
Sample Collection Clotted blood was collected by
venepuncture frcm diabetic and non diabetic individuals in 
plastic containers free of preservative. Serum was separated 
within four hours of sampling and initially stored at -20° C. 
Samples that could not be analysed within 4 weeks of venepuncture 
were stored at -40°C.
Materials - Glycogel Analytical Mini Columns containing 1.0ml of 
immobilized m-aminophenyl-boronic acid on cross linked 6% beaded 
agarose gel in an aqueous medium containing 0.02% sodium azide 
were used as the affinity matrix. The Equilibration/Wash Buffer 
consisted of 250 mmol/L ammonium acetate, 50 mmol/l magnesium 
chloride, and 3 mmol/l sodium azide, pH 8.3. The Elution Buffer 
comprised sodium citrate and 0.02% sodium azide, pH 4.5. 
Colorimetric determination of albumin was made using brcmocresol 
Green reagent (containing brcmocresol green, citric acid and 
trisodium citrate), pH 4.8. In addition brcmocresol Purple 
reagent (containing brcmocresol purple, sodium acetate, acetic 
acid, Brij and sodium citrate (BDH Chemicals, Poole, UK)), pH 
5.2, was also assessed as a sensitive indicator of albumin. 1 
litre volumes of 0.1N and 0.001N HCl were made up in deairated 
deionised water to serve as column regeneration and storage 
solutions respectively. All materials were stored at 4°C between 
use, and Glycogel B columns were kept out of direct light during 
storage and during assay runs.
Standard Assay Procedure - The columns and buffers are 
removed frcm storage at 4°C and allowed to return to rocm 
temperature (20-25°C). The 0.001N HCl storage solution is
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withdrawn after removal of the top column stopper only. The 
bottom column stopper is then removed and the column is placed in 
a rack. The columns are then equilibrated by adding 5ml of the 
Equilibration/Wash Buffer (EWB) solution, and the effluent is 
discarded. The column is then ready for use. Duplicate runs are 
carried out for all sanples. A 200pl sample (either neat or 
diluted serum) or saline blank is added to the top disc and 
allowed to pass through. This is followed by 0.5ml of EWB to 
ensure complete transmission of the sample through the top disc 
and into the gel. 4.5ml of EWB is then applied to the column 
followed by 3 consecutive 5ml fractions of the same buffer and 
the total 20.2ml (0.2ml sample, 20ml EWB) effluent containing the 
non-glycosylated albumin fraction is collected and mixed well. 
Thereafter the remaining bound glycosylated albumin fraction 
which is adherent to the affinity gel is released by applying 3ml 
of the elution buffer to the column, and the total fraction is 
collected. 1ml of the non-bound albumin fraction is added to 3ml 
of the BCG albumin reagent whilst 2ml of the bound albumin 
fraction is mixed with 1ml of the BCG reagent, and both sanples 
are mixed well. The spectrophotometer is set at 630nM and the 
absorbance to zero using the column blank non-bound tube. The 
absorbance of the two fractions is recorded and the % of GSA is 
calculated from the following equation :- 
%GSA = 1.5 (Aq3o B) x 100
20.2 (A eaoNBJ+l.SfAeaoB), 
where h€30 B is the absorbance at 630 nM of the bound 
(glycosylated) fraction and 2^30 NB is the absorbance of the non­
bound (non-glycosylated) fraction. After use the columns are
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regenerated with 5ml of 0.1N HCl solution, discarding the 
effluent, 5ml of 0.001N HCl column storage solution is then run 
through the column of which 2ml is kept in the column, with the 
rest discarded. The columns were then stored in the dark at 4°C 
for re-use.
The method outlined above is that recanmended by the 
manufacturers and was used in the initial assessment although 
modifications were made of volumes of sample and albumin reagent 
when assessing BCP (branocresol purple) and BCG reagents of 
differing pH.
Furthermore the method finally found to maximise yield of 
GSA. without overloading the columns with albumin used lOOpl of 
serum diluted 1/16 with 1.5ml of deionised water, of which 100 pi 
is applied to the column and eluted with only 9.9ml of the EWB. 
In addition the glycosylated albumin was subsequently eluted by 
4ml of a Sorbitol buffer comprising 200 mmol/L Sorbitol, 50 
mmol/L EDTA, 100 mmol/L tris (hydroaymethyl) amincmethane and 3 
mmol/L of sodium azide with a pH of 8.3 - 8.8.
Results: (1) Normal and Diabetic Ranges - Sanples were 
taken fran 25 healthy non-diabetic individuals without clinical 
or biochemical evidence of hepatic or renal dysfunction, and 
compared with 53 sanples frcm insulin treated diabetic patients 
with varying degrees of glycaemic control. The observed range in 
the healthy controls was 0.46 - 3.42%, mean value 1.7%; 95% 
confidence intervals 0.3 - 3.1%. This compared favourably with 
the 0.80 - 3.20% range, mean value 2.0%, quoted by the
manufacturers of the kit. The range of values in the diabetic 
sanples was 0.70 - 20.06% with a mean of 7.61% which was
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significantly higher (pCO.OOOl) using Student's unpaired t-test. 
The highest value in the control population belonged to an obese 
individual who was later found to have impaired glucose tolerance 
in response to a 75g glucose tolerance test. The lowest value 
frcm the diabetic sanples belonged to a well controlled insulin- 
treated diabetic with chronic pancreatitis secondary to 
alcoholism who had experienced recurrent hypoglycaemic episodes. 
The maximum figure of 20.06% was recorded in a young insulin 
dependent diabetic female who was in diabetic ketoacidosis at the 
time of sampling, having stopped her insulin therapy for a period 
of 2-3 weeks prior to hospital admission.
(2) Effect of Albumin Concentration (Experiments 1-4) - The 
effect of varying the volume of sample and thereby the 
concentration of albumin was investigated to examine whether 
applying increasing albumin concentrations exceeded the capacity 
of the columns to remove all glycosylated albumin. 5ml of a 
healthy control serum (GSA value estimated frcm 200 pi sample as 
1.44%) was applied to the column, and the serum collected after 
passage through the column gel. When this was subsequently 
reapplied to a fresh column, a GSA value of 1.16% was estimated 
which demonstrated that the column was inefficient at trapping 
all GSA when such high albumin loads (roughly 200 mg) were 
applied. In fact it took a further 4 passages of the original 
5cc volume before no further GSA was detected.
I then went on to examine the effects of loading much 
smaller volumes of serum (10 pL to 400 pL) with albumin loads 
roughly varying between 0.4 and 16mg. It became apparent that no 
reproducable measurement was obtained with serum volumes of less
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than 50 pL because of the insensitivity of the BCG dye at such 
low albumin concentrations (v.i.). However a clear relationship 
between reducing serum volumes and increasing GSA values was 
observed in healthy control and controlled and ketotic diabetic 
sera (Table 8), which confirmed that 50-100 pL was probably a 
more suitable volume of serum to apply, although this was later 
found to stretch the capacity of the BCG method to determine 
albumin levels.
Table 8 EFFECT OF SERUM VOLUME (ALBUMIN LOAD) ON RECOVERY
OF GSA~X%T
VOLUME OF SERUM APPLIED
Sample 50 pL 100 pL 200 pL 400 pL
HEALTHY 3.58% 2.81% 2.33% 2.20%
CONTROL
CONTROLLED 7.51% 7.33% 6.43% 6.10%
DIABETIC
KETQACIDOTIC 23.63% 18.11% 18.55% 17.60%
DIABETIC
It can be seen that applying 50 pL of serum (roughly 2mg of 
albumin) increased the yield of GSA by around 54% in healthy 
controls and by 17-27% in the diabetic sanples. A similar
pattern emerged in several other patients when different amounts 
of sera were applied to columns, which tended to confirm that 
overloading the column with albumin reduced the yield of GSA.
I then attempted to demonstrate whether GSA was definitely 
lost with the elution buffer during overloading or whether it 
remained adherent to the column matrix. I applied 200 pL of 
diabetic serum to 2 columns, directly measuring the % GSA by the 
standard method in one case, and eluting the second column with 5
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5 ml of wash buffer, which would in theory have only removed non-
glycosylated albumin. The eluted 5.2ml volume was then reapplied
to a fresh affinity column to which 3 ml of albumin elution
buffer was applied, to remove any GSA that had not adhered to the
original column. 8.77% of albumin was found to be glycosylated
after direct measurement by the standard method, but 1.44% of
albumin was found to be glycosylated in the eluted fraction after
the second passage. This confirmed that adding 200 pL of serum
(8mg of albumin) did overload the column, leading to loss of GSA
frcm the matrix during elution with the wash buffer. In effect
seme 14.1% of the glycosylated albumin (1.44 x 100 %) passed
T8777 + 1.44 "J
through the column without adhering thereby underestimating the 
true % GSA.
These observations do not of course preclude the possibility 
that the failure of the columns to adhere all the glycosylated 
albumin was secondary to too high a concentration of albumin 
rather than the absolute quantity of albumin applied to the 
column. Accordingly I studied the effect of prediluting the 200 
pL serum samples of 2 diabetic patients with 2ml of wash buffer 
prior to passage through the column, and examined whether 
reapplying the 200 pL of serum once it had been washed through 
the column with 5ml of wash buffer would alter the recovery of 
GSA. In both cases the routine procedure was followed after these 
initial modifications (Table 9).
278
Table 9. EFFECT OF PREDILUTION AND POSTDILUTION OF 200 pL SERUM
SAMPLE ON RECOVERY OF GSA FROM DIABETIC SERA
STANDARD PREDILUTION WITH REPASSAGE (POSTDILUTION) . 
METHOD 2ml of EWB of 5.2ml (SAMPLE PLUS 5ml EWB)
% GSA
DIABETIC 11.28 11.16 10.15
(1)
DIABETIC 10.85 10.02 9.15
(2)
Both diabetic sanples shew that predilution does not 
increase the yield of GSA, and that rather then encouraging 
adherance of GSA which was erroneously eluted during the initial 
passage by reapplication, repassage of the diluted sample leads 
to a further reduction of GSA which is outwith the standard
deviation for the assay performance at this level of GSA (v.i.)
and suggests if anything that repassage of the sanple with wash 
buffer might lead to elution of GSA which is less strongly bound 
to the boronate matrix.
3. Precision - (Experiments 5-6) - The within and between 
batch variation was analysed for 10 pairs of duplicate samples at 
3 different levels of glycosylation (non-diabetic, and well 
controlled and poorly controlled diabtic serum) and the results 
are shown in Table 10.
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Table 10 PRECISION FOR GSA USING AFFINITY CHRCMATOGRAFTIY
NON DIABETIC MEAN (SD)
GSA (%)
WITHIN BATCH 
(no. = TO) 
2.78 (0.20)
BETWEEN BATCH 
(no. = TO) 
1.85 (0.39)
COEFFICIENT OF VARIATION 11 23
(%)
WELL CONTROLLED DIABETIC 7.00 (0.45) 
MEAN (SD)
7.40 (0.55)
COEFFICIENT OF VARIATION (%) 7 8
POORLY CONTROLLED DIABETIC 16.80 (0.60) 
MEAN (SD)
16.80 (0.96)
COEFFICIENT OF VARIATION (%) 3 8
As expected the method was much less accurate within the 
normal range although it appeared reproducable in diabetic 
sanples.
4. Effect of Freezing and Thawing Samples (Experiment 7) - I 
studied the effect on recovery of GSA of storage and thawing 
separated aliquots of the same diabetic sample on 5 occasions 
over a 2 week period. The initial level was 3.79% and over the 
period of observation after repeated rethawing the mean value was 
3.43%, which is not signifcantly different, as the between run 
mean and standard deviation for the sanple was 3.21 +0.41%. In 
addition all other sanples measured during the two week period 
after thawing were within the standard deviations of the between 
run mean value (Figure 8).
This suggests that rethawing of sanples does not alter the 
recovery of GSA. The fact that the % GSA after 2 weeks freezing 
was 3.43% in comparison to 3.79% in the initial run also 
confirmed that freezing itself did not alter the level of GSA.
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FIG. 8 Effect on recovery of GSA of freezing and rethawing samples.
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5. Regeneration of the Gel (Experiments 8-10) - The efficiency 
of the boronate gel to bind GSA after being used several times 
was assessed by measuring a sample frcm a diabetic subject on a 
fresh column and on columns that been used 2,6 and 10 times. On 
these columns the initial GSA was 6.77% and was thereafter 6.70%, 
6.68% and 6.60%. Other experiments using columns where colour 
changes or air bubbles had developed in the gel showed that 
either of these alterations led to significant reductions in 
recovery of GSA (greater than 20% of the original values).
6. Effect of Prior Dialysis of Samples (Experiments 11 -12) In 
order to investigate the possibility that the Glycogel Affinity 
Chromatography might bind labile Schiff base GSA as well as the 
stable fraction, which would have necessitated a time consuming 
preliminary pretreatment of sanples by hydrolysis or dialysis, I 
examined the change in GSA in duplicate sanples run before and 
after dialysis to remove any free glucose bound to albumin. 5 
diabetic samples with high levels of ambient blood glucose at the 
time of sampling were studied before and after a 24 hour period 
of dialysis of the sanples against normal saline at 4°C. The 
results are shown in table 11.
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Table 11. EFFECT OF DIALYSIS WITH SALINE ON GSA RECOVERY, AND
LEVELS OF BLOOD GLUCOSE AND SERUM ALBUMIN
BLOOD GLUCOSE SERUM ALBUMIN GSA (%)
mmol/1 g/L
SAMPLE NO. PRE POST PRE POST PRE POST
1 17.0 0.1 36 35 3.98 3.98
2 19.0 0.5 43 38 5.57 5.78
3 15.8 0.2 37 32 5.76 6.06
4 19.0 0.8 37 35 14.86 15.79
5 17.1 0.8 45 42 7.54 7.56
This experiment confirmed that the affinity chromatography 
method satisfactorily measured stable GSA and was unaffected by 
removal of free glucose which could artifically have raised GSA 
levels if labile GSA was also isolated by affinity 
chromatography. Even with dilution of samples with saline as 
evidenced by falls in albumin concentration, no change in GSA has 
resulted. This suggests that separation of the labile (Schiff 
base) and stable forms of GSA took place during the initial 
passage of serum through the affinity matrix.
I considered whether the mechanism of this separation was 
due to glucose separating frcm albumin and itself adhering to the 
boronate ligand in the gel. However after passing a sample of 
serum down the column, followed by a glucose oxidase reagent 
(Glucose Oxidase/ Peroxidase, Phenol and 4-amino-phenozene) which 
would have produced a specific colour change in the presence of 
significant amounts of glucose, no such reaction took place after 
24 hours incubation at room temperature, suggesting that the
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boronate adhered only stable GSA without affinity for free 
glucose or labile GSA.
7. Linearity (Experiment 13) - In order to assess linearity 
of the GSA assay, the % of GSA was determined in sanples from a 
healthy control and a poorly controlled diabetic, and was found 
to be 2.07% and 15.04% respectively. 200 pL serum loads of a 
pooled sample in varying amounts (0 - 100 % of diabetic serum 
mixed with control serum) were then applied to the column, in 
varying dilutions (up to 1/4) and left on the columns for varying 
periods of time ( 0-90 minutes). The most reproducable and 
linear results were obtained when sanples were diluted 1/4 with 
saline and left on the column for 1 hour, confirming that 
linearity of GSA with varying amounts of diabetic Vs control sera 
was a feature of the assay (Figure 9).
8. Effect of Temperature Variation (Experiment 14) - I 
investigated the effects of the ambient temperature on the 
affinity system in both the normal and diabetic range by cooling 
the chamber where experiments were carried frcm 25° C to 20° C. A 
decrease in GSA% of less than 5% was found when the temperature 
fell frcm 25° C to 20° C for both diabetic and control sanples with 
negligible differences observed for the former.
9. Effect of Variation in pH and Type of Dye (Experiments 15 -16) 
- Suggestions of inproved sensitivity using more specific dyes to 
measure albumin led to assessment of brcmocresol green (BCG) dyes 
of varying pH and brcmocresol purple. The standard BCG dye which 
was supplied with the kit had a pH of 4.8. Increasing or
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reducing the pH of BCG within the range 4.2 -7.0 produced 
reactions but standardisation was difficult and did not lead to 
improved reproducibility over the . suggested method. Because 
brcmocresol purple (BCP) is supposed to be more sensitive than 
BCG in measuring smaller quantities of albumin, I investigated 
whether BCP would prove more useful in measuring GSA in the 
DIABETIC range. Paired duplicate runs using the BCP and BCG 
dyes were carried out on 5 diabetic samples. The pH of the 
commercial BCP was 5.2 and the consequent yellow colouration 
after reaction with buffers was different to the green 
colouration with the BCG dye. It was found by trial and error 
that whilst the maximum absorption with BCG was with the 
spectrophotometer setting at 630 nm, it was 590 nm for BCP. The 
measured GSA comparing BCP or BCG reagents is seen in table 12. 
Table 12. COMPARISON OF BRCMOCRESOL PURPLE (BCP) WITH 
BRCMOCRESOL GREEN (BCG) IN THE DETERMINATION OF GSA
DIABETIC SAMPLE STANDARD BCG METHOD BCP METHOD
1 5.70% 0.94%
2 8.11% 3.45%
3 7.75% 4.07%
4 8.07% 3.22%
5 8.10% 4.52%
A consistent reduction in measured GSA was observed using 
the BCP. Despite increasing the absorption by setting the 
spectrophotometer to 590 nm, the pH of albumin elution and wash 
buffers were found to be outside the range where BCP produced a 
reproducable measureable colour reaction, so that the BCP 
solution of pH 5.2 was unsuitable for GSA measurements.
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10. Accuracy - John and Jones (163) claimed that despite apparent 
reproducibility of the assay the lack of a standard and 
insensitivity of BCG to detect low levels of albumin precluded 
the use of the kit for clinical practice in its existing form. 
Consequently I investigated the accuracy of both BCG and BCP to 
detect low concentrations of albumin to definitely state whether 
or not dye binding techniques could be applied to the measurement 
of albumin in both glycosylated and non-glycosylated fractions.
A standard human albumin solution (Hbechst Pharmaceuticals, 
Hounslow, UK) was made up in doubling dilutions in saline in the 
range 5-1280 pg/ml. The absorption on the spectrophotometer was 
measured at 630 nm for BCG (added in a ratio of 1/2 with the 
albumin) and at 600 nm for BCP (also added in a ratio of 1/2 with 
the albumin solution). The capacity of the two dyes to measure 
varying concentrations of albumin is seen in figure 10.
Whilst BCP is undoubtedly more accurate at measuring albumin 
that BCG, there is a definite lack of correlation below albumin 
concentrations of 80 pg/ml. In trying to exploit the assay to 
its full it was previously stated that the affinity column gave 
the highest yield of GSA when 50 pL of undiluted serum was 
applied thereby taking care not to overload the capacity of the 
boronate gel to efficiently trap all glycosylated albumin (163). 
Assuming an average albumin concentration of 40g/L of serum, 
roughly 2mg of albumin would be present in the 50 pL serum 
sample, effectively a concentration of 40 mg/ml of albumin, which 
would be the maximum load which could safely be applied to the 
column. Previous experiments suggested that the ideal volume
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FIG. 10 Accuracy of BCG and BCP in measurement of low albumin con­
centration.
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of serum to apply for maximum affinity for GSA was between 25 and 
50 pL which is roughly equivalent to albumin concentrations of 
1000 pg/ml and 2000 pg/ml. Whilst both BCP and BCG would be 
expected to measure these concentrations of albumin reliably in 
undiluted serum frcm the accuracy experiments, these dyes also 
have to be capable of measuring the glycosylated fraction. In a 
diabetic sample where 10% of albumin may be glycosylated only the 
BCP could reliably estimate the 100-200 pg/ml of glycosylated 
albumin. In normal samples where perhaps only 2.5% of albumin is 
glycosylated, even BCP would be unreliable in measuring the 25 - 
50 pg/L concentrations.
My conclusion from the above experiments is that the 
affinity column component of the method is robust and efficient 
in separating glycosylated frcm non-glycosylated albumin if small 
volumes (less than 100 pi) of plasma are applied to the column, 
but that dye binding methods of measuring albumin are too 
insensitive to measure the small amounts of albumin present in 
the glycosylated fractions.
If a 50 pL non-diabetic serum sample is applied to the 
column and GSA diluted with 3ml of albumin elution buffer, a 
concentration of roughly 13 pg/ml of albumin might be present if 
2% of the original albumin load was glycosylated. With this is 
mind I then went on to explore other more accurate methods 
capable of determining such low levels of albumin concentration.
ii. VALIDATION OF GSA MEASUREMENT BY AFFINITY CHROMATOGRAPHY 
AND IMMUNQTURBIDIMETRY
I carried out an assessment of a combined affinity
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chranatography and iirraunoturbidimetric assay for the precise 
measurement of GSA. with the assistance of Mr. Paul Reed and Dr. 
Deepak Bhatnagar of the Dept. of Chemical Pathology at Hope 
Hospital and Mrs Hankah Dahr who worked as a research technician 
with me during the study. 
a) Materials and Methods
Sanples - Fasting venous blood sanples were collected and sera 
separated by ultracentrifugation and stored at -20° C as 
previously described.
Affinity Chranatography - The method employed the Glycogel B kit 
which was used as previously described except that lOOpL of serum 
diluted 1/16 in water was applied to the column and only 9.9ml of 
wash buffer was then applied to the column. It was also found 
that glycosylated albumin was best eluted using 4ml of sorbitol 
buffer (200 mmol/L sorbitol, 50 mmol/L EDTA, 100 mmol/L Tris and 
3 mmol/L sodium oxide; pH 8.8), as opposed to the sodium citrate 
solution in the original experiments.
Immunoturbidimetric measurement of albumin
Reagents: Antiserum - Goat antihuman albumin (Atlantic Antibodies 
Antiserum ALB2) of nephelanetric grade was obtained frcm American 
Hospital Supplies (UK) Limited, Didcot, UK. This was diluted 1 in 
170 with 4% PEG (polyethylene glycol 6000) in phosphate buffered 
saline (0.3g/L NaH2P04, 2H20, 1.15g/L Na2HP04, 8.6g/L NaCl; pH 
7.4) (Mercia Brocades M99A, UK), left for 10 minutes and 
centrifuged for 5 minutes at 1500g at room temperature before 
use.
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Standards: A stock standard was prepared frcm BR99 (reference 
normal human serum, Unipath Limited, Bedford, UK) by 1/1000 
dilution in the affinity chranatography wash buffer (pH 8.8) with
0.05% sodium azide as a preservative. This solution was stable 
for at least one month at 4°C. Before each assay appropriate 
dilutions were made in wash buffer to cover a standard curve frcm 
Img/L to 20 mg/L. A pooled serum sample frcm healthy controls 
and frcm poorly controlled diabetics (20ml samples) served as 
glycosylated albumin standards.
Controls: Working controls were prepared at concentrations
corresponding to 2.6 mg/L (QC1), 8.7 mg/L (QC2) and 15.4 mg/L 
(QC3) frcm a stock solution prepared by a 1/1000 dilution of 
Hoechst 041015 (material of human origin, Behring Diagnostics, 
Hoechst House, Hounslow, UK) in affinity chranatography wash 
buffer (pH 8.8) with 0.05% sodium azide added.
Instrumentation for Albumin Measurement; The glycosylated and 
non-glycosylated albumin fractions were separated using affinity 
chranatography as previously described with diluted serum, and 
sorbitol was used as an albumin elution buffer. The eluates 
containing glycosylated albumin were assayed neat whilst those 
containing non-glycosylated albumin were diluted 1/2 in the wash 
buffer. Albumin in the two eluates was measured by 
immunoturbidimetry on a centrifugal analyser, the Multistat III 
plus F/LS (Instrumentation Laboratories (UK) Limited, Warrington, 
Cheshire, UK), which provided initial data. The method was later 
adapted to run on the Cobas Fara analyser (Roche Products Ltd., 
Welwyn Garden City, Herts., UK). Instrument settings for both
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centrifugal analysers use shown in Tables 13 and 14. The % 
glycosylated serum albumin was determined frcm the following 
equation:
% GSA = GSA concentration x 100______________________
GSA concentration +4.88 (non-glycosylated albumin)
( concentration )
b. Results
1. Normal and Diabetic ranges of GSA - GSA was measured in 25 
healthy control subjects and in 37 type 1 insulin-dependent 
diabetic patients. The range of % GSA obtained in the healthy 
controls was 2.3 to 6.3% with a mean value and standard deviation 
of 3.42+0.97%. The predicted normal range was therefore 1.5- 
5.4% (95% confidence intervals) which is similar to although 
greater than the 0.3-3.1% range described using the Glycogel B 
method with subsequent albumin measurement by dye binding 
techniques. In the 37 insulin-dependent diabetics GSA varied 
frcm 2.1 to 15.1% with a mean value and standard deviation of 7.9 
+3.3%, so that considerable overlap between the control and 
diabetic ranges was observed (figure 11).
2. Optimisation of Albumin Measurement - Increasing the 
percentage of polyethylene glycol frcm 4% to 6% which is added to 
the antisera had no apparent effect on the sensitivity of albumin 
detection. However when the sample size for measurement was 
increased frcm 20 pL to 36 pL with an equivalent alteration in 
the dilution of antisera (originally 1/300; with alteration in 
sample dye 1/200 x 36/20 = 1/170 as described in method section), 
the A  Albumin across the standard curve doubled and precision 
was improved. Altering the pH of the antisera solution altered 
the yield, more alkaline pH increasing and acidic pH reducing the
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FIG. 11 Range of GSA in normals and diabetics. 
Lines are Mean ± 2 SD
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results, so both eluents had to have the same pH, which is why 
sorbitol rather than sodium citrate was used to elute GSA frcm 
the affinity column.
3. Standardisation and Parallelism - Human serum albumin 
standard prepared in the wash buffer or the sorbitol buffer gave 
almost superimposed standard curves (figure 12) thus enabling 
one set of standards prepared in wash buffer at pH 8.8 to be used 
in the assay of both glycosylated and non-glycosylated fractions. 
In addition when serial dilutions of human serum albumin were 
made in wash buffer (pH 8.8) and put through the albumin assay, 
parallelism was observed with the standard curve showing 
linearity of the assay to 18mg/L.
4. Accuracy - The lower limit of detection was assessed by 
assaying the albumin eluted in column wash buffer 10 times within 
batch. The resultant mean value was 0.39 mg/L with a standard 
deviation of 0.21 giving a detection limit of 0.81 mg/L (upper 
95% confidence limit).
5. Carry Over - Wash buffer was placed after the highest 
standard (20 mg/L) in the assay run on 6 occasions, and carry over 
of albumin was found to be negligible compared with the detection 
limit (range -0.3 to 0.9 mg/L, mean 0.32 mg/L).
6. Stability Studies - Both glycosylated and non-glycosylated 
albumin fractions in 10 sanples of varying concentrations were 
found to be stable when stored at 4°C for 22 hours (Table 15).
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Table 13. INSTRUMENT SETTINGS ON THE MULTISTAT III PLUS F/LS FOR
ALBUMIN MEASUREMENT
The DILUTOR:
SAMPLE VOLUME 36 pL
VOLUME DILUENT 60 pL
VOLUME 2nd REAGENT 0
POSITION 2nd REAGENT 0
VOLUME DILUENT 10 pL
VOLUME 1st REAGENT 200 pL
POSTION 1st REAGENT 1
1st SAMPLE 2
LAST SAMPLE 20
REFERENCE CUVETTE lw
ROTOR FORMAT:
CUP 1 
CUP 2 
CUPS 3 - 7  
CUP 8 
CUP 9
CUPS 10 - 17 
CUP 18 
CUP 19 
CUP 20
INSTRUMENT PARAMETERS:
STANDARD 1 lmg/L
STANDARD 2 5mg/L
STANDARD 3 lQmg/L
STANDARD 4 15mg/L
STANDARD 5 2Gmg/L
TEMPERATURE 30 °C
CALIBRATION MODE 2
REAGENT BLANK 2
UNITS mg/L
DATAPOINTS 12
FILTER CODE 1 340nM
FILTER CODE 2 340nM
STARTMODE 2
DELAY INTERVAL 3 secs
DATA INTERVAL 90 secs
DATA MODE 4
ANTIGEN EXCESS CHECKPOINT 5 
ANTIGEN EXCESS DETECTION 10 
PRE INCUBATION TIME 0 secs
REFERENCE, EMPTY 
BLANK, WASH, BUFFER 
STANDARDS 
QC 2 
QC 1
SAMPLE ELUATES
HIGH POOLED GSA STANDARD ELUATES 
LOW POOLED GSA STANDARD ELUATES 
QC 3
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Table 14. INSTRUMENT SETTINGS ON COBAS FARA FOR ALBUMIN
MEASUREMENT
REACTION MODE
CALIBRATION MODE
WAVELENGTH
TEMPERATURE
SAMPLE
REAGENT
DILUENT
FIRST READING
INTERVAL
NUMBER OF READING 
STANDARDS
CALCULATION MODEL
P-T-AO 
NON-LINEAR 
340 riM 
30 °C 
34 pL 
200 pL 
56 pL
0.5.secs 
19 secs 
25
1. WASH BUFFER
2. 1.0 mg/L
3. 5.0 mg/L
4. 10.0 mg/L
5. 15.0 mg/L
6. 20.0 mg/L
POLYNOMIAL 5
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FIG. 12 Standard curves for albumin measurement with standards prepared in 
wash buffer and sorbitol buffer.
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7. Recovery - i) FRCM AFFINITY CHROMATOGRAPHY - The total 
albumin concentration was measured in 10 cases in the original 
sample prior to application to the column and related to the 
albumin content measured in the bound and non-bound albumin 
fractions after passage through the columns. The mean recovery 
was 101.5%. Recoveries of less than 85% were subsequently 
encountered in up to 10% of cases which necessitated routine 
assessment of recovery and repeating measurements when necessary.
Table 15 STABILITY OF GLYCOSYLATED AND NON-GLYCOSYLATED ALBUMIN 
FRACTIONS STORED FOR 22 HOURS AT 4°C.
GLYCOSYLATED FRACTION NON-GLYCOSYLATED FRACTION % GSA
mg/L mg/L (ABSORPTION)
4 hours 22 hours 4 hours 22 hours 4 hours 22 horn
1 3.2 3.7 16.4 17.4 3.8 4.1
2 3.8 4.3 13.1 15.4 5.6 5.4
3 4.1 4.5 13.6 15.6 5.8 5.6
4 4.8 5.5 13.3 13.8 6.9 7.6
5 5.5 6.2 14.1 14.4 7.4 8.1
6 2.1 2.4 16.6 17.1 2.5 2.8
7 6.7 6.7 15.2 16.3 8.3 7.8
8 7.8 8.0 13.8 15.3 10.4 9.8
9 10.3 11.8 12.8 14.9 14.2 14.0
10 1.4 1.7 14.1 16.1 2.0 2.1
Recovery - ii) FRCM IMMUNOTURBIDIMETRIC ASSAY OF ALBUMIN -
Known amounts of human serum albumin in wash buffer were added to 
fractions containing 3mg glycosylated albumin and put through the 
immunoturbidimetric assay. The percentage recovered when 5mg/l 
was added to give a concentration of 8.0 mg/1 was 96%, 99% when 
lOmg was added to give an expected concentration of 13mg/l and 
98% when 15mg was added to give an expected yield of 18mg.
298
8. Precision - 10 duplicate sanples of working controls of 
varying concentrations were measured simultaneously to calculate 
the within-batch coefficient of variation and 3 other duplicate 
sanples of varying concentrations were measured on 20 separate 
occasions to produce between-batch coefficient of variations to 
assess precision of the immunoturbidimetric canponent of the 
assay. The data are shown in table 16. I also assessed the 
precision of the ccnibined affinity chranatography and 
immunoturbidimetric procedure for the determination of GSA of 
varying levels in diabetic sanples. The results are shown in 
Table 17, and confirm that the method was reproducable.
Table 16. WITHIN AND BETWEEN BATCH PRECISION ON ALBUMIN 
CONCENTRATION IN WORKING CONTROLS MEASURES BY IMMUNOTURBIDIMETRY
WITHIN BATCH COEFFICIENT OF VARIATION (CV)
Standard DeviationSample Concentration (mg/1) CV(%)
1.59 20.4 0.3
4.55 6.5 0.3
8.05 1.5 0.1
13.50 4.9 0.7
18.57 2.4 0.4
BETWEEN BATCH COEFFICIENT OF VARIATION (CV)
Sample Concentration (mg/1) CV(%) Standard Deviation
2.65 13.8 0.4
8.89 4.7 0.4
15.51 4.6 0.7
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Table 17. WITHIN AND BETWEEN BATCH PRECISION (CV) OF GSA
MEASUREMENT IN DIABETIC SAMPLES.
% GSA No. of Measurements CV(%) Std. Deviation
i. WITHIN BATCH
3.2
7.7
13.2
9
9
9
9.9
4.4
3.5
0.3
0.3
0.5
ii.BETWEEN BATCH
3.0
7.6
17.7
10
9
8
11.0
6.2
3.7
0.3
0.5
0.7
Canment: The immunoturbidlmetric measurement of albumin was 
found to be sensitive and reproducable enough to allow reliable 
measurement of the small concentrations of albumin that could 
safely be applied to the affinity chromatographic columns without 
overloading them. The major advantage of this method was that by 
measuring the total albumin concentration in serum prior to 
application to the column, and the albumin concentration in the 
glycosylated and non-glycosylated fractions, I could confidently 
state the concentrations of glycosylated albumin and confirm 
whether or not recovery of albumin frcm the column was complete. 
In the event mean recovery was 101.5% in the initial series of 
experiments although subsequent experience found less than 85% 
albumin recovery frcm the columns in up to 10% of cases. This 
was usually in columns where the boronate gel was discoloured or 
where air bubbles were evident within the gel. Discarding such 
columns minimised the frequency of reduced recovery of albumin 
frcm columns. Although no glycosylated albumin standard was 
initially available we confirmed reliabilty between-batches by 
the use of pooled high and low GSA sera.
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1:5 FRUCTOSAMINE
Serum fructosamine was measured using a canmercial kit which 
measured NBT reduction on the Cobas Fara centrifugal analyser. 
The kit was validated by Dr. Deepak Bhatnagar of the Dept of 
Chemical Pathology at Hope Hospital and both he and I in 
collaboration with Dr. Paramjeet Kalsi, Research Technician in 
the Department of Medicine at Hope Hospital, carried out the 
initial assays, although the samples were subsequently analysed 
by Dr. Kalsi.
Reagents and Hardware
I employed the Fructosamine kit manufactured by Roche 
Products Ltd., Welwyn Garden City, Herts. UK, and adapted the 
method of Baker et al (209) for use on the Cobas Fara centrifugal 
analyser. The canmercial reagent consisted of 0.25 mmol/1 
nitroblue tetrazolium chloride (NBT) in a 0.1 mmol/1 carbonate 
buffer (NaH003/Na2003) with a pH of 10.35. The settings of the 
Cobas Fara analyser are seen in Table 18.
The standards used were a canmercial secondary standard 
solution of 'glycosylated albumin1 calibrated against a primary 
series standard curve of synthetic deoxy-morpholino-fructose 
(DMF) at a concentration 3.22 mmol/L, and pooled patients samples 
with good or poor glycaemic control were used in each batch to 
ensure quality control.
301
Table 18. PARAMETER LISTINGS FOR THE SERUM FRUCTOSAMINE ASSAY ON 
THE COBAS FARA (ROCHE) CENTRIFUGAL ANALYSER.
General Parameters
Measurement Mode 
Reaction Mode 
Calibration Mode 
Reagent Blank 
Wavelength 
Temperature 
Unit
Analysis
Sample 20 pi 
Reagent 200 pi 
+ Delay Time 1 sec. 
AO Readings 
First 500 seconds 
Interval 300 seconds
Absorb
P-T-AQ
Std nonlin
Reag
530 nM
37.0°C
mmol/1
Diluent, 40 pL
Number 2
Calculation
Conversion Factor, 1.00 
Reaction Direction Increase 
Test Range low 0.00 
Norm Range low 0.60 
Calcs steps I 
Calcs steps A Endpoint 
Readings First 1 
Limit Calibration 3.50
Off 0.000 
Check On 
High 5.00 
High 1.85
Last 2 
Point 2
Calbration interval. On request 
Standard non linear
1. 0.00 2. 0.50 7.
3. 1.00 4. 1.50
5. 2.00 6. 2.50
5.00
Calc model 
Std. Replicate 
Calib. correction 
Reag. Range low 
Blank Range low
Lin. Regress
Single
Off
- 0.10 High 1.00 
- 0.10 High 1.00
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Procedure
The colorimetric fructosamine assay is based on the fact 
that ketoamine bonds in alkaline media form corresponding 
eneaminols which then reduce NBT to the corresponding formazan. 
The reagent is warmed to 37° C prior to use and the optical 
density absorbance change between 10 and 15 minutes is recorded 
at a wavelength of 530 nM. Serum albumin was also measured on a 
separate occasion on the Cobas Fara analyser and fructosamine 
levels corrected to a standard albumin concentration of 40g/l.
Results
Normal Range - Serum frcm 50 non-diabetic ostensibly healthy 
bus drivers was analysed to produce a normal range of 1.87 - 2.97 
mmol/1.
Precision and Quality Control - Using pooled patients' sera 
and samples frcm healthy and diabetic individuals we attained 
within batch precision of 1-2% and between batch precision 
averaging 3% throughout the range of samples measured. 
Thereafter internal quality control was ensured despite the lack 
of a non-synthetic standard by using pooled sera.
I did not routinely correct for albumin concentration in 
initial assessment of the assay although in the light of recent 
publication suggesting this is necessary (227,229) where 
proteinuria or hypcalbuminaemia is present, I also standardised 
the fructosamine values to an albumin concentration of 40g/l, to 
examine whether or not it affected interpretation of results.
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1:6. LIPID AND LIPOPROTEIN MEASUREMENTS
I fully acquainted myself with the techniques for isolation 
and measurement of lipids and apoproteins within the lipoprotein 
fractions during the course of the study. The assays were mainly 
carried out by Ms. Monica Ishola, Research Technician in the 
Laboratory of Dr. Paul N. Durrington, Senior Lecturer in the 
University Department of Medicine at the Manchester Royal 
Infirmary.
Lipid concentrations were measured enzymatically, 
cholesterol with reagent supplied by Diamed AG, (Murten, 
Switzerland) and triglycerides by the GPO-PAP method by 
Boehringer (Mannheim, W.Germany). To isolate HDL and HDL3 by 
ultracentrifugation, the background density of plasma was 
adjusted to 1.063 g/ml and 1.125 g/ml respectively, by addition 
of a solution of sodium chloride and potassium bromide (731): 
after ultracentrifugation at 105g for 48 hours ('Superspeed 65' 
ultracentrifuge with 18 x 6.5 ml rotor, MSE Ltd., Crawley, 
Sussex, UK), the infranatants were separated by tube-slicing 
('Spinco' Tube Slicer, Beckman Instruments, Palo Alto, 
California). The concentration of cholesterol in HDL2 was 
determined by subtraction of HDL3 cholesterol frcm total HDL 
cholesterol (299) and LDL cholesterol was calculated frcm total 
serum cholesterol, triglycerides and the HDL concentration by the 
Friedewald formula (270). In addition LDL cholesterol was 
determined directly in 48 insulin-dependent diabetic patients 
after preparative ultracentrifugation (v.i.) by subtraction of 
HDL (density greater than 1.063 g/ml) and VLDL (density less than 
1.006 g/ml) cholesterol frcm total cholesterol. HDL cholesterol
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was also isolated following the precipitation of other 
lipoproteins with sodium phosphotungstate and magnesium chloride 
as previously described (732) and LDL cholesterol indirectly 
estimated using this HDL. Serum apolipoprotein B concentrations 
were determined by Immunoelectrophoresis (733) using goat anti­
human serum obtained frcm Immuno, Dunton Green, Kent, UK.
Apolipoprotein E phenotypes were measured by Dr. Leslie 
Tetlow of the Department of Chemical Pathology at the University 
Hospital of South Manchester. The method was a refinement of a 
previously described method (734) and was carried by flat bed 
agarose gel isoelectric focussing. Prior to delipidation of the 
isolated VLDL fraction containing the bulk of apolipoprotein E, 
serum was mixed with neuraminidase to remove sialic acid and non- 
enzymatically bound glucose residues attached to apo E that might 
have affect interpretation of the different isoforms. Apo E 
bands were identified by nitrocellulose blotting of the agarose 
gel followed by incubation of the nitrocellulose with mouse 
monoclonal anti-apo E (Biogenesis, Bournemouth, UK) and 
thereafter with immunoperoxidase linked rabbit antimouse antibody 
(Dako, High Wyccmbe, Bucks., UK).
Validation of the FRIEDEWALD FORMULA for the measurement of low 
density lipoprotein cholesterol in insulin-dependent diabetes
mellitus
The Friedewald formula was devised in order to obviate the 
need for preparative ultracentrifugation in the measurement of 
LDL cholesterol, and allows LDL cholesterol levels to be 
calculated with a knowledge of the concentrations of total serum
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cholesterol and triglycerides and of the HDL cholesterol (270).
It relies on the assumption that the mass ratio of serum 
triglycerides to very low density lipoprotein (VLDL) cholesterol 
is 5:1 (equivalent to a molar ratio of 2.2:1), when LDL 
cholesterol is equal to :
Total serum cholesterol - HDL cholesterol + total serum
triglycerides
2.2
The fomula is based on the assumption that the relative 
quantities of VLDL and LDL triglycerides remain constant, as 
does the ratio of cholesterol to triglyceride within VLDL.
However compositional abnormalities of both VLDL and LDL in 
IDEM might lead to an underestimation of LDL cholesterol by the 
Friedewald method. I therefore compared the LDL cholesterol 
levels derived from the Friedewald formula and preparative 
ultracentrifugation in 48 subjects with IDEM.
42 of the subjects were normotriglyceridaemic (fasting 
triglycerides less than 2.50 mmol/1), and 6 had 
hypertriglyceridaemia (fasting triglycerides 2.98-5.30 mmol/1). 
Renal function was well preserved in all cases. Serum urea was 
5.8 (1.8) mmol/1 (mean (SD)) and serum creatinine 87 (20) pmol/1. 
Urinary protein excretion was 0.1 (0.05-6.6) g/24hours (median 
(range)), and greater than 0.5g/24 hours in 6 patients.
Results
Glycaemic control for the group as a whole was moderately 
good (fasting blood glucose 8.8+3.5 mmol/1 (mean+SD), Hh^ 8.8+ 
1.7%).
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FIG. 13 Correlation between LDL Cholesterol calculated by the Friedewald 
formula and determined by preparative ultracentrifugation in insulin- 
dependent diabetes mellitus.
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Lipid and lipoprotein values for the group as a whole were 
as follows: total cholesterol 5.87+1.65 mmol/1; total
triglycerides 1.67+1.10 mmol/1; HDL cholesterol 1.36+0.34 mmol/1. 
The mean value for LDL cholesterol when LDL was calculated 
directly was 3.89+1.27 whereas the mean LDL cholesterol using the 
Friedewald formula was slightly less at 3.68+1.13 mmol/1.
In the 42 normotriglyceridaemic (<2.5 mmol/1) individuals a 
close correlation between LDL calculated by the Friedewald 
formula and determined by preparative ultracentrifugation was 
noted (r = 0.98, p<0.0001; slope 0.98), and this close
relationship persisted when data frcm the 6 patients whose serum 
triglycerides exceeded 2.5 mmol/1 (figure 13) were incorporated.
Discussion
The Friedewald formula was found to be an appropriate method 
to derive LDL cholesterol values in insulin-dependent diabetics 
with relatively well preserved renal function when they were 
normotriglyceridaemic or moderately hypertriglyceridaemic, 
irrespective of compositional abnormalities that might take place 
in VLDL and LDL in IDDM. The close correlation and the slope of 
unity when the linear regression line was calculated suggests 
that 2.2 is an appropriate value for the molar ratio of 
triglyceride to cholesterol in IDDM in the absence of advanced 
nephropathy.
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1:7 C-peptide and other Measurements
C-peptide secretion was assessed 1 hour following a standard 
meal which has previously been found to yield results comparable 
to that obtained following stimulation with lmg glucagon 
administered intravenously (553). The assays were carried out by 
Dr. Chris Gordon of the Department of Endocrinology of the 
Manchester Royal Infirmary. A radioimmunoassay method (IRE, 
Belgium) was used. The lower limit of detection of the assay was 
0.015 pmol/ml, the between batch variation of the assay averaged 
10% for pooled plasma and 5.5% to 10% for quality control sera; 
the intra-batch coefficient of variation ranged between 1.3 and 
3.1%.
HBA*
Glycosylated (glycated) haemoglobin measurements were made 
in the Dept. of Chemical Pathology at Hope Hospital by ion 
exchange chromatography using a commercial kit (Boehringer, 
Mannheim, W.Germany). The normal range in our laboratory for 50 
healthy individuals was 5.0-8.0%.
Insulin Antibodies
Antibodies to bovine and human insulin were measured by the 
laboratory of Dr. T. Wilkin at the University Dept of Medicine at 
Southampton University, using an enzyme-linked immunosorbent 
assay (ELISA) (735).
Other Measurements
Serum biochemical profiles (including serum albumin) and 
urinary creatinine clearance were measured in the Dept. of 
Chemical Pathology at Hope Hospital with a multichannel
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autoanalyser. Total urinary protein was measured by turbidimetry 
using benzethonium chloride routinely used in the same laboratory 
and the lower limit of detection was found to be 0.05g/l. 
Creatinine clearance and urinary protein excretion were 
calculated frcm timed urine collections and expressed per 24 
hours corrected for body surface area (to 1.73 m2). Urinary 
sodium excretion was determined by flame photometric methods.
Data Collection and Analysis
All data was initially collected on trial document forms 
(see Appendix). Data was then put on computer file either by 
myself or by Mrs Glynis Medlicott, Diabetic Clerk to whom I am 
indebted. Latterly I was also assisted by Mrs. Hazel Downs, 
Diabetic Clerk, in transposing data onto the microcomputer for 
analysis.
We used a Sirius Microcomputer with a Winchester disk drive 
to extend the capacity for storage of information. Initial plans 
to transfer all data directly to the mainframe (AMDAHL) computer 
at the Regional Computer Centre in the University of Manchester 
via a link proved a time consuming and ultimately inappropriate 
approach and subsequently floppy discs containing data were taken 
to the Computing Centre for analysis. Analysis of data was 
carried out with the assistance of Dr. Valerie Hillier of the 
Dept, of Computation at Manchester University for whose help I am 
most grateful. Data was analysed using the Statistical package 
for Social Sciences (SPSS). Data are usually presented as mean 
. (SD) or (SEM) unless stated otherwise. The distribution of 
characteristics was assessed initially to see whether parametric
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or non-parametric statistics were appropriate using the 
Kolmogorov Smirnoff goodness of fit test. Log transformation was 
carried out for analysis of triglyceride and M Value data. 
Analysis for paired or more usually unpaired data utilised 
Student’s t-test, one-way analysis of variance, Wilcoxon's Rank 
Test, the Mann-Whitney U-test or the Kruskal-Wallis ANOVA for 
quantitative outcome measures. Groups were compared at each time 
point by the Wilcoxon Rank sum test and the Kruskal-Wallis one­
way test ANOVA. To assess the changes over time within the 
groups the paired samples t-test, analysis of variance for 
repeated measurements, the Wilcoxon's matched pairs signed rank 
test and the Friedman two-way ANOVA were applied. The chi-squared 
test or the Fischer's exact test were used to analyse variables 
with categorical classification. The McNamar test was used to 
compare the frequencies of complications initially and after the 
first year. Correlations were made using Wilcoxon's signed rank 
sum test or Kendall's correlation coefficient. In all cases 
statistical significance was assumed at a two tailed p<0.05. A 
glossary of the statistical tests used in the study and their 
roles is in the appendix section of the thesis.
